Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria (Review)

Bukirwa H, Unnikrishnan B, Kramer CV, Sinclair D, Nair S, Tharyan P

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2014, Issue 3

http://www.thecochranelibrary.com

WILEY
# Table of Contents

**HEADER**  
**ABSTRACT**  
**PLAIN LANGUAGE SUMMARY**  
**SUMMARY OF FINDINGS FOR THE MAIN COMPARISON**  
**BACKGROUND**  
**OBJECTIVES**  
**METHODS**  
**RESULTS**  
- Figure 1.  
- Figure 2.  
- Figure 3.  
**ADDITIONAL SUMMARY OF FINDINGS**  
**DISCUSSION**  
**AUTHORS’ CONCLUSIONS**  
**ACKNOWLEDGEMENTS**  
**REFERENCES**  
**CHARACTERISTICS OF STUDIES**  
**DATA AND ANALYSES**

- Analysis 1.1. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 1 Total failure (Day 28).  
- Analysis 1.2. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 2 Total failure (Day 42).  
- Analysis 1.3. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 3 Early treatment failure.  
- Analysis 1.4. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 4 Parasite clearance time (hours).  
- Analysis 1.5. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 5 Fever clearance time (hours).  
- Analysis 1.6. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 6 Gametocyte clearance time.  
- Analysis 1.7. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 7 Serious adverse events.  
- Analysis 1.8. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 8 Adverse events leading to withdrawal from treatment.  
- Analysis 1.9. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 9 Patient reported symptoms.  
- Analysis 1.10. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 10 Patient reported symptoms judged as drug-related.  
- Analysis 1.11. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 11 Abnormal LFTs; grade 3 and 4 toxicity.  
- Analysis 1.12. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 12 Change in haemoglobin.  
- Analysis 1.13. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 13 Anaemia as an adverse event.  
- Analysis 2.1. Comparison 2 Artesunate-pyronaridine versus artemether-lumefantrine; subgroup analysis, Outcome 1 Total failure PCR-adjusted (Day 28); subgrouped by age.  
- Analysis 2.2. Comparison 2 Artesunate-pyronaridine versus artemether-lumefantrine; subgroup analysis, Outcome 2 Total failure PCR-adjusted (Day 28); subgrouped by region.  
- Analysis 2.3. Comparison 2 Artesunate-pyronaridine versus artemether-lumefantrine; subgroup analysis, Outcome 3 Total failure PCR-adjusted (Day 28); subgrouped by country.  
- Analysis 3.1. Comparison 3 Artesunate-pyronaridine versus artemether-lumefantrine; sensitivity analysis, Outcome 1 Total failure PCR-unadjusted (Day 28); Sensitivity analysis.  
- Analysis 3.2. Comparison 3 Artesunate-pyronaridine versus artemether-lumefantrine; sensitivity analysis, Outcome 2 Total failure PCR-adjusted (Day 28); Sensitivity analysis.  
- Analysis 4.1. Comparison 4 Artesunate-pyronaridine versus artemether-mefloquine, Outcome 1 Total failure (Day 28).
Analysis 4.2. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 2 Total failure (Day 42).
Analysis 4.3. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 3 Early treatment failures.
Analysis 4.4. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 4 Parasite clearance time (hours).
Analysis 4.5. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 5 Fever clearance time (hours).
Analysis 4.6. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 6 Gametocyte clearance time (hours).
Analysis 4.7. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 7 Serious adverse events.
Analysis 4.8. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 8 Adverse events leading to withdrawal from treatment.
Analysis 4.9. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 9 Patient reported symptoms.
Analysis 4.10. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 10 Abnormal LFTs; Grade 2 toxicity.
Analysis 4.11. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 11 Abnormal LFTs; Grade 3 or 4 toxicity.
Analysis 4.12. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 12 Haemoglobin (g/dL).
Analysis 4.13. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 13 Platelet counts (x 10^9/L).
Analysis 4.14. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 14 White blood counts (x 10^9/L).
Analysis 4.15. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 15 Abnormal ECG finding.
Analysis 5.1. Comparison 5 Artesunate-pyronaridine versus artesunate-mefloquine; subgroup analysis, Outcome 1 Total failure PCR-adjusted (Day 28); subgrouped by region.
Analysis 5.2. Comparison 5 Artesunate-pyronaridine versus artesunate-mefloquine; subgroup analysis, Outcome 2 Total failure PCR-adjusted (Day 28); subgrouped by country.
Analysis 6.1. Comparison 6 Artesunate-pyronaridine versus artesunate-mefloquine; sensitivity analysis, Outcome 1 Total failure PCR-unadjusted (Day 28); Sensitivity analysis.
Analysis 6.2. Comparison 6 Artesunate-pyronaridine versus artesunate-mefloquine; sensitivity analysis, Outcome 2 Total failure PCR-adjusted (Day 28); Sensitivity analysis.
Analysis 7.1. Comparison 7 Pyronaridine alone or with artesunate versus another antimalarial: laboratory findings, Outcome 1 Abnormal LFTs; Grade 3 or 4 toxicity.
Analysis 7.2. Comparison 7 Pyronaridine alone or with artesunate versus another antimalarial: laboratory findings, Outcome 2 Combined abnormal LFTs.
Analysis 7.3. Comparison 7 Pyronaridine alone or with artesunate versus another antimalarial: laboratory findings, Outcome 3 Renal function tests.
Analysis 7.4. Comparison 7 Pyronaridine alone or with artesunate versus another antimalarial: laboratory findings, Outcome 4 Haemoglobin.
Analysis 7.5. Comparison 7 Pyronaridine alone or with artesunate versus another antimalarial: laboratory findings, Outcome 5 Abnormal ECG findings.
Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria

Hasifa Bukirwa1, B Unnikrishnan2, Christine V Kramer3, David Sinclair4, Suma Nair5, Prathap Tharyan6

1Makerere University Medical School, Kampala, Uganda. 2Department of Community Medicine, Kasturba Medical College, Mangalore, India. 3Cochrane Infectious Diseases Group, Liverpool School of Tropical Medicine, Liverpool, UK. 4Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK. 5Community Medicine, Kasturba Medical College, Manipal, India. 6South Asian Cochrane Network & Centre, Prof. BV Moses Centre for Evidence-Informed Health Care and Health Policy, Christian Medical College, Vellore, India

Contact address: Hasifa Bukirwa, Makerere University Medical School, Mulago Hospital Complex, PO Box 24943, Kampala, Uganda. hbukirwa@hotmail.com, hbukirwa@hotmail.com.

Editorial group: Cochrane Infectious Diseases Group.

Publication status and date: New, published in Issue 3, 2014.

Review content assessed as up-to-date: 16 January 2014.

Citation: Bukirwa H, Unnikrishnan B, Kramer CV, Sinclair D, Nair S, Tharyan P. Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No.: CD006404. DOI: 10.1002/14651858.CD006404.pub2.

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

ABSTRACT

Background
The World Health Organization (WHO) recommends that people with uncomplicated Plasmodium falciparum malaria are treated using Artemisinin-based Combination Therapy (ACT). ACT combines three-days of a short-acting artemisinin derivative with a longer-acting antimalarial which has a different mode of action. Pyronaridine has been reported as an effective antimalarial over two decades of use in parts of Asia, and is currently being evaluated as a partner drug for artesunate.

Objectives
To evaluate the efficacy and safety of artesunate-pyronaridine compared to alternative ACTs for treating people with uncomplicated P. falciparum malaria.

Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL), published in The Cochrane Library; MEDLINE; EMBASE; LILACS; ClinicalTrials.gov; the metaRegister of Controlled Trials (mRCT); and the WHO International Clinical Trials Search Portal up to 16 January 2014. We searched reference lists and conference abstracts, and contacted experts for information about ongoing and unpublished trials.

Selection criteria
Randomized controlled trials of artesunate-pyronaridine versus other ACTs in adults and children with uncomplicated P. falciparum malaria.

For the safety analysis, we also included adverse events data from trials comparing any treatment regimen containing pyronaridine with regimens not containing pyronaridine.
Data collection and analysis

Two authors independently assessed trial eligibility and risk of bias, and extracted data. We combined dichotomous data using risk ratios (RR) and continuous data using mean differences (MD), and presented all results with a 95% confidence interval (CI). We used the GRADE approach to assess the quality of evidence.

Main results

We included six randomized controlled trials enrolling 3718 children and adults.

Artesunate-pyronaridine versus artether-lumeфантрин

In two multicentre trials, enrolling mainly older children and adults from west and south-central Africa, both artesunate-pyronaridine and artether-lumeфантрин had fewer than 5% PCR adjusted treatment failures during 42 days of follow-up, with no differences between groups (two trials, 1472 participants, low quality evidence). There were fewer new infections during the first 28 days in those given artesunate-pyronaridine (PCR-unadjusted treatment failure: RR 0.60, 95% CI 0.40 to 0.90, two trials, 1720 participants, moderate quality evidence), but no difference was detected over the whole 42 day follow-up (two trials, 1691 participants, moderate quality evidence).

Artesunate-pyronaridine versus artesunate plus mefloquine

In one multicentre trial, enrolling mainly older children and adults from South East Asia, both artesunate-pyronaridine and artesunate plus mefloquine had fewer than 5% PCR adjusted treatment failures during 28 days follow-up (one trial, 1187 participants, moderate quality evidence). PCR-adjusted treatment failures were 6% by day 42 for those treated with artesunate-pyronaridine, and 4% for those with artesunate-mefloquine (RR 1.64, 95% CI 0.89 to 3.00, one trial, 1116 participants, low quality evidence). Again, there were fewer new infections during the first 28 days in those given artesunate-pyronaridine (PCR-unadjusted treatment failure: RR 0.35, 95% CI 0.17 to 0.73, one trial, 1720 participants, moderate quality evidence), but no differences were detected over the whole 42 days (one trial, 1146 participants, low quality evidence).

Adverse effects

Serious adverse events were uncommon in these trials, with no difference detected between artesunate-pyronaridine and comparator ACTs. The analysis of liver function tests showed biochemical elevation were four times more frequent with artesunate-pyronaridine than with the other antimalarials (RR 4.17, 95% CI 1.38 to 12.62, four trials, 3523 participants, moderate quality evidence).

Authors’ conclusions

Artesunate-pyronaridine performed well in these trials compared to artether-lumeфантрин and artesunate plus mefloquine, with PCR-adjusted treatment failure at day 28 below the 5% standard set by the WHO. Further efficacy and safety studies in African and Asian children are required to clarify whether this combination is an option for first-line treatment.

Plain language summary

Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria

What is uncomplicated malaria and how might artesunate-pyronaridine work

Uncomplicated malaria is the milder form of malaria which usually causes fever, with or without headache, tiredness, muscle pains, abdominal pains, nausea, and vomiting. If left untreated, uncomplicated malaria can rapidly develop into severe malaria with kidney failure, fitting, unconsciousness, and eventually death. Plasmodium falciparum is the most common parasite causing malaria in sub-Saharan Africa and causes most of the severe malaria worldwide.

The World Health Organization currently recommends countries use one of five different artemisinin-based combination therapies (ACTs) to treat malaria. These combinations contain an artemisinin component (artether, dihydroartemisinin, or artesunate), which works quickly to clear the parasite from the person’s blood, and a longer-acting drug which clears the remaining parasites from the blood and may prevent new Plasmodium infections for several weeks. Artesunate plus pyronaridine is a new combination and in this review we evaluate its effectiveness and safety compared to the other ACTs.

After examining the research published up to 16 January 2014, we included six randomized controlled trials, enrolling 3718 children and adults.
What the research says

Based on studies of mostly older children and adults living in Africa and Southeast Asia, artesunate-pyronaridine is probably as effective as artemether-lumefantrine at treating uncomplicated malaria and preventing further malaria infections after treatment (moderate quality evidence).

In a study primarily of older children and adults in Asia, artesunate-pyronaridine is probably as effective as artesunate plus mefloquine at treating *P. falciparum* malaria and preventing recurrent parasitaemias (moderate quality evidence).

Serious adverse events were rare in people treated with either artesunate-pyronaridine or other ACTs. However, short-lasting liver toxicity was more frequent in people treated with artesunate-pyronaridine than with the other antimalarials (moderate quality evidence).

Authors’ conclusions

Artesunate-pyronaridine performed well compared to the other two ACT with which it has been compared, but further studies in African and Asian children are required to help clarify whether this combination is an option for first-line treatment.
### Summary of Findings for the Main Comparison

**Artesunate-pyronaridine compared to artemether-lumefantrine for treating people with uncomplicated falciparum malaria**

**Patient or population:** Adults and children with uncomplicated falciparum malaria  
**Settings:** Malaria endemic areas in Africa and Asia  
**Intervention:** Artesunate-pyronaridine  
**Comparison:** Artemether-lumefantrine

| Outcomes                  | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of participants (trials) | Quality of the evidence (GRADE) |
|---------------------------|-----------------------------------------|--------------------------|-----------------------------|--------------------------------|
|                           | Assumed risk                            | Corresponding risk       |                             |                                |
|                           | Artemether-lumefantrine                 | Artesunate-pyronaridine  |                             |                                |
| **Treatment failure (day 28)** |                                         |                          |                             |                                |
| PCR-unadjusted            |                                         | RR 0.60 (0.40 to 0.90)   | 1720 (2 trials)             | ⊕⊕⊕ moderate1,2,3,4             |
| 7 per 100                 | 4 per 100                               | (3 to 6)                 |                             |                                |
| PCR-adjusted             |                                         | RR 1.69 (0.56 to 5.10)   | 1650 (2 trials)             | ⊕⊕⊕ moderate1,2,3,5            |
| 1 per 100                 | 1 per 100                               | (0 to 4)                 |                             |                                |
| **Treatment failure (Day 42)** |                                         | RR 0.85 (0.53 to 1.36)   | 1691 (2 trials)             | ⊕⊕⊕ moderate1,2,3,5            |
| PCR-unadjusted            |                                         | 17 per 100 (9 to 23)     |                             |                                |
| 15 per 100                |                                         | (9 to 23)                |                             |                                |
| PCR-adjusted             |                                         | RR 1.53 (0.73 to 3.19)   | 1472 (2 trials)             | ⊕⊕⊕ low1,6,3,5                 |
| 2 per 100                 | 3 per 100                               | (1 to 6)                 |                             |                                |
The assumed risk is the mean risk across the trials in those treated with artemether-lumefantrine. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio.

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1. No serious risk of bias: Both trials were well conducted and at low risk of bias.
2. No serious inconsistency: The trend was towards benefit with artesunate-pyronaridine in both trials but only reached statistical significance in one.
3. Downgraded by one for serious indirectness: The two trials were conducted in children aged between three months and 12 years and had trial sites in Africa and Asia. However, across both trials only 152 children aged <five years received artesunate-pyronaridine, and only 115 children in total were randomized to artesunate-pyronaridine in Asia. Further adequately powered studies in children in Africa and adults and children in Asia would be needed to fully generalize this result.
4. No serious imprecision: The result is statistically significant and the meta-analysis is adequately powered. However, it should be noted that these multicentred trials are underpowered to show equivalence at the country level. We did not downgrade.
5. No serious imprecision: The finding is of no substantial difference between the two ACTs. However, it should be noted that these multicentred trials are underpowered to show equivalence at the country level. We did not downgrade.
6. Downgraded by one for serious inconsistency: Although statistical heterogeneity was low, PCR-adjusted treatment failure was above 5% in the one trial recruiting children aged <five years.
7. For adverse events see the additional Summary of Findings table in Appendix 2.
Malaria continues to pose a serious global health challenge despite considerable progress over the past decade to control and eliminate malaria in some parts of the world. In 2010, there were an estimated 219 million malaria illness episodes, resulting in around 600,000 deaths (WHO 2012).

Description of the intervention

Pyronaridine is a benzaphthylhydrine derivative first synthesized in China in 1970 (Fu 1991). It was used extensively as a monotherapy to treat *P. falciparum* and *P. vivax* infections in the Hunan and Yunnan provinces of China for more than 20 years (Chen 1992), and to treat *P. falciparum* in some parts of Africa during the 1980s. Between 1985 and 1995, some in vitro pyronaridine-resistant strains of *P. falciparum* emerged along the China-Lao and China-Myanmar border areas (Yang 1997).

Elsewhere, in vitro studies using clinical isolates of *P. falciparum* from Africa, Cambodia, and Thailand in the 1990s demonstrated high activity of pyronaridine against chloroquine-sensitive and chloroquine-resistant *P. falciparum* strains (Childs 1988; Basco 1992; Chen 1992; Pradines 1998; Ringwald 1999), and more recent in vitro studies have also shown pyronaridine to be effective against multiple-drug resistant *P. falciparum* schizonts and gametocytes in Thailand and Indonesia (Chavalitshewinkoon-Petmitr 2000; Price 2010), and against chloroquine-resistant *P. falciparum* strains in Gabon (Kurth 2009). However, almost half of 28 *P. falciparum* isolates tested in vitro in Abidjan, Cote d’Ivoire, were resistant to pyronaridine and also showed some evidence of cross resistance to dihydroartemisinin (Bricc 2010).

Pyronaridine interferes with the glutathione-dependent detoxification of haem and targeting of β-haematin formation (Auparakittanon 2006). Its activity in multi-drug resistant strains of *P. falciparum* is believed to be due to its ability to inhibit P-glycoprotein function and reverse multi-drug resistance in cell lines (Qi 2002; Pradines 2010).

Pyronaridine is structurally related to amodiaquine, leading to some concerns that pyronaridine may have similar toxicity related to the formation of a reactive metabolite (quinoneimine) in the liver and white blood cells. However, some studies suggest that pyronaridine and other bis-Mannich compounds are structurally advantaged and do not form the bioactive quinoneimine metabolite (Naisbitt 1998; Ruscoe 1998).

Assessment of antimalarial drug efficacy

The WHO recommends that new antimalarials should have a treatment failure rate of less than 5%, and that failure rates greater than 10% with existing first-line antimalarials should trigger a change in treatment policy (WHO 2010a).

Treatmen failure can be classified as:
- Early treatment failure:
  - the development of danger signs or severe malaria on days 1, 2, or 3 in the presence of parasitaemia;
  - parasitaemia on day 2 higher than on day 0;

The WHO recommends that new antimalarials should have a treatment failure rate of less than 5%, and that failure rates greater than 10% with existing first-line antimalarials should trigger a change in treatment policy (WHO 2010a).

The partner drugs are longer-acting and are used to clear any residual infection (Nosten 2007; Kurzhals 2008; WHO 2010a). The combinations with very long half-lives (AS+MQ and DHA-P) can provide a period of post-treatment prophylaxis which may last for up to six weeks (Sinclair 2009).

Resistance to the artemisinin-derivatives was first reported among *P. falciparum* strains in 2008 along the Thai-Cambodian border (Dondorp 2010; Lim 2010; WHO 2010b). This has led to global initiatives to contain the spread of artemisinin resistance, which includes the development of new drugs to partner and protect the artemisinin-derivatives in ACT (WHO 2011).

The background

Description of the condition

Malaria continues to pose a serious global health challenge despite considerable progress over the past decade to control and eliminate malaria in some parts of the world. In 2010, there were an estimated 219 million malaria illness episodes, resulting in around 600,000 deaths (WHO 2012).

Five species of *Plasmodium* parasite cause malaria in humans; *Plasmodium falciparum* and *P. vivax* are the most common, and *P. falciparum* causes most of the severe disease cases (WHO 2012). Uncomplicated malaria is the mild form of the disease, typically characterized by fever with or without associated headache, tiredness, muscle pain, abdominal pain, rigors, nausea, and vomiting (WHO 2010a). If left untreated, uncomplicated malaria can rapidly develop into severe, life-threatening forms of the disease, particularly in people that have not acquired immunity. Effective immunity generally requires repeated infections over five to 10 years, and is reduced during pregnancy. Consequently in highly endemic settings, as seen in many areas of rural sub-Saharan Africa, young children and pregnant women are most at risk, while in settings with low or seasonal transmission, all age groups can be equally at risk (WHO 2010a).

In many parts of the world, *P. falciparum* has developed resistance to most antimalarial drugs used as monotherapy (White 2004; WHO 2010b). Consequently, the World Health Organization (WHO) now recommends that *P. falciparum* malaria is always treated with a combination of two drugs that act at different biochemical sites within the parasite (WHO 2010a). If a parasite mutation producing drug resistance arises spontaneously during treatment, the parasite should then be killed by the partner drug, thus reducing or delaying the development of resistance and increasing the useful lifetime of the individual drugs (White 1996; White 1999).

Five artemisinin-based combination therapies (ACTs) are now recommended for the first-line treatment of uncomplicated malaria; artemether-lumefantrine (AL), artesunate plus amodiaquine (AS+AQ), artesunate plus mefloquine (AS+SP), and dihydroartemisinin-piperaquine (DHA-P) (WHO 2010a). The artemisinin components (artemether, artesunate, or dihydroartemisinin) are highly effective schizonticides, and over three days of treatment rapidly eliminate up to 90% of the blood stage asexual forms of *P. falciparum*. The partner drugs are longer-acting and are used to clear any residual infection (Nosten 2007; Kurzhals 2008; WHO 2010a). The combinations with very long half-lives (AS+MQ and DHA-P) can provide a period of post-treatment prophylaxis which may last for up to six weeks (Sinclair 2009).

Resistance to the artemisinin-derivatives was first reported among *P. falciparum* strains in 2008 along the Thai-Cambodian border (Dondorp 2010; Lim 2010; WHO 2010b). This has led to global initiatives to contain the spread of artemisinin resistance, which includes the development of new drugs to partner and protect the artemisinin-derivatives in ACT (WHO 2011).
parasitaemia and axillary temperature > 37.5 °C on day 3;
parasitaemia on day 3 > 20% of count on day 0.

Late treatment failure:
- development of danger signs, or severe malaria, after day 3 with parasitaemia;
- presence of \textit{P. falciparum} parasitaemia and axillary temperature > 37.5 °C on or after day 4;
- presence of \textit{P. falciparum} parasitaemia after day 7.

The late reappearance of \textit{P. falciparum} parasites in the blood of an infected person can be due to failure of the drug to completely clear the original parasite (a recrudescence) or due to a new infection, which is especially common in areas of high transmission. A molecular genotyping technique called polymerase chain reaction (PCR) can be used in clinical trials to distinguish between recrudescence and new infection, giving a clearer picture of the efficacy of the drug and its post-treatment prophylactic effect (White 2002; Cattamanchi 2003; WHO 2008).

The WHO recommends a minimum follow-up period of 28 days for antimalarial efficacy trials, but longer periods of follow-up may be required for antimalarials with long elimination half-lives (White 2002; Bloland 2003). Treatment failure due to true recrudescence of malaria parasites may be delayed until the drug concentration falls below the minimum concentration required to inhibit parasite multiplication, which may be beyond 28 days. The WHO recommends 42 days follow-up for trials involving lumefantrine and piperaquine and 63 days follow-up for trials of mefloquine (WHO 2010a).

**Why it is important to do this review**

Early studies of pyronaridine monotherapy conducted in Africa showing efficacy against chloroquine-resistant \textit{P. falciparum} malaria (Ringwald 1999), and promising dose finding studies of the artesunate-pyronaridine combination from the Gabon (Ramhartter 2008), have led to the promotion of artesunate-pyronaridine as a possible addition to the current list of recommended ACTs (Vivas 2008; Croft 2010). This review aims to systematically evaluate the available trials on the effectiveness and safety of artesinin plus pyronaridine for consideration by global and national policy makers.

**Objectives**

To evaluate the efficacy and safety of artesunate-pyronaridine compared to alternative ACTs for treating people with uncomplicated \textit{P. falciparum} malaria.

**Methods**

**Criteria for considering studies for this review**

**Types of studies**

Randomized controlled trials (RCTs).

**Types of participants**

Adults and children with uncomplicated \textit{P. falciparum} malaria, as confirmed by either microscopy or rapid diagnostic tests.

**Types of interventions**

**Intervention**

Artesunate plus pyronaridine.

**Control**

WHO-recommended ACTs for treating malaria.

For an additional safety analysis we extended the inclusion criteria to all RCTs comparing pyronaridine alone or in combination with any other antimalarial.

**Types of outcome measures**

We used current WHO recommendations to guide the selection of outcomes for this review (Bloland 2003; WHO 2008).

**Primary outcomes**

Total treatment failure at day 28, 42, or 63 (PCR-unadjusted and PCR-adjusted).

**Secondary outcomes**

- Early treatment failure
- Parasite clearance
- Fever clearance
- Gametocyte carriage

**Adverse events**

- Serious adverse events (leading to death, requiring hospitalization or prolongation of existing hospitalization, are life threatening, or result in persistent or significant disability or incapacity)
- Adverse events leading to withdrawal from treatment (discontinuation of trial drug or withdrawal from trial)
  - Patient reported symptoms
  - Abnormal liver function tests (LFTs)
  - Abnormal WBC counts
  - Abnormal electrocardiogram (ECG) findings
Search methods for identification of studies

We attempted to find all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).

Electronic searches

We updated previous literature searches done in February 2007 and August 2012 of the following databases using the search terms and strategy described in Appendix 1 up to 16 January 2014: Cochrane Infectious Diseases Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL), published in The Cochrane Library; MEDLINE; EMBASE; and LILACS. We also searched ClinicalTrials.gov, the metaRegister of Controlled Trials (mRCT) and the WHO’s International Clinical Trials Registry Platform Search Portal for ongoing or recently completed trials using ‘pyronaridine’ and ‘malaria’ as search terms.

Searching other resources

Conference proceedings

We searched the following conference proceedings for relevant abstracts: The American Society of Tropical Medicine and Hygiene Annual Meetings (2007, 2008, 2009, and 2010); The Third ASEAN Congress of Tropical Medicine and Parasitology (ACTMP3); the MIM Pan-African Malaria Conference (2005 and 2009); the International Congress on Infectious Diseases (ICID) (2002, 2004, 2008, and 2010); the International Conference on Malaria: 125 years of Malaria Research 2005; the Keystone Symposia Global Health Series: and Malaria (Immunology, pathogenesis and perspectives) 2008.

Reference lists

We checked the reference lists of all trials identified by the above methods.

Contacting organizations and experts

We contacted the Medicines for Malaria Venture and the WHO for information about ongoing and unpublished trials.

Data collection and analysis

Selection of studies

Hasifa Bukirwa (HB) and Prathap Tharyan (PT) independently scanned the results of the search strategy and retrieved the full text articles of all potentially relevant trials, conscious of the possibility of multiple publications of the same trial. HB and PT independently assessed each potentially relevant trial for inclusion in the review using an eligibility form based on the inclusion criteria. There were no disagreements. We excluded studies that did not meet the eligibility criteria and listed the reasons for exclusion in the ‘Characteristics of excluded studies’ table.

Data extraction and management

HB and PT independently extracted the data from the trials using data extraction forms. We resolved disagreements through discussion. For dichotomous outcome measures, we recorded the number of participants experiencing the event and the number analysed in each group. For continuous outcome measures, we extracted arithmetic means and standard deviations for each group together with the numbers analysed in each group.

Primary outcome

Our primary analysis drew on the WHO’s protocol for assessing and monitoring antimalarial drug efficacy (Bloland 2003). This protocol has been used to guide most efficacy trials since its publication in 2003, even though it was designed to assess the level of antimalarial resistance in the trial area rather than for comparative trials. As a consequence, a high number of randomized participants are excluded from the final efficacy outcome as losses to follow-up or voluntary or involuntary withdrawals (see Table 1).

PCR-unadjusted total failure

We calculated PCR-unadjusted total failure (P. falciparum) as the sum of early treatment failures and late treatment failures (without PCR adjustment). The denominator excludes participants for whom an outcome was not available (for example, those who were lost to follow-up, withdrew consent, took other antimalarials, or failed to complete treatment) and those participants who did not fulfill the inclusion criteria after randomization.

PCR-adjusted total failure

We determined PCR-adjusted total failure (P. falciparum) as the sum of early treatment failures and late treatment failures due to PCR-confirmed recrudescence. We treated participants with indeterminate PCR results, missing PCR results, or PCR-confirmed new infections as involuntary withdrawals and excluded them from the calculation. The denominator excludes participants for whom an outcome was not available (for example, those who were lost to follow-up, withdrew consent, took other antimalarials, or failed to complete treatment) and participants who did not fulfill the inclusion criteria after randomization.

These primary outcomes relate solely to failure due to P. falciparum. For both PCR-unadjusted and PCR-adjusted total failure, we retained in the calculation participants who developed P. vivax
parasitaemia during follow-up if they were treated with chloroquine and continued to be monitored by the trialists. We classified them as treatment successes provided they did not go on to develop *P. falciparum* parasitaemia. We excluded from the calculation participants who developed *P. vivax* parasitaemia and were removed from the trial’s follow-up at the time of *P. vivax* parasitaemia.

**Assessment of risk of bias in included studies**

For efficacy outcomes we assessed the risk of bias for each included trial using the Cochrane tool for assessing the risk of bias (Higgins 2011). For each of six domains; sequence generation; allocation concealment; blinding of participants, trial personnel and outcome assessors; incomplete outcome data; selective reporting; and other sources of bias, we assigned a judgment regarding the risk of bias. We classified these judgments as ‘high risk’, ‘low risk’, or ‘unclear risk’ of bias. We recorded these assessments in the standard ‘risk of bias’ tables and summarized the risk of bias for each trial in a summary risk of bias graph.

For patient reported adverse events, we assessed the risk of bias by examining if monitoring was active or passive; whether participants and outcome assessors were blinded; whether the outcome data reporting was complete; whether all participants were included; and whether data analysis was independent of pharmaceutical companies (Table 2).

For laboratory reported adverse events, we assessed the risk of bias by examining which tests were performed, the timing of the tests, the completeness of reporting, and the independence of the data analysis (Table 2).

**Measures of treatment effect**

We extracted data from each included trial to calculate risk ratios, 95% confidence intervals (CIs) for dichotomous data, and mean differences with 95% CIs for continuous data.

**Unit of analysis issues**

We did not encounter any unit of analysis issues.

**Dealing with missing data**

If data from the trial reports were insufficient, unclear, or missing, we attempted to contact the trial authors for additional information. If we considered that the missing data rendered the result uninterpretable, we excluded the data from the meta-analysis and clearly stated the reason for exclusion. We explored the potential effects of missing data through a series of sensitivity analyses (Table 1).

**Assessment of heterogeneity**

We assessed heterogeneity amongst trials by inspecting the forest plots, applying the Chi² test with a 10% level of statistical significance, and also using the I² statistic with a value of 50% used to denote moderate levels of heterogeneity.

**Assessment of reporting biases**

There were too few trials to examine funnel plot asymmetry for evidence of small trial effects or publication bias.

**Data synthesis**

We analysed data using Review Manager 2011. For the primary analysis we stratified by comparator ACT, and when outcomes were assessed and reported at different time-points, we also stratified the analyses by time point. We performed meta-analysis where appropriate after assessment and investigation of heterogeneity. In the first instance, we used a fixed-effect model and applied a random-effects model when the Chi² test P value was < 0.1 or the I² statistic was > 50%.

Arithmetic means and standard deviations used to summarize continuous data are assumed to be normally distributed; however, sometimes these summary statistics are incorrectly used when the data are not normally distributed. Therefore, when arithmetic means were reported, we checked the normality of the data by calculating the ratio of the mean over the standard deviation. If this ratio (mean/standard) was < 2, then it is likely that the data are skewed as the mean cannot then lie in the centre of a normal distribution. It is possible to combine data with less severe degrees of skew in meta-analyses and when ratio of the mean over the standard deviation was more than one (ratios less than one indicate that data were severely skewed), we combined data from these trials with normally distributed data.

**Subgroup analysis and investigation of heterogeneity**

There were too few trials to use subgroup analyses to explore the causes of heterogeneity. However, to explore the generalizability of the evidence we subgrouped the available data by age (< 5 years versus ≥ 5 years), country, and geographic region.

**Sensitivity analysis**

We assessed that all three trials were at low risk of bias so we did not perform a sensitivity analysis exploring effects of risk of bias. To investigate the robustness of the methodology used in the primary analysis, we conducted a series of sensitivity analyses. The aim of this was to restore the integrity of the randomization process by adding excluded groups back into the analysis in a stepwise fashion (see Table 1 for details).
Quality of evidence

We assessed the quality of evidence across each outcome measure using the GRADE approach. The quality rating across studies has four levels: high, moderate, low, or very low. RCTs are initially categorized as high quality but can be downgraded after assessment of five criteria: risk of bias, consistency, directness, imprecision, and publication bias (Guyatt 2008).

RESULTS

Description of studies

See Characteristics of included studies, and Characteristics of excluded studies sections.

Results of the search

Of the 52 reports we retrieved by the search, we identified 39 potentially relevant reports. Three trials comparing artesunate-pyronaridine with other ACTs met the inclusion criteria for the main review (Tshefu 2010; Kayentao 2012; Rueangweerayut 2012). We included three additional trials for a further assessment of the effect of pyronaridine on liver function (Ringwald 1996; Ringwald 1998; Poravuth 2011). We described the results of the search in a flow diagram (Figure 1).
Figure 1. Flow diagram.

Records identified by database searching (N = 52) → Records identified as not relevant to review question (N = 13)

Records identified as potentially relevant (N = 39) → Records excluded (N = 17)
- Not RCT (N = 13)
- Quasi-RCT (N = 2)
- RCT: did not meet inclusion criteria (N = 2)

Full text articles obtained (N = 22) → Records excluded (N = 5)
- Quasi-RCT (N = 2)
- RCT: did not fulfill inclusion criteria (N = 3)

Studies included in qualitative synthesis (N = 6 RCTs; 17 records)

Studies included in quantitative synthesis (N = 6 RCTs; 17 records)
Included studies

Efficacy trials
The three efficacy trials were all Phase III non-inferiority trials conducted by the public-private partnership of Medicines for Malaria Venture (Switzerland) and Shin Poong Pharmaceuticals (Korea) for registration with the European Medicines Agency (Tshefu 2010; Kayentao 2012; Rueangweerayut 2012).

Artesunate-pyronaridine versus artemether-lumefantrine
Two multicentre trials that included 1807 participants evaluated this comparison (Tshefu 2010; Kayentao 2012). Most participants (88.3%) were recruited from trial sites in Africa (Burkina Faso, Cote d’Ivoire, Democratic Republic of Congo, Gabon, The Gambia, Ghana, Kenya, Mali, Mozambique, and Senegal), with a small number (11.7%) from Southeast Asia (Indonesia and the Philippines). All recruiting sites were endemic for P. falciparum malaria and most were reported as highly endemic. Most participants were older children or adults, and only 232 children aged under five years, and 15 aged under one year were included.
Important exclusion criteria were severe malaria, cerebral malaria, severe anaemia, pregnant and lactating women, and people with hepatic or renal disorders. 
Tshefu 2010 also excluded those with severe malnutrition and Kayentao 2012 excluded children with HIV infection.
In both trials, artesunate-pyronaridine was administered once daily for three days, and artemether-lumefantrine twice daily for three days in the standard dosing (see Table 3).

Artesunate-pyronaridine versus artemether plus mefloquine
A single multicentre trial, enrolling 1271 participants evaluated this comparison (Rueangweerayut 2012). Most participants (81.3%) were from Southeast Asia (Cambodia, India, Thailand, and Vietnam), with a smaller number (18.7%) from Africa (Burkina Faso, Ivory Coast, and Tanzania). Malaria endemicity was high in most sites.
Although the trial planned to recruit participants aged between 3 to 60 years, the youngest participant was five years old.
Important exclusion criteria were severe malaria, cerebral malaria, severe anaemia, severe malnutrition, pregnant and lactating women, and people with hepatic or renal disorders.
Both artesunate-pyronaridine and artesunate plus mefloquine were administered once daily for three days (see Table 3).

Additional safety trials
The three additional safety trials compared artesunate-pyronaridine versus chloroquine (Poravuth 2011), and pyronaridine alone versus chloroquine (Ringwald 1996; Ringwald 1998). 
Poravuth 2011 was conducted in Asia and primarily evaluated the effects of artesunate-pyronaridine on P. vivax malaria (Cambodia, India, Indonesia, and Thailand). Ringwald 1996 and Ringwald 1998 were conducted in Cameroon. 
Poravuth 2011 randomized 456 participants aged seven years to 60 years; Ringwald 1996 randomized 96 adults aged 15 to 64 years, and Ringwald 1998 recruited 88 children only, aged five years to 15 years.
For further details of the included trials see the ‘Characteristics of included studies’ tables.

Excluded studies
We excluded 21 trials (22 records) for the reasons described in the ‘Characteristics of excluded studies’ table. In brief; 13 were not randomized, four were quasi-randomized (used alternation), and five did not have populations, comparisons, or outcomes of relevance to this review (Figure 1).
One trial comparing pyronaridine alone for three days versus dihydroartemisinin alone for seven days versus a combination of pyronaridine and dihydroartemisinin for three days did not meet the inclusion criteria for the primary efficacy analysis due to the lack of an appropriate comparison arm with an ACT, and was not included in the safety analysis as LFTs were not reported (Liu 2002).

Risk of bias in included studies
See Figure 2.
Figure 2. Risk of bias summary table (Methodological quality summary): review authors' judgements about each methodological quality item for each included trial.

| Study               | Bias in random sequence generation (selection bias) | Allocation concealment (selection bias) | Selective reporting (reporting bias) | Incomplete outcome data (attrition bias) | Objective outcomes (parasitological and biochemical) | Subjective outcomes: adverse events |
|---------------------|-----------------------------------------------------|----------------------------------------|-------------------------------------|----------------------------------------|---------------------------------------------------|-----------------------------------|
| Kayertac 2012       | ✗                                                   | ✗                                      | ✗                                  | ✗                                      | ✗                                                 | ✗                                 |
| Puravuth 2011       | ✗                                                   | ✗                                      | ✗                                  | ✗                                      | ✗                                                 | ✗                                 |
| Ringwald 1998       | ✗                                                   | ✗                                      | ✗                                  | ✗                                      | ✗                                                 | ✗                                 |
| Ringwald 1998       | ✗                                                   | ✗                                      | ✗                                  | ✗                                      | ✗                                                 | ✗                                 |
| Rueangweerayut 2012 | ✗                                                   | ✗                                      | ✗                                  | ✗                                      | ✗                                                 | ✗                                 |
| Tshefu 2010         | ✗                                                   | ✗                                      | ✗                                  | ✗                                      | ✗                                                 | ✗                                 |

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Allocation
All trials were at low risk of selection bias.

Blinding
The four non-inferiority trials were at low risk for performance and detection bias as they used double-dummy techniques, or independent outcome assessors and trial personnel who were not aware of allocation (Tshefu 2010; Poravuth 2011; Kayentao 2012; Rueangweerayut 2012). The additional two safety trials (Ringwald 1996; Ringwald 1998) were open label or inadequately masked but were at low risk of bias, since blinding would not affect detection of the adverse outcomes sought in this review.

Incomplete outcome data
All of the included trials reported attrition with details of all randomized participants.

Selective reporting
Tshefu 2010; Poravuth 2011; Kayentao 2012 and Rueangweerayut 2012 were prospectively registered and appeared free of selective reporting, as ascertained from the data presented in the reports, the registration documents, and where available, the trial protocols.

Other potential sources of bias
We considered that Ringwald 1996; Ringwald 1998; and Tshefu 2010 had other potential biases (see Risk of bias tables) but the effects on these on outcomes are uncertain.

Effects of interventions
See: Summary of findings for the main comparison Artesunate-pyronaridine compared to artemether-lumefantrine for uncomplicated falciparum malaria; Summary of findings 2 Artesunate-pyronaridine compared to artesunate plus mefloquine for treating uncomplicated *P. falciparum* malaria; Summary of findings 3 Liver toxicity of pyronaridine compared to other antimalarials

Comparison 1. Artesunate-pyronaridine versus artemether-lumefantrine
Two trials, including 1595 participants from Africa and 212 from Southeast Asia, compared artesunate-pyronaridine with artemether-lumefantrine (Tshefu 2010; Kayentao 2012). Only Kayentao 2012 included children aged under five years (232 children), of which only 15 were aged under one year. Follow-up was until day 42.

Treatment failure
At day 28, the proportion of participants with recurrent parasitaemia was lower in those treated with artesunate-pyronaridine compared to artemether-lumefantrine (PCR-unadjusted treatment failure; RR 0.60, 95% CI 0.40 to 0.90; two trials, 1650 participants, Analysis 1.1, Figure 3). However, after PCR-adjustment treatment failure, it was below 5% with both ACTs, with no differences between groups (PCR-adjusted treatment failure: two trials, 1650 participants, Analysis 1.1).
At day 42, there were no significant differences between artesunate-pyronaridine and artemether-lumefantrine for PCR-unadjusted (two trials, 1691 participants, Analysis 1.2) or PCR-adjusted treatment failure (two trials, 1472 participants, Analysis 1.2). PCR-adjusted treatment failure with artesunate-pyronaridine was marginally above 5% in one trial at this time-point (6.8%). Only two people on artesunate-pyronaridine and one on artemether-lumefantrine experienced early treatment failure (two trials, 1676 participants, Analysis 1.3).

Parasite clearance
Both trials reported that artesunate-pyronaridine cleared parasites from the peripheral blood quicker than artemether-lumefantrine. *Tshefu 2010* reported a slightly lower mean clearance time (MD 3.2 hours, 95% CI 4.38 to 2.02; one trial, 1170 participants; Analysis 1.4), and *Kayentao 2012* reported a slightly lower median clearance time (24.1 hours, 95% CI 24.0 to 24.1 with artesunate-pyronaridine versus 24.2 hours, 95% CI 24.1 to 32.0 with artemether-lumefantrine; *P* = 0.02, authors' own figures, one trial, 535 participants, Table 6). These differences are probably not clinically important.

Fever clearance
Fever clearance times were similar between groups in both trials. *Tshefu 2010* reported mean fever clearance time as marginally shorter following treatment with artesunate-pyronaridine than artemether-lumefantrine (MD 1.2 hours, 95% CI 2.38 to 0.02 hours, one trial, 1170 participants, Analysis 1.5), while *Kayentao 2012* reported equal median clearance times (8.1 hours with artesunate-pyronaridine versus 8.1 hours with artemether-lumefantrine, *P* = 0.049, authors' own figures, one trial, 535 participants, Table 6).

Gametocyte clearance and carriage
In *Tshefu 2010*, 8% of participants given artesunate-pyronaridine and 5% of those given artemether-lumefantrine had peripheral gametocytaemia at baseline. The mean time to gametocyte clearance was 10.5 hours shorter with artesunate-pyronaridine (MD 10.5 hours, 95% CI 12.4 to 8.60; one trial, 1170 participants, Analysis 1.6).

In *Kayentao 2012*, 13% of participants had gametocytes at baseline. No subsequent statistically significant differences in gametocyte carriage, or gametocyte development were reported (one trial, 532 participants, Table 6).

Serious adverse events
Neither trial reported any deaths. There were six serious adverse events in total with no significant difference between groups (0.3% with artesunate-pyronaridine versus 0.3% with artemether-lumefantrine; two trials, 1787 participants, Analysis 1.7).

Adverse events leading to withdrawal from treatment
There was no significant difference between groups in the proportion of participants withdrawn from the trial due to adverse events (2.3% with artesunate-pyronaridine versus 1.7% with artemether-lumefantrine; two trials, 1787 participants, Analysis 1.8).

Patient-reported symptoms
There were no significant differences in patient-reported symptoms between the two ACTs (two trials, 1807 participants, Analysis 1.9, Analysis 1.10). The trial authors reported symptoms of vomiting, headache, abdominal pain, vertigo, haematuria, upper abdominal pain, and anorexia.

Biochemical monitoring and adverse events
Both trials measured biochemical LFTs in all participants at baseline and on days three and seven (Kayentao 2012 also measured LFTs on day 28). Although the two trials used slightly different grading scales, there were no significant differences between groups in grade 3 or 4 liver toxicity by any of the measures used (two trials, 1807 participants, Analysis 1.11, Analysis 1.12).

Haematological monitoring and adverse events
In both trials the mean haemoglobin fell compared to baseline during the first seven days after starting treatment, before recovering by day 28 (two trials, 1807 participants, Analysis 1.12). At day seven the reduction in haemoglobin was greater with artesunate-pyronaridine but this is unlikely to be of clinical significance (MD -0.16, 95% CI -0.28 to -0.05; two trials, 1741 participants, Analysis 1.12). Kayentao 2012 also reported the occurrence of anaemia as an adverse event with no differences between groups (one trial, 535 participants, Analysis 1.13).

ECG monitoring and adverse events
Both trials conducted ECG monitoring at baseline, days 2, 7, 14 and 28. Tshefu 2010 reported two participants in each group having abnormal ECG readings and reported these as “mild”. Kayentao 2012 reported that there were "no post-baseline clinically important abnormal ECG results” (see Table 7).

Subgroup analysis
We have presented a subgroup analysis of PCR-adjusted treatment failure at day 28 by age of participants in Analysis 2.1. This demonstrates the paucity of data for the under-five age group. Further subgroup analyses by geographical region and country are in Analysis 2.2 and Analysis 2.3. Again, these demonstrate that the data remain severely underpowered to inform national decision-making. Primary outcome data was available for only 194 participants from East Africa, compared to 816 from West Africa, 490 from South-central Africa, and 175 from Asia.

Sensitivity analysis
We conducted a sensitivity analysis to explore the influence of different methods for analysing the primary outcome data. For PCR-unadjusted treatment failure, our primary analysis following the WHO guidelines for analysing trials of antimalarials was the least conservative (Analysis 3.1). The per-protocol and intention-to-treat analyses as presented by the trial authors, where missing data were considered treatment failure, were more conservative and the result did not reach statistical significance. For PCR-adjusted treatment failure, there were no substantial differences (Analysis 3.2).

We did not undertake a sensitivity analysis by risk of bias criteria as both of the included trials were at low risk of bias.

Comparison 2. Artesunate-pyronaridine versus artesunate plus mefloquine
Only one trial, enrolling 1033 participants from Asia and 238 from Africa, compared artesunate-pyronaridine versus artemether-lumefantrine (Rueangweerayut 2012). This trial excluded children under five years of age and follow-up was until day 42.

Treatment failure
At day 28, the proportion of participants with recurrent parasitaemia was lower in those treated with artesunate-pyronaridine compared to artesunate plus mefloquine (PCR-unadjusted treatment failure: RR 0.35, 95% CI 0.17 to 0.73; one trial, 1200 participants, Analysis 4.1). However, after PCR-adjustment treatment failure was below 5% with both ACTs with no differences between groups (one trial, 1187 participants, Analysis 4.1). At day 42, there were no statistically significant differences between artesunate-pyronaridine and artesunate plus mefloquine for PCR-unadjusted or PCR-adjusted treatment failure (one trial, 1146 participants, Analysis 4.2). At this time point, PCR-adjusted treatment failure was 5.8% with artesunate-pyronaridine versus 3.6% with artesunate plus mefloquine. One person treated with artesunate plus mefloquine experienced early treatment failure and developed cerebral malaria (one trial, 1103 participants, Analysis 4.3).

Parasite clearance
The mean parasite clearance time was slightly lower with artesunate-pyronaridine compared to artesunate plus mefloquine (MD 2.60 hours, 95% CI 4.94 to 0.26, one trial, 1259 participants, Analysis 4.4).
Fever clearance
Fever clearance time was similar between treatment arms (one trial, 1051 participants, Analysis 4.5).

Gametocyte clearance and carriage
Rueangweerayut 2012 only reported the mean time to gametocyte clearance for the 27 participants (13 on artesunate-pyronaridine versus 14 on artesunate plus mefloquine) who cleared their gametocytes within the first 72 hours. There was no difference between groups (one trial, 27 participants, Analysis 4.6).

Serious adverse events
Rueangweerayut 2012 did not report any deaths. There were nine serious adverse events in total with no significant difference between groups (0.7% with artesunate-pyronaridine versus 0.7% with artesunate plus mefloquine; one trial, 1271 participants, Analysis 4.7).

Adverse events leading to withdrawal from treatment
There was no significant difference between groups in the proportion of participants withdrawn from the trial due to adverse events (0.6% with artesunate-pyronaridine versus 0.9% with artesunate plus mefloquine; one trial, 1271 participants, Analysis 4.8).

Patient-reported symptoms
Rueangweerayut 2012 only reported symptoms if they occurred in at least 2% of patients. Dizziness was twice as common in those treated with artesunate plus mefloquine than with artesunate-pyronaridine (RR 0.46, 95% CI 0.28 to 0.78; one trial, 1271 participants, Analysis 4.9). The other reported symptoms were headache, cough, diarrhoea, vomiting, and myalgia.

Biochemical monitoring and adverse events
Biochemical tests for liver function monitoring were performed on all participants on days 0, 3, 7, 28, and 42. Artesunate-pyronaridine was associated with more participants recording elevated ALT and AST levels following treatment. For ALT, grade 2 toxicity (up to five times the upper limit of normal) was significantly higher with artesunate-pyronaridine (21/843 versus 0/417; RR 21.30, 95% CI 1.29 to 350.7; one trial, 1260 participants, Analysis 4.10), and grade 3 or 4 toxicity (> five times the upper limit of normal) approached statistical significance (15/843 versus 0/417; RR 7.41, 95% CI 0.98 to 55.98; one trial, 1260 participants, Analysis 4.11). There were no significant differences for other liver enzymes or bilirubin. No patients developed signs or symptoms of liver disease.

Haematological monitoring and adverse events
The mean haemoglobin level fell in both groups during the first seven days after starting treatment (Analysis 4.12) This drop was slightly larger with artesunate-pyronaridine compared to artesunate plus mefloquine (Day 3: MD -0.22 g/dL, 95% CI -0.36 to -0.08; one trial, participants, Analysis 4.12), but by day 28 mean haemoglobin levels were better than baseline in both groups. A similar pattern was observed with platelet counts (Analysis 4.13), and white cell counts (Analysis 4.14). However the differences were small and unlikely to be of clinical significance.

ECG monitoring and adverse events
Rueangweerayut 2012 conducted ECG monitoring on all participants in this trial but the timing and frequency of ECGs was unclear. The trial authors reported abnormal ECGs in under 1% of participants in both groups, and described all abnormalities as mild and transient (one trial, 1271 participants, Analysis 4.15).

Subgroup analysis
We did not conduct a subgroup analysis by age of participants as this trial did not include children aged under five years. We have presented subgroup analyses by geographical region and country in Analysis 5.1 and Analysis 5.2. The majority of PCR-adjusted treatment failures occurred in Thailand and Cambodia, with almost none elsewhere. They also demonstrate the paucity of data from Africa. Trial authors noted that participants enrolled in Pailin, Cambodia (an area of low-transmission for P. falciparum) had significantly longer parasite clearance times than people in the other trial sites; only 63% cleared parasites within 72 hours compared to 98% of participants in the other sites. Recrudescence at this site was reportedly higher with artesunate-pyronaridine than with artesunate plus mefloquine (10.2% versus 0%, P = 0.04; authors’ own figures).

Sensitivity analysis
We conducted a sensitivity analysis to explore the influence of different methods for analysing the primary outcome data. For PCR-unadjusted treatment failure, our primary analysis following the WHO guidelines for analysing trials of antimalarials was similar to the per-protocol analysis of the trial authors (Analysis 6.1). In the most conservative estimates the effect size was dramatically reduced and the estimate was no longer statistically significant (Analysis 6.1). For PCR-adjusted treatment failure we did not observe any substantial differences (Analysis 6.2). We did not perform any further sensitivity analyses as there was only one trial.
Part 3. Biochemical, haematological and ECG adverse events

In light of concerns about liver toxicity with pyronaridine, we included three additional RCTs of pyronaridine. Two trials compared pyronaridine alone to chloroquine (Ringwald 1996; Ringwald 1998) and one trial compared artesunate-pyronaridine to chloroquine (Poravuth 2011).

Biochemical monitoring and adverse events

The six trials reported abnormalities in liver functions in different ways. We assessed the adequacy of monitoring and completeness of results reporting in Table 5. Artesunate-pyronaridine was associated with a four-fold increase in the incidence of ALT and AST grade 3 or 4 toxicity (elevations > five times the upper limit of normal) (ALT: RR 4.17, 95% CI 1.38 to 12.62, AST: RR 4.08, 95% CI 1.17 to 14.26; four trials, 3528 participants, Analysis 7.1). Grade 3 or 4 toxicity measured with ALP and bilirubin were not substantially different. The three main efficacy trials also reported cases with both raised ALT (3 x ULN) and raised bilirubin (2 x ULN) as an indicator for drug induced liver injury (Tshefu 2010; Kayentao 2012; Rueangweerayut 2012). Only five of the 2052 participants in the artesunate-pyronaridine group and one of 1020 participants in the comparator groups had raised ALT and bilirubin. This difference was not statistically significant (three trials, 3072 participants, Analysis 7.2). Ringwald 1996 reported that 5/40 participants given pyronaridine had elevated bilirubin levels compared to 0/41 with chloroquine but did not give any further details.

Renal function tests

Three trials reported serum creatinine levels as a measure of renal function. At day 7, creatinine values were marginally lower in the pyronaridine-treated group than in those treated with comparator regimens (artemether-lumefantrine, artesunate+mefloquine, chloroquine) (MD -2.76, 95% CI -4.58 to -0.94; three trials, 1808 participants, Analysis 7.3).

Haematological monitoring and adverse events

Four trials reported mean haemoglobin on days 0, 3, 7, and 28, and in all four trials the mean haemoglobin fell in both groups between day 0 and day 7 before recovering by day 28 (four trials, 3534 participants, Analysis 7.4). At day 7 the mean haemoglobin was ¼ gram lower in those treated with artesunate-pyronaridine (MD -0.24 g/dL, 95% CI -0.32 to -0.16; four trials, 3394 participants, Analysis 7.4).

ECG monitoring and adverse events

Four trials conducted ECG monitoring and ECG adverse effects were rare in all four trials (see Table 7). Prolonged QT interval was less common with artesunate-pyronaridine than comparators (RR 0.25, 95% CI 0.07 to 0.90; three trials, 2991 participants, Analysis 7.5).
### ADDITIONAL SUMMARY OF FINDINGS

**Artesunate-pyronaridine compared to artesunate plus mefloquine for treating people with uncomplicated *P. falciparum* malaria**

**Patient or population:** People with uncomplicated *P. falciparum* malaria  
**Settings:** Malaria endemic areas in Africa and Asia  
**Intervention:** Artesunate-pyronaridine  
**Comparison:** Artesunate plus mefloquine

| Outcomes                        | Assumed risk | Corresponding risk | Relative effect (95% CI) | No of participants (trials) | Quality of the evidence (GRADE) |
|---------------------------------|--------------|--------------------|--------------------------|----------------------------|---------------------------------|
| **Treatment failure (Day 28)**  |              |                    | RR 0.35 (0.17 to 0.73)   | 1200 (1 trial)             | ⊕⊕⊕ moderate1,2,3,4              |
| PCR-unadjusted                  | 4 per 100    | 2 per 100 (1 to 2) |                          |                            |                                 |
| PCR-adjusted                    | 2 per 100    | 1 per 100 (0 to 2) | RR 0.38 (0.14 to 1.02)   | 1187 (1 trial)             | ⊕⊕⊕ moderate1,2,3,5              |
| **Treatment failure (Day 42)**  |              |                    | RR 0.86 (0.57 to 1.31)   | 1146 (1 trial)             | ⊕⊕⊕ moderate1,2,3,5              |
| PCR-unadjusted                  | 8 per 100    | 7 per 100 (5 to 11)|                          |                            |                                 |
| PCR-adjusted                    | 4 per 1000   | 6 per 100 (3 to 11)| RR 1.64 (0.89 to 3.00)   | 1116 (1 trial)             | ⊕⊕⊕ low1,2,3,5,6                 |
The **assumed risk** is the risk in the group treated with artesunate plus mefloquine in the single trial. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio.

| GRADE Working Group grades of evidence |
|----------------------------------------|
| **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. |
| **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. |
| **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. |
| **Very low quality:** We are very uncertain about the estimate. |

1. No serious risk of bias: This trial was well conducted with low risk of bias.
2. No serious inconsistency: Not applicable as only one trial.
3. Downgraded by one for serious indirectness: Of the 1271 children and adults aged greater than five years enrolled in this trial, 81.3% (1033) were enrolled and treated in trial sites in Asia (Cambodia, India, Thailand, Vietnam), and only 18.7% (237) in Africa (Bukina Faso, Ivory Coast, and Tanzania). Further studies in African children are necessary to fully generalize this result.
4. No serious imprecision: The result is statistically significant and the meta-analysis is adequately powered. However, it should be noted that this multicentred trial is underpowered to show equivalence at the country level. Not downgraded.
5. No serious imprecision: The result is of no clinically important differences between ACTs. However, it should be noted that this multicentred trial is underpowered to show equivalence at the country level. Not downgraded.
6. PCR-adjusted treatment failure was just above 5% with artesunate-pyronaridine in this trial.
7. For adverse events see the additional Summary of Findings table in Appendix 3.
Liver toxicity of pyronaridine compared to other antimalarials

**Patient or population:** People with uncomplicated falciparum malaria  
**Settings:** High and low-transmission settings for *P. falciparum* and *P. vivax* malaria  
**Intervention:** Pyronaridine alone or with an artemisinin-derivative  
**Comparison:** Another antimalarial

| Outcomes                                      | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | Number of participants (trials) | Quality of the evidence (GRADE) |
|-----------------------------------------------|-----------------------------------------|--------------------------|--------------------------------|-------------------|
| Assumed risk                                  | Corresponding risk                       | RR 4.17 (1.38 to 12.61)  | 3523 (4 trials)                | ⊕⊕⊕ moderate¹,²,³,⁴ |
| Comparator antimalarial                        | Pyronaridine alone or with artesunate    | RR 4.08 (1.17 to 14.26)  | 3528 (4 trials)                | ⊕⊕⊕ moderate¹,²,³,⁴ |

  | Elevated alanine aminotransaminase levels  |
  | Grade 3, 4 toxicity                        |
  | 2 per 1000                                  |
  | 10 per 1000 (3 to 30)                       |

  | Elevated aspartate aminotransferase levels |
  | Grade 3, 4 toxicity                        |
  | 2 per 1000                                  |
  | 8 per 1000 (2 to 29)                        |

  | Elevated alkaline phosphatase levels       |
  | Grade 3, 4 toxicity                        |
  | 2 per 1000                                  |
  | 1 per 1000 (0 to 5)                         |

  | Elevated bilirubin                         |
  | Grade 3, 4 toxicity                        |
  | 3 per 1000                                  |
  | 6 per 1000 (2 to 19)                        |

*The basis for the **assumed risk** (for example, the median control group risk across trials) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

1. **No serious risk of bias:** Trials were well conducted, although the data analysis was not clearly independent of the drug manufacturer in three trials.

2. **No serious inconsistency:** Statistical heterogeneity was low.

3. **Downgraded by one for serious indirectness:** Only 232 children aged less than five years were included in these trials.

4. **No serious imprecision:** The 95% CI is wide, and there are few events. Larger trials would be necessary to have full confidence in this result but not downgraded.

5. **No serious imprecision:** The 95% CI is narrow and probably excludes clinically important differences.

6. **Downgraded by one for serious imprecision:** The 95% CI is wide and includes no difference and clinically important effects.
DISCUSSION

Summary of main results

Artesunate-pyronaridine versus artemether-lumefantrine
In two multicentre trials, enrolling mainly older children and adults from west and south-central Africa, both artemether-pyronaridine and artemether-lumefantrine had fewer than 5% PCR adjusted treatment failures during 42 days of follow-up, with no differences between groups (low quality evidence). There were fewer new infections during the first 28 days in those given artemether-pyronaridine (moderate quality evidence), but no difference was detected over the whole 42 day follow-up (moderate quality evidence).

Artesunate-pyronaridine versus artesunate plus mefloquine
In one multicentre trial, enrolling mainly older children and adults from South East Asia, both artesunate-pyronaridine and artesunate plus mefloquine had fewer than 5% PCR adjusted treatment failures during 28 days follow-up (moderate quality evidence). PCR-adjusted treatment failures had risen to 6% by day 42 in those treated with artesunate-pyronaridine, but this was not substantially different to artesunate plus mefloquine (low quality evidence). Again, there were fewer new infections during the first 28 days in those given artesunate-pyronaridine, but no differences were detected over the whole 42 days (low quality evidence).

Adverse effects

Serious adverse events were rare in these trials with no statistically significant differences between artesunate-pyronaridine and the comparator ACTs. However, biochemical elevation of LFTs occurred four times more frequently with artesunate-pyronaridine than with the other antimalarials (moderate quality evidence).

Overall completeness and applicability of evidence

Artesunate-pyronaridine performed well in all three efficacy trials included in this review, with low levels of PCR-adjusted treatment failure at day 28 in all settings. All three trials were multicentre trials, with trial sites in 11 African countries and six countries in Asia, which broadens the applicability of the findings. However, the actual number of participants recruited from many trial sites was small and the trials were underpowered to evaluate either superiority or equivalence at country level. East Africa is particularly under represented, with only 232 participants from Kenya and Tanzania, and several of the West African countries recruited fewer than 100 participants.

The other major limitation on the applicability of these trials is the age of the participants. The trials predominantly recruited older children and adults. The combination appeared to be effective in these groups but little is known about the main target group; children aged under five years. These trials included only 232 children aged below five years compared to over 7000 in trials of dihydroartemisinin-piperaquine.

Notably, all three efficacy trials excluded people with known pre-existing liver disease, and one trial explicitly excluded those with raised LFTs at baseline. Screening of this kind may not be feasible in many malaria-endemic settings.

Quality of the evidence

We assessed the quality of the evidence in this review using the GRADE approach and presented it in two summary of findings tables for efficacy (Summary of findings for the main comparison; Summary of findings 2). The evidence that artesunate-pyronaridine is equivalent to established ACTs at preventing PCR-adjusted treatment failures was of moderate quality due to two main concerns:

1. Indirectness: The trials to date have largely been conducted in older children and adults, with exclusion of young children who bear the greatest burden and risks of malaria infection and illness.

2. Imprecision: The trials were not powered to examine the efficacy of artesunate-pyronaridine in individual regions or countries. This is problematic for national decision-making, and limits the wider generalizability of these results. Larger trials would be required to have full confidence in these results.

We also assessed the quality of evidence on comparative adverse effects and presented these in Appendix 2 and Appendix 3. In general the evidence was of moderate to low quality, and downgraded for similar reasons.

Potential biases in the review process

The objectives of the review changed significantly between the published protocol and final review. The basis for the change was to focus on only interventions of relevance to current malaria treatment policies (see Differences between protocol and review). We used standard methods described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) and complied with the Cochrane Collaboration's methodological standards for the conduct of new reviews of interventions (MECIR 2011).

We believe that we have identified all pyronaridine trials relevant to inform clinical decisions and policy regarding the use of pyronaridine combinations for the treatment of uncomplicated P. falciparum malaria. The three trials were all conducted under the auspices of the public-private partnership, Medicines for Malaria Venture, and Poong Pharmaceutical Company Ltd, Seoul, Republic of Korea.

Agreements and disagreements with other studies or reviews

Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria (Review)
We found one further systematic review of artesunate-pyronaridine published by authors from the Medicines for Malaria Venture (MMV), the co-developers of the artesunate-pyronaridine combination (Duparc 2013). The authors include four of the studies included here, plus one study we excluded as it was not randomized (Ramharter 2008), and one unpublished study. The authors conclude that 'Pyronaridine-arteresunate was well tolerated with no safety concerns with the exception of mostly mild transient rises in transaminases. Efficacy was high and met the requirements for use as first-line therapy'. While we agree that artesunate-pyronaridine shows promise as a further addition to the ACT combinations, we think it requires further studies in the main target group, children aged less than five years, before countries consider this as a first-line treatment.

AUTHORS’ CONCLUSIONS

Implications for practice
Artesunate-pyronaridine performed well in these trials compared to artemether-lumefantrine and artesunate-mefloquine, with PCR-adjusted treatment failure at day 28 below the 5% standard set by the WHO.

Artesunate-pyronaridine is well-tolerated, apart from transient gastrointestinal adverse effects, similar to other antimalarials. However, the potential for liver toxicity in people treated with artesunate-pyronaridine needs further investigation and will necessitate caution in using this treatment combination, particularly in people with pre-existing liver disorders.

Implications for research
Further efficacy and safety studies in African and Asian children are required before this combination could be established as a first or second-line treatment option.

ACKNOWLEDGEMENTS

We acknowledge the South Asian Cochrane Network & Centre; the Effective Health Care Research Programme Consortium (supported by the Department for International Development (DFID), UK); the Indian Council of Medical Research (ICMR) that funds the Prof. BV Moses & ICMR Centre for Advanced Research & Training in Evidence-Informed Healthcare at CMC Vellore. Thanks to Rajeev Aravindakshan for his initial contributions to the review; to Pascal Ringwald for unpublished data, and for additional references; Nitya Gogty, Mumbai, and editors of the Cochrane Infectious Diseases Group, for constructive comments as referees and editorial guidance; and Isabelle Borghini-Fuhrer, of Medicines for Malaria Venture, for a list of trials involving artesunate-pyronaridine. We are grateful to Yang Wu for translation of studies from Chinese. We are grateful to the considerable editorial support that ensured this review was completed and that the focus of this review reflected current issues in the treatment of malaria. The editorial base for the Cochrane Infectious Diseases Group is funded by UKaid from the UK Government for the benefit of developing countries.

REFERENCES

References to studies included in this review
Kayentao 2012 [published data only]
Kayentao K. Pyronaridine-artsunate versus artemether/ lumefantrine: efficacy in malaria patients with uncomplicated acute falciparum malaria: results of a pivotal Phase III trial. American Journal of Tropical Medicine and Hygiene. 2008; Vol. 79 (6 Suppl):114.
* Kayentao K, Doumbo OK, Pénéni LK, Offianan AT, Bhatt KM, Kimani J, et al. Pyronaridine-artsunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malaria Journal 2012;11:364.
NCT00541385. Pyronaridine artesunate 3:1 granule formulation vs. Coartem® crushed tablets in P. falciparum malaria pediatric patients. www.clinicaltrials.gov/show/NCT00541385 (accessed 30 November 2010).

Poravuth 2011 [published data only]
Duparc S, Borghini-Fuhrer I, Craft JC, Arbe-Barnes S, Miller RM, Shin CS, et al. Safety of pyronaridine/arteresunate in clinical trials in patients with uncomplicated Plasmodium vivax malaria: results of an integrated analysis. American Journal of Tropical Medicine and Hygiene. 2009; Vol. 81 Suppl: 51–100.

Duparc S, Borghini-Fuhrer I, Craft JC, Arbe-Barnes S, Miller RM, Shin CS, et al. Efficacy of pyronaridine/arteresunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One 2011;6(1):e14501.

S, Miller RM, Shin CS, et al. Efficacy of pyronaridine/arteresunate in clinical trials in patients with uncomplicated acute Plasmodium falciparum or Plasmodium vivax malaria: results of an integrated analysis. American Journal of Tropical Medicine and Hygiene. 2009; Vol. 81 Suppl: 51–100.

Acknowledgments

We acknowledge the South Asian Cochrane Network & Centre; the Effective Health Care Research Programme Consortium (supported by the Department for International Development (DFID), UK); the Indian Council of Medical Research (ICMR) that funds the Prof. BV Moses & ICMR Centre for Advanced Research & Training in Evidence-Informed Healthcare at CMC Vellore. Thanks to Rajeev Aravindakshan for his initial contributions to the review; to Pascal Ringwald for unpublished data, and for additional references; Nitya Gogty, Mumbai, and editors of the Cochrane Infectious Diseases Group, for constructive comments as referees and editorial guidance; and Isabelle Borghini-Fuhrer, of Medicines for Malaria Venture, for a list of trials involving artesunate-pyronaridine. We are grateful to Yang Wu for translation of studies from Chinese. We are grateful to the considerable editorial support that ensured this review was completed and that the focus of this review reflected current issues in the treatment of malaria. The editorial base for the Cochrane Infectious Diseases Group is funded by UKaid from the UK Government for the benefit of developing countries.

ARTESUNATE PLUS PYRONARIDINE FOR TREATING UNCOMPPLICATED Plasmodium falciparum Malaria (Review)
References to studies excluded from this review

Cai 1999 [published data only]
Cai X, Chen C, Zheng X, Wang X. Preliminary study of dihydroartemisinin for treatment of falciparum malaria. *Journal of Practical Parasitic Disease* 1999;7(3):104–5.

Chang 1997 [published data only]
Chang C, et al. Analysis on the results of antimalarial pyronaridine combined with sulfadoxine and pyrimethamine to falciparum malaria. *Journal of Practical Parasitic Disease* 1997;5(3):104–7.

Che 1987 [published data only]
Che LG, Huang KG, Yang HL, Yu L, Lin ZL, Huang R. Combined use of pyronaridine, sulfadoxine and primaquine in areas with chloroquine-resistant falciparum malaria. *Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chuang Bing Za Zhi [Chinese Journal of Parasitology and Parasitic Diseases]* 1987;5(3):194–6. [: ISSN: 1000–7423]

Che 1990 [published data only]
Che L, Huang K, Ying D, Yang H, Yang P. Efficacy of two combined therapies for treatment of chloroquine-resistant falciparum malaria. *Chinese Journal of Parasitic Disease Control* 1990;3(1):24–6.

Chen 1989 [published data only]
Chen L, Dai ZR, Qian YL, Ma ZM, Guo FC, Liao ZH, et al. Observation on the efficacy of combined use of some new antimalarials for the treatment of falciparum malaria in Hainan Province. *Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chuang Bing Za Zhi 1989;7(2):81–4.

Fleckenstein 2007 [published data only]
Fleckenstein L, Ramharter M, Kremsner PG. Pharmacokinetics of pyronaridine: Artesunate (Pyramax®) for treatment of children with acute uncomplicated *Plasmodium falciparum* malaria. *Tropical Medicine and International Health.* 2007; Vol. 12 Suppl 1:222.

Huang 1988 [published data only]
Huang ZS, Shao BR, Meng F, Zeng LH, Ye XY, Huang J, et al. Effects of combined dose of pyronaridine/sulfadoxine/pyrimethamine on falciparum malaria. *Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chuang Bing Za Zhi [Chinese Journal of Parasitology and Parasitic Diseases]* 1988;6(4):285–8.

Huang 1989 [published data only]
Huang ZS, Feng Z, Meng F, Zeng LH, Lin X, Zhen Y, Xing QE, Guo RN. Therapeutic effect of pyronaridine in plain tablets and enteric coated tablets in falciparum malaria patients. *Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chuang Bing Za Zhi [Chinese Journal of Parasitology and Parasitic Diseases]* 1989;7(1):19–21.

Huang 1993 [published data only]
Huang Z, Shao B, Meng F, Shi X. Comparison of different regimen of pyronaridine and sulfadoxine combined with pyrimethamine in the treatment of malignant malaria. *Chinese Journal of Infectious Diseases* 1993;11(Suppl 3):175–7. [: ISSN: CN–00256187]

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)
Artemisinin plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

Huang 1996  [published data only]
Huang Z, Meng F, Fu S. Comparative studies on the treatment of drug-resistant falciparum malaria with single-dose or two-day regimen of pyronaridine/sulfadoxine-pyrimethamine plus primaquine. *Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi* [Chinese Journal of Parasitology and Parasitic Disease] 1996;14(4):314–7.

Liu 2002  [published data only]
Liu DQ, Lin SG, Feng XP, Chen WJ, Chen PL, Wu HM, et al. Study on treatment of multi-drug resistant Falciparum Malaria by using a combination of Dihydroartemisinin and Pyronaridine. *Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi* [Chinese Journal of Parasitology and Parasitic Disease] 2002;20(4):193–6.

Looareesuwan 1996  [published data only]
Looareesuwan S, Kyle DE, Vitavan C, Vanjanonta S, Wilairatana P, Werensdorfer WH. Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. *American Journal of Tropical Medicine and Hygiene* 1996;54(2):205–9.

Looareesuwan 2007  [published data only]
Looareesuwan S, Gaye O, Tijitra E, Bojang K, Socheat D, Poila P. Results of a randomized, multicentre, phase II, dose-ranging, clinical study to assess the safety and efficacy of fixed dose, orally administered pyronaridine and artesunate in adult patients with acute uncomplicated *Plasmodium falciparum* malaria. Abstracts of the 56th Annual Meeting of the American Society of Tropical Medicine and Hygiene. 2007:287.

NCT01156389  [published data only]
NCT01156389. Pyronaridine/Artesunate-Ritonavir drug drug interaction study. www.clinicaltrials.gov/show/NCT01156389. (accessed 09 August 2010).

No authors listed 1985  [published data only]
No authors listed. Efficacy of pyronaridine in 510 acute malaria cases. *Zhonghua Nei Ke Za Zhi* 1985;24(11):646-7, 700.

Pang 1989  [published data only]
Pang X, Xing Q, Lin K, Li X, Ou F, Ou L, et al. Efficacy of combined use of various preparations of pyronaridine, sulfadoxine and pyrimethamine in the treatment of falciparum malaria. *Chinese Journal of Parasitic Disease Control* 1989;2(3):167–8.

Piola 2008  [published data only]
Piola P, Fleckenstein L. Pharmacokinetics, clinical and safety outcomes of pyronaridine/artsunate treatment of acute *Plasmodium falciparum* malaria in Uganda. Abstracts of the 57th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Available at: www.astmh.org; American Society of Tropical Medicine and Hygiene. 2008: 252.

Piola P, Fleckenstein L. Pharmacokinetics, clinical and safety outcomes of pyronaridine/artsunate treatment of acute *Plasmodium falciparum* malaria in Uganda. *American Journal of Tropical Medicine and Hygiene* 2008; Vol. 79 Suppl:195.

Ramharter 2008  [published data only]
Ramharter M, Kurth F, Schreier AC, Nemeth J, Glasenapp Iv, Belard S, et al. Fixed-dose pyronaridine-artsunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. *Journal of Infectious Diseases* 2008;198(6):911–9.

Shao 1991  [published data only]
Shao BR, Huang ZS, Shi XH, Meng F. A 5-year surveillance of sensitivity in vivo of *Plasmodium falciparum* to pyronaridine/sulfadoxine/pyrimethamine in Diaoluo area, Hainan Province. *Southeast Asian Journal of Tropical Medicine and Public Health* 1991;22(1):65–7.

Tan 2008  [published data only]
Tan B, Fleckenstein IL, Yu KS, Jang IJ. Population pharmacokinetics of artesunate and dihydroartemisinin in healthy volunteers. *American Journal of Tropical Medicine and Hygiene*. 2008; Vol. 79 Suppl:100–49.

Wattanavijitkul 2008  [published data only]
Wattanavijitkul T, Fleckenstein L, Yu KS, Jang IJ. Multiple-dose population pharmacokinetics of pyronaridine in healthy volunteers. *American Journal of Tropical Medicine and Hygiene*. 2008; Vol. 79 Suppl:250–99.

Additional references

Auparakkitanon 2006
Auparakkitanon S, Chapoomrom S, Kuaha K, Chitacharitayvej T, Wilairat P. Targeting of hematin by the antimalarial pyronaridine. *Antimicrobial Agents and Chemotherapy* 2006;50(6):2197–200.

Basco 1992
Basco LK, Le Bras J. In vitro activity of pyronaridine against African strains of *Plasmodium falciparum*. *Annals of Tropical Medicine and Parasitology* 1992;86(5):447–54.

Boland 2003
Boland PB. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria [WHO/HTM/RBM/2003.50]. Geneva: World Health Organization, 2003.

Brice 2010
Brice BK, William Y, Lacina O, Félix Y, Hugues A, Léonardo B, et al. In vitro susceptibility of *Plasmodium falciparum* isolates from Abidjan, Côte d’Ivoire, to artesinin, chloroquine, dihydroartemisinin and pyronaridine. *Tanzanian Journal of Health Research* 2010;12(1):73–9.

Cattamanchi 2003
Cattamanchi A, Kyabazinga D, Hubbard A, Rosenthal PJ, Doresey G. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and gplur. *American Journal of Tropical Medicine and Hygiene* 2003;68 (2):133–9.

Chavalitshewinkoon-Petmitr 2000
Chavalitshewinkoon-Petmitr P, Wongkathiratt G. Auparakkitanon S, Wilairat P. Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors.
Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria (Review)

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

against multidrug-resistant Plasmodium falciparum in vitro. *Parasitology International* 2000;48(4):275–80.

Chen 1992
Chang C, Lin-Hua T, Jantanavivat C. Studies on a new antimalarial compound: pyronaridine. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1992;86(1):7–10.

Childs 1988
Childs GE, Häusler B, Milhous W, Chen C, Wimonwatrawate T, Pooyindee N, et al. In vitro activity of pyronaridine against field isolates and reference clones of Plasmodium falciparum. *American Journal of Tropical Medicine and Hygiene* 1988;38(1):24–9.

Croft 2010
Review of pyronaridine anti-malarial properties, product characteristics. Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein I, et al. *Malaria Journal* 2010;11:270.

Dondorp 2010
Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, et al. Artemisinin resistance: current status and scenarios for containment. *Nature Reviews Microbiology* 2010;8(4):272–80.

Duparc 2013
Duparc S, Borghini-Fuhrer I, Craft CJ, Arbe-Barnes S, Miller RM, Shin CS, et al. Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials. *Malaria journal* 2013;12(70):Epub 2013/02/26.

Fu 1991
Fu S, Xiao SH. Pyronaridine: a new antimalarial drug. *Parasitology Today* 1991;7(11):310–3.

GRADE 2008
Jan Brozek, Andrew Oxman, Holger Schünemann. GRADEpro. 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008.

Guyatt 2008
Guyatt GH, Oxman AD, Kunz R, Vist GE, Falek-Ytter Y, Schünemann HJ. What is “quality of evidence” and why is it important to clinicians?. *BMJ* 2008;336(7651):995–8.

Higgins 2011
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Jüni 2001
Jüni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. *BMJ* 2001;323(7303):42–6.

Kurth 2009
Kurth F, Pongratz P, Bélard S, Mordmüller B, Kremsner PG, Ramharter M. In vitro activity of pyronaridine against *Plasmodium falciparum* and comparative evaluation of antimalarial drug susceptibility assays. *Malaria Journal* 2009;8:79.

Kurtzhals 2008
Kurtzhals JAL. Importance of the long-acting partner drug in artemisinin-based combination therapy. *Expert Reviews in Pharmacology* 2008;1(6):75–7.

Lim 2010
Lim P, Wongvichanalai C, Chim P, Khim N, Kim S, Chy S, et al. Decreased in vitro susceptibility of *Plasmodium falciparum* isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007. *Antimicrobial Agents and Chemotherapy* 2010;54(5):2135–42.

MECIR 2011
Chandler J, Churchill R, Higgins J, Lasserson T, Tovey D. Methodological Expectations of Cochrane Intervention Reviews (MECIR). Methodological standards for the conduct of new Cochrane Intervention Reviews. Version 2.1, 8 December 2011. Available at: http://www.editorial-unit.cochrane.org/sites/editorial-unit.cochrane.org/files/uploads/MECIR˙conduct˙standards%202.1.pdf (accessed on 4 November 2012).

Naisbitt 1998
Naisbitt DJ, Williams DP, O'Neill PM, Maggs JL, Willock DJ, Pirmohamed M, et al. Metabolism-dependent neutrophil cytotoxicity of amodiaquine: A comparison with pyronaridine and related antimalarial drugs. *Chemical Research in Toxicology* 1998;11(12):1586–95.

Nosten 2007
Nosten N, White NJ. Artemisinin-based combination treatment of falciparum malaria. *American Journal of Tropical Medicine and Hygiene* 2007;77(Suppl 6):181–92.

Pradines 1998
Pradines B, Tall A, Parzy D, Spiegel A, Fusai T, Hienne R, et al. In-vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of *Plasmodium falciparum* in comparison with standard antimalarial agents. *Journal of Antimicrobial Chemotherapy* 1998;Vol. 42, issue 3:333–9.

Pradines 2010
Pradines B, Briolant S, Henry M, Oeuuvray C, Baret E, Amalvict R, et al. Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in *Plasmodium falciparum*. *Malaria Journal* 2010;9:339.

Price 2010
Price RN, Marfurt J, Chalfein F, Kenangalem E, Piera KA, Tjitra E, et al. In vitro activity of pyronaridine against
multidrug-resistant *Plasmodium falciparum* and *Plasmodium vivax*. *Antimicrobial Agents and Chemotherapy* 2010;54(12): 5146–50.

Qi 2002
Qi J, Yang CZ, Wang CY, Wang SB, Yang M, Wang JH. Function and mechanism of pyronaridine: a new inhibitor of P-glycoprotein-mediated multidrug resistance. *Acta Pharmacologica Sinica* 2002;23(6):544–50.

Review Manager 2011
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.

Ringwald 1999
Ringwald P, Eboumbou EC, Bickii J, Basco LK. In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against *Plasmodium falciparum*. *Antimicrobial Agents and Chemotherapy* 1999;43(6):1525–7.

Ruscoe 1998
Ruscoe JE, Tingle MD, O'Neill PM, Ward SA, Park BK. Effect of disposition of mannich antimalarial agents on their pharmacology and toxicity. *Antimicrobial Agents and Chemotherapy* 1998;42(9):2410–6.

Schünemann 2008
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1* [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2008.

Sinclair 2009
Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. *Cochrane Database of Systematic Reviews* 2009, Issue 3. [DOI: 10.1002/14651858.CD007483.pub2]

Vivas 2008
Vivas L, Rattray L, Stewart L, Bongard E, Robinson BL, Peters W, et al. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. *Acta Tropica* 2008;105(3):222–8.

White 1996
White NJ, Olliaro PL. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. *Parasitology Today* 1996;12(10): 399–401.

White 1999
White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al. Averting a malaria disaster. *Lancet* 1999; 353(9168):1965–7.

White 2002
White NJ. The assessment of antimalarial drug efficacy. *Trends in Parasitology* 2002;18(10):458–64.

White 2004
White NJ. Antimalarial drug resistance. *Journal of Clinical Investigation* 2004;113(8):1084–92.

WHO 2008
World Health Organization. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. http://whqlibdoc.who.int/publications/2008/9789241596305_eng.pdf (accessed 28 December 2010).

WHO 2010a
World Health Organization. Malaria treatment guidelines - 2nd edition. www.who.int/malaria/publications/atoz/9789241547925/en/index.html (accessed 20 November 2010).

WHO 2010b
World Health Organization. Global report on antimalarial drug efficacy and drug resistance 2000-2010. www.who.int/malaria/publications/atoz/9789241500470/en/index.html (accessed 28 December 2010).

WHO 2011
World Health Organization. Global plan for artemisinin resistance containment (GPARC). www.who.int/malaria/publications/atoz/9789241500838/en/index.html (accessed 4 February 2011).

WHO 2012
WHO Global Malaria Programme. World Malaria Report 2012. *World Malaria Report* 2012. Geneva: World Health Organization, 2012.

Yang 1997
Yang HL, Liu DQ, Yang YM, Huang KG, Dong Y, Yang PF, et al. In vitro sensitivity of *Plasmodium falciparum* to eight antimalarials in China-Myanmar and China-Lao PDR border areas. *Southeast Asian Journal of Tropical Medicine and Public Health* 1997;28(3):460–4. * Indicates the major publication for the study.

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)
### Characteristics of included studies  
**[ordered by study ID]**

#### Kayentao 2012

| Methods | **Trial design:** Randomized, multicentre, open-label, active-controlled, parallel group, non-inferiority trial  
Period of trial: November 2007 to November 2008 |
|---|---|
| Participants | **Number randomized:** 535  
**Age:** Three months to 12 years  
**Gender:** Both  
**Inclusion criteria:**  
1. Male or female patients ≤ 12 years of age.  
2. Body weight \(\geq 5\) kg and \(< 25\) kg with no clinical evidence of severe malnutrition (defined as a child whose weight-for-height is below -3 standard deviations or less than 70% of the median of the NCHS/WHO normalized reference values).  
3. Presence of acute uncomplicated *P. falciparum* mono-infection confirmed by: fever, as defined by axillary temperature \(\geq 37.5^\circ\)C or oral, tympanic, or rectal temperature \(\geq 38^\circ\)C, or documented history of fever in the previous 24 hours and positive microscopy of *P. falciparum* with parasite density between 1,000 and 200,000 asexual parasite count/µL of blood.  
4. Written informed consent, in accordance with local practice, provided by parent or guardian. If the parent or guardian is unable to write, witnessed consent is permitted according to local ethical considerations. Where possible, patient assent will be sought.  
5. Ability to swallow whole volume of liquid in which medication is suspended.  
6. Female patients of child-bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures to not become pregnant during the trial period.  
7. Ability and willingness to participate based on information given to parent or guardian and access to health facility. The patient is to comply with all scheduled follow-up visits until Day 42.  
**Exclusion criteria:**  
1. Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the WHO Criteria.  
2. Mixed *Plasmodium* infection.  
3. Severe vomiting, defined as \(> 3\) times in the 24 hours prior to inclusion in the trial or inability to tolerate oral treatment, or severe diarrhoea defined as \(\geq 3\) watery stools per day.  
4. Known history or evidence of clinically significant disorders such as cardiovascular (including arrhythmia, QTc interval greater or equal to 450 milliseconds), respiratory (including active tuberculosis), history of jaundice, hepatic, renal, gastrointestinal, immunological (including active HIV-AIDS), neurological (including auditory), endocrine, infectious, malignancy, psychiatric, history of convulsions, or other abnormality (including recent head trauma).  
5. Presence of significant anaemia, defined as Hb \(< 8\) g/dL.  
6. Presence of febrile conditions caused by diseases other than malaria.  
7. Known history of hypersensitivity, allergic or adverse reactions to pyronaridine,  
---

**Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)**

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
lumefantrine or artesunate or other artemisinins.
8. Patients with known disturbances of electrolytes balance, for example, hypokalaemia or hypomagnesaemia.
9. Use of any other antimalarial agent within two weeks prior to start of the trial as evidenced by reported patient history.
10. Pregnant or breast feeding.
11. Patients taking any drug which is metabolized by the cytochrome enzyme CYP2D6 (flecainide, metoprolol, imipramine, amitriptyline, clomipramine).
12. Received an investigational drug within the past four weeks.
13. Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (HCV Ab).
14. Known positive for HIV antibody.
15. LFTs [ASA T/ALA T levels] > 2.5 times upper limit of normal range.
16. Known significant renal impairment as indicated by serum creatinine of > 1.4 mg/dL.
17. Previous participation in any clinical trial with pyronaridine artesunate.

Interventions

Randomized 2:1 to

**Intervention:**
1. Fixed-dose oral artesunate-pyronaridine granule formulation (60:20 mg)* once daily for three days by direct observation (N = 355)

**Control:**
1. Artemether-lumefantrine crushed tablets (20/120 mg)** twice daily for three days by direct observation (N = 180)

*Artesunate-pyronaridine was given once daily: 5 kg to < 9 kg, one sachet; 9 kg to <17 kg, two sachets; 17 kg to < 25 kg, three sachets (dose range 6.7/2.2 to 13.3/4.4 mg/kg/dose mixed in water, milk, or soup)

**Artemether-lumefantrine was given twice daily crushed and shaken to a suspension in 50 mL water: 5 kg to < 15 kg, one tablet; 15 kg to < 25 kg, two tablets (dose range 1.3/8.0 to 4.0/24.0 mg/kg/dose); the second day 0 dose was 8 hrs after the first dose, the first Day 1 dose was 24 hrs after the first Day 0 dose, with all subsequent doses 12 hrs apart

Outcomes

**Primary outcomes:**

*Efficacy*
1. PCR-corrected adequate clinical and parasitological response rate (ACPR) on Day 28

*Safety*
1. Adverse events (categorized using MedDRA Version 10.1)
2. Laboratory abnormalities (graded using the Division of Microbiology and Infectious Diseases Toxicity Scale (February 2003))

**Secondary outcomes:**
1. Day 28 crude (non-PCR corrected) ACPR
2. Day 42 PCR-corrected and crude ACPR
3. Parasite clearance time (time from first dose until aparasitaemia (two consecutive negative readings taken between 7 and 25 hours apart))
4. Fever clearance time (time from first dose to apyrexia (two consecutive normal readings taken between 7 and 25 hours apart))

**Exploratory efficacy outcomes:**
1. Proportion of patients with gametocytes

**Outcomes reported but not used in quantitative synthesis in this review**

1. ECG abnormalities
2. Proportion of patients with parasite clearance or fever clearance on days 1, 2, and 3
3. Gametocyte density
4. Gametocyte clearance time (defined as for parasite clearance time)

**Notes**

**Countries of recruitment:** Six countries in Africa (96.3%; Burkina Faso, Democratic Republic of Congo, Gabon, Côte d’Ivoire, Kenya, and Mali) and one in Asia (3.7%; The Philippines)

**Setting:** Local hospitals and clinics at seven centres in six countries in Africa and one in the Philippines

**Funding:** Medicines for Malaria Venture, Poong Pharmaceutical Company Ltd, Seoul, Republic of Korea

**Endemicity:** High

**Duration of follow-up:** 42 days

**Comment:**
- Age range of participants: 45% in Py-AS aged ≤ 5 years, 3.4% < 1 year; 40% in AL6 aged ≤ 5 years, 1.7% < 3 years
- Sample size estimation: For the primary efficacy outcome the sample size was estimated to have 91% power to reject the null hypothesis (day-28 cure rate ≤ 90%) using a 1-sided exact binomial test with a nominal significance level of 2.5%; for the main secondary outcome comparing efficacy to artemether-lumefantrine, the sample provided > 99% power to demonstrate non-inferiority of artesunate-pyronaridine versus artemether-lumefantrine with a non-inferiority limit of 10%.
- Recrudescence was defined with PCR as at least one matching allelic band in the three *P. falciparum* genes *msp1*, *msp2*, and *glurp* between baseline and post-day 7 samples
- Treatment failures were classified as early treatment failure, late clinical failure, and late parasitological failure according to WHO criteria (Bloland 2003).
- Definition of Grade 3 and 4 toxicity: ALT and AST grade 3 toxicity was 10 to 15 times the upper limit of normal, and grade 4 toxicity was > 15 times the upper limit of normal. Total bilirubin grade 3 toxicity was 3.0 to 7.5 times the upper limit of normal.

**Trials registration:** ClinicalTrials.gov: identifier NCT00541385

---

Risk of bias

| Bias                              | Authors’ judgement | Support for judgement |
|-----------------------------------|--------------------|-----------------------|
| Random sequence generation (selection bias) | Low risk           | Quote from report: "The sponsor provided a computer-generated randomisation schedule. Patients were randomised 2:1 to artesunate-pyronaridine or artemether-lumefantrine" |
| Allocation concealment (selection bias) | Low risk           | Quotes from report: "Individually numbered treatment packs of similar appearance were masked on allocation." Quote from report: "The study sponsor remained blinded to treatment allocation" |
| Source | Bias Type | Risk | Description |
|--------|-----------|------|-------------|
| Kayentao 2012 (Continued) | Blinding (performance bias and detection bias) Objective outcomes: parasitological and biochemical | Low risk | Quote from report: "Drugs were given open-label". Quote from report: "Clinical assessments and drug administration were performed by different clinical personnel." Comment: Unlikely to have introduced detection bias for objective outcomes |
| | Blinding (performance bias and detection bias) Subjective outcomes: adverse events | Low risk | Comment: Outcome assessors were blinded to allocation, and were not involved in drug administration |
| | Incomplete outcome data (attrition bias) All outcomes | Low risk | Comment: The participants randomized were accounted for in the trial report and missing data and participants were not differentially distributed in treatment arms, or substantial |
| | Selective reporting (reporting bias) | Low risk | Comment: This trial was prospectively registered and though some changes in the timing of assessments were noticed between the protocol and the trial report, these are not of much importance; all other pre-stated outcomes were adequately reported |
| | Other bias | Low risk | Quote: “The sponsors and study site principal investigators developed the protocol, interpreted the data and developed the report. The study sponsors were responsible for data collection and statistical analysis. All authors had access to the primary data, take responsibility for data reporting accuracy and completeness” Comment: Three of the authors are employed by the study sponsors. However, the report states the study sponsors were blind to treatment allocation, and the final report appears to have been approved by all authors |
**Methods**

**Trial design:** Randomized, multicentre, double-blind, double-dummy, parallel-group, non-inferiority trial  
**Period of trial:** March 2007 to March 2008

**Participants**

**Number randomized:** 456  
**Age range:** Seven years to 60 years  
**Gender:** Both  
**Inclusion criteria:**  
1. Aged three years to 60 years  
2. Fever or documented fever in the previous 24 hrs  
3. Microscopically confirmed mono-infection with *P. vivax* (parasite density: $\geq 250 \mu\text{L}$ with at least 50% asexual parasites/$\mu\text{L}$ blood)  
4. Body weight 20 kg to 90 kg  
5. Written informed consent from participants or their guardians, with assent from children able to understand the trial  
6. Able to swallow oral medication  
7. Willingness to comply with protocol  
8. Negative urine test for pregnancy and agreement to practice contraception (women of child-bearing potential)  
**Exclusion criteria:**  
1. Complicated or severe malaria  
2. Mixed infections  
3. Anaemia ($< 8 \text{ g/dL}$); severe vomiting  
4. Clinical severe malnutrition  
5. Hepatic or renal impairment  
6. Presence or history of clinically important disorders  
7. Hypersensitivity or allergy to trial drugs or excipients  
8. Use of antimalarials in the previous two weeks by testing; or use of any trial drug for previous four weeks  
9. Treatment with any drug metabolised by CYP2D6; pregnant and lactating women  
10. Previous inclusion in a similar trial of artesunate-pyronaridine

**Interventions**

**Intervention:** Artesunate-pyronaridine tablets (180:60 mg) once daily for three days* ($N = 228$)  
**Control:** Chloroquine based on body weight once daily for three days** ($N = 228$)  
*For artesunate-pyronaridine, drug dose was based on body weight: 20 kg to 25 kg, 1 tablet; 26 kg to 44 kg, two tablets; 45 kg to 64 kg, three tablets; and 65 kg to 90 kg, four tablets, (giving a artesunate-pyronaridine target dose of between 7.2:2.4 mg/kg and 13.8:4.6 mg/kg).  
**The chloroquine dose for adults was 620 mg on Day 0 and 1, and 310 mg on Day 2. The chloroquine target dose for children was 10 mg/kg on Days 0 and 1, and 5 mg/kg on Day 2

**Outcomes**

**Outcomes used in this review:**  
1. Adverse events affecting liver functions (Grade 3 and 4 toxicity: aspartate amino transferase, alanine amino transferase, bilirubin)  
**Outcomes reported but not used in this review:**  
1. Cure rates on days 14, 21, 35, and 42  
2. Treatment failure
## Notes

**Countries of recruitment:** Four countries in Asia (Cambodia, India, Indonesia, and Thailand)

**Setting:** Five local hospitals in four countries in Asia

**Funding:** Medicines for Malaria Venture, Poong Pharmaceutical Company Ltd, Seoul, Republic of Korea

**Endemicity:** High

**Duration of follow-up:** Until day 42

**Comment:**
- Age range of participants: 14 (6.1%) in the Py-AS arm and 13 (5.7%) in the chloroquine arm were < 12 years of age
- Sample size estimation: Assuming a day-14 cure rate of 95%, and a dropout rate of 10%, the sample size was estimated to provide > 99% power to demonstrate non-inferiority of artesunate-pyronaridine compared to chloroquine
- G6PD deficiency was detected in 16/228 (7.0%) of patients in each treatment group
- Primaquine was administered to 185/228 (87.3%) patients in the artesunate-pyronaridine group and 181/228 (85.4%) in the chloroquine group starting on Day 28 of the trial
- Definitions of Grade 3 and 4 toxicity: Grade 3 toxicity: Hb (65 to 79 g/L); ALT/AST/ALP (5.1 to 10.6 times the upper limit of normal); TBIL (2.6 to 5.6 times the upper limit of normal). Grade 4 toxicity: ALT/AST (>10.6 times the upper limit of normal).

**Trials registration:** ClinicalTrials.gov identifier: NCT00440999

### Risk of bias

| Bias                                | Authors' judgement | Support for judgement                                                                 |
|-------------------------------------|--------------------|---------------------------------------------------------------------------------------|
| Random sequence generation (selection bias) | Low risk           | Quote from report: “A computer-generated randomisation scheme was provided by the sponsor. Subjects were randomised 1:1 within each study site in blocks of six.” |
| Allocation concealment (selection bias) | Low risk           | Quotes from report: “Subjects were randomised...to receive either artesunate-pyronaridine plus matching chloroquine placebo or oral chloroquine plus matching artesunate-pyronaridine placebo”. “The subject was allocated an individually numbered treatment pack, which contained sufficient tablets for 3 days’ therapy plus an overage bottle containing tablets in case the subject vomited the first dose. All study investigators, laboratory technicians and pa- |
Patients were blind to treatment assignment. “Sealed opaque envelopes containing the study medication assignment for each subject were provided to the study site investigator for use in an emergency; no code breaks were required.”

| Bias Type                                    | Risk Level | Description                                                                                                                                 |
|----------------------------------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Blinding (performance bias and detection bias) Objective outcomes: parasitological and biochemical | Low risk   | Quotes from report: “Study drugs were administered on a double-blind, double-dummy basis. The investigator calculated the appropriate dose and study drug was administered by a different member of staff, designated by the investigator”. “Active drugs and placebos were packaged similarly.” |
| Blinding (performance bias and detection bias) Subjective outcomes: adverse events | Low risk   | Comment: The double-blind, double-dummy design used minimized the risk of performance and detection bias. Pruritis that is common with chloroquine could potentially compromise blinding but was not reported in > 2% of participants |
| Incomplete outcome data (attrition bias) All outcomes | Low risk   | Quote from report: “Most patients (83.3%) completed the study. A similar number of patients withdrew prematurely from the study in both groups.” Comment: The results were assessed in per-protocol and intention-to-treat analyses |
| Selective reporting (reporting bias)          | Low risk   | Comment: This trial was prospectively registered and reported all pre-stated outcomes adequately |
| Other bias                                    | Low risk   | Quote from report: “The sponsors and study site principal investigators developed the protocol, interpreted the data and developed the report. The study sponsors were responsible for data collection and statistical analysis. All authors had access to the primary data, take responsibility for data reporting accuracy and completeness and had responsibility for the final decision to submit for publication.” Comment: Some of the authors are employed by the trial sponsors but all authors had access to data and assumed responsibility for reporting accuracy |
### Methods

**Trial design:** Randomized, parallel group, active controlled trial

**Duration of trial:** Recruitment: April 1994 to May 1995

### Participants

- **Number randomized:** 96
- **Age:** 15 to 64 years
- **Gender:** 42 males; 54 females

#### Inclusion criteria:

1. Acute falciparum malaria with fever within the past 24 hrs or a temperature above 37.5 °C at the time of consultation
2. Over 5000 asexual parasites/µL
3. No signs and symptoms of severe and complicated malaria
4. No recent self-medication

#### Exclusion criteria:

1. Pregnant women
2. Mixed infections

### Interventions

**Intervention**

1. Pyronaridine: 32 mg/kg in divided doses over 3 days* (N = 47)

**Control**

2. Chloroquine: 25 mg/kg in divided doses over 3 days (N = 49)

* Pyronaridine dose: 16 mg/kg on day 1 and 8 mg/kg on days 2 and 3
* Chloroquine dose: 10 mg/kg on days 1 and 2 and 5 mg/kg on day 3

### Outcomes

#### Outcome used in this review:

1. Numbers with elevated transaminase enzyme levels at day 7 in those with normal baseline values (extent of elevation not reported)

#### Outcomes reported but used in this review:

1. Fever clearance
2. Parasite clearance
3. Early treatment failure
4. Parasitaemia on day 14
5. Gametocyte carriage at day 14
6. Adverse events.
7. Haematological (haemoglobin, counts); biochemical mean (liver function values, creatinine, urea).
8. In vitro drug sensitivity

### Notes

**County of recruitment:** Cameroon

**Setting:** Nlongkak Catholic missionary dispensary in Yaounde; outpatients; all doses of drugs supervised

**Source of funding:** French Ministere de la Cooperation (Grant 93A43); pyronaridine was supplied by the Institute of Parasitic Diseases, Chinese Academy of Preventive Medicine, Shanghai, China

**Endemicity:** High; 50% to 60% chloroquine resistant

**Duration of follow-up:** Until day 14 (for all, and in four participants until day 238)

**Comment:** Proportions with normal transaminase enzyme levels at baseline that were elevated in each arm at day 7 provided in the text of results were used for analysis; the extent of elevation was not reported. The values were normal on day 14 on whom the levels were
Repeated, but the numbers in whom these were repeated are not reported

**Trials registration:** Nil

## Risk of bias

| Bias                                      | Authors’ judgement | Support for judgement                                                                                                                                 |
|------------------------------------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Random sequence generation (selection bias) | Low risk           | Quote from report: “Patients were randomly assigned in blocks” Comment: Unpublished information provided through correspondence with authors reveal that randomisation was done “in blocks of 10” |
| Allocation concealment (selection bias)  | Low risk           | Comment: Not mentioned in report. Quote from correspondence with senior author: “central randomisation was used”                                          |
| Blinding (performance bias and detection bias) Objective outcomes: parasitological and biochemical | Low risk           | Comment: Not mentioned in report. Quote from correspondence: “It was blinded but the tablets were different and many patient treated with CQ suffered of pruritus” Comment: Blinding was probably compromised but risk of bias due to this is unlikely to have affected the biochemical outcomes assessing liver functions that were used in this review |
| Blinding (performance bias and detection bias) Subjective outcomes: adverse events | Low risk           | Comment: As above. Comment: Blinding was probably compromised and risk of bias due to this may have affected the reporting or detection of some subjective adverse events, but only biochemical liver functions were used in this review |
| Incomplete outcome data (attrition bias) All outcomes | Low risk           | Quote from report: “After enrolment, six patients treated with chloroquine and five patients treated with pyronaridine were lost to follow-up. Two additional patients from each group were withdrawn because of self-medication with quinine” Comment from correspondence: “Drop out were mainly lost to follow-up and most of- ten after the patients were cured. We do not think that it was related to intervention.” Comment: Equal numbers dropped out from each intervention arm and hence are |
Ringwald 1996  (Continued)

| **Selective reporting (reporting bias)** | Low risk | unlikely to have differentially influenced liver toxicity outcomes used in this review |
|-----------------------------------------|----------|------------------------------------------------------------------------------------------|
| **Other bias**                          | Unclear risk | Comment: The trial was not prospectively registered and the trial protocol was not available, but all outcomes stated in methods were reported |

Ringwald 1998

**Methods**

- **Trial design:** Randomized, parallel group, active controlled trial
- **Duration of trial:** 1996; duration not stated

**Participants**

- **Number randomized:** 88
- **Age:** Children in the age range five to 15 years
- **Gender:** Both
- **Inclusion criteria:**
  1. Fever at consultation or within previous 24 hrs
  2. Monoinfection with *P. falciparum* (parasite density > 5000 asexual parasites/µL blood)
  3. Easy access to health services
  4. Informed consent of parent or guardian
- **Exclusion criteria:**
  1. History of self-medication with antimalarials (confirmed by negative urine test)
  2. Signs and symptoms of severe or complicated malaria
  3. Severe anaemia (haemoglobin < 5.0 g/dL)
  4. Moderate or severe malnutrition

**Interventions**

- **Intervention:** 1. Pyronaridine: 32 mg/kg (N = 48) (16 mg/kg on day 0, in two divided doses; 8 mg/kg on days 1 and 2)
  2. Chloroquine: 35 mg/kg (N = 48) (10 mg on days 0 and 1; 5 mg on day 2)
- **Control:**

**Outcomes**

- **Outcomes used in this review:**
  Proportions with normal serum aspartate aminotransferase (AST) enzyme levels at baseline and two-fold or greater elevations at day 7
- **Outcomes reported but not used in this review:**
  1. Fever clearance (defined as the time from onset of treatment until rectal temperature remained below 37.5 °C).
  2. Parasite clearance (the time required to obtain the first negative thick blood smear with subsequent blood smears remaining negative until day 14).
  3. Parasitaemia on day 14
### Early treatment failure

1. Early treatment failure
2. Fever clearance time
3. Parasite clearance time
4. Adverse events
5. Others

### Other measurements

6. Haematological (Haemoglobin, counts); biochemical (mean liver functions values, creatinine, urea).
7. In vitro drug sensitivity
8. Gametocyte clearance
9. Others

### Notes

- **Country of recruitment:** Cameroon
- **Setting:** Nlognkak Catholic missionary dispensary in Yaoundé; outpatients. All interventions were supervised
- **Source of funding:** Pyronaridine provided by Institute of Parasitic Diseases, Chinese Academy of Preventive Medicine, Shanghai, China
- **Endemicity:** High; 50 to 60% chloroquine resistant
- **Duration of follow-up:** Until day 14
- **Comment:** Proportions on whom transaminase enzyme levels were repeated on day 14 and in those in whom they were normal were not reported

### Risk of bias

| Bias                                           | Authors' judgement | Support for judgement |
|------------------------------------------------|--------------------|-----------------------|
| Random sequence generation (selection bias)    | Low risk           | Quote from report: “Patients were randomly assigned in blocks” |
| Allocation concealment (selection bias)        | Low risk           | Comment: Not mentioned in trial report. Quote from correspondence with authors: “central randomisation was used.” |
| Blinding (performance bias and detection bias) | Low risk           | Comment: Not mentioned in report. Quote from correspondence: “It was blinded but the tablets were different and many patient treated with CQ suffered of pruritus” |
| Objective outcomes: parasitological and biochemical | Low risk           | Comment: Blinding was probably compromised but risk of bias due to this may have affected the reporting of liver enzymes that was the outcome used in this review |

| Bias                                           | Authors' judgement | Support for judgement |
|------------------------------------------------|--------------------|-----------------------|
| Blinding (performance bias and detection bias) | Low risk           | Comment: As above. Comment: Blinding was probably compromised and risk of bias due to this may have |
**Ringwald 1998 (Continued)**

| Bias Type                                      | Risk  | Comment                                                                                                                                 |
|-----------------------------------------------|-------|----------------------------------------------------------------------------------------------------------------------------------------|
| Incomplete outcome data (attrition bias)      | Low risk | Quote from report: “Of the 88 patients enrolled in the study, 81 completed the 14-day follow-up (dropout rate, 8%). Three patients in the pyronaridine group and four in the chloroquine group were lost to follow-up.”
| All outcomes                                  |       | Quote from correspondence: “Drop out were mainly lost to follow-up and most often after the patients were cured. We do not think that it was related to intervention.”
| Comment: Equal numbers dropped out from each intervention arm and hence are unlikely to have differentially influenced the outcomes used in this review |
| Selective reporting (reporting bias)          | Low risk | Comment: The trial was not prospectively registered and the trial protocol was not available, but all outcomes stated in methods were reported |
| Other bias                                    | Unclear risk | Comment: The proportions re-tested for liver transaminases at day 14 and the proportions in whom they were normal were not reported |

**Rueangweerayut 2012**

**Methods**

- **Trial design:** Randomized, multicentre, parallel-group, double-blind, double-dummy, non-inferiority trial
- **Duration of trial:** January 2007 to October 2008

**Participants**

- **Numbers randomized:** 1271
- **Age:** Four years to 59 years
- **Gender:** Both
- **Inclusion criteria:**
  1. Fever in the last 24 hrs
  2. Microscopically confirmed mono-infection with *P. falciparum* (parasite density: 1000 to 100,000 asexual parasites/µL of blood)
  3. Age range 3 years to 60 years
  4. Body weight 20 kg to 90 kg
  5. Written informed consent from participants or their guardians, with assent from children able to understand the trial
  6. Able to swallow oral medication
  7. Willingness to comply with protocol
8. Negative urine test for pregnancy and agreement to practice contraception (women of child-bearing potential)

**Exclusion criteria:**
1. Complicated or severe malaria
2. Mixed infections
3. Anaemia (< 8 g/dL)
4. Severe vomiting
5. Severe malnutrition
6. Any clinically significant illness other than malaria
7. Hepatic or renal impairment
8. Known hypersensitivity or allergy to trial drugs
9. Use of antimalarials in the previous two weeks; or use of any trial drug for previous four weeks
10. Treatment with any drug metabolised by CYP2D6
11. Pregnant and lactating women
12. Previous participation in the trial

**Interventions**
Randomized in a 2:1 ratio to:

**Intervention:**
1. Artesunate-pyronaridine combination (7.2: 2.4 mg/kg respectively) once a day for three days (N = 848)

**Control:**
2. Mefloquine plus artemether combination (6.2 to 12.5 mg/kg and 2.2 to 5.0 mg/kg respectively) once a day for three days (N = 423)

**Outcomes**

**Primary outcome**
1. PCR-corrected adequate clinical and parasitological response rate (ACPR; absence of parasitaemia, irrespective of axillary temperature, without previous treatment failure) at day 28

**Secondary outcomes**
1. Adequate clinical and parasitological response rate without correction for reinfection at day 28
2. Parasite clearance time (time from first dose to first negative parasite reading for two consecutive readings 7 to 25 hours apart)
3. Fever clearance time (time from first dose to being afebrile for two consecutive readings 7 to 25 hours apart)
4. Proportion of patients who had cleared parasites at day 1, 2, and 3
5. Proportion of patients without fever at days 1, 2, and 3

**Exploratory efficacy outcomes**
1. PCR-corrected and uncorrected ACPR rate on day 42
2. Gametocyte carriage

**Safety outcomes**
Incidence of adverse events

*Outcomes reported but not used in quantitative synthesis*
1. Gametocyte clearance time
2. Results of urinalysis and other clinical laboratory tests
3. Results of electrocardiography
Notes

**Countries of recruitment:** Four countries in Asia (Cambodia, India, Thailand, and Vietnam; 81.3%); and three countries in Africa (Bukina Faso, Ivory Coast, Tanzania; 18.7%)

**Setting:** Local hospitals and health centres

**Endemicity:** High in most sites

**Source of funding:** Primary sponsor: Medicines for Malaria Venture; secondary sponsor: Shin Poong Pharmaceuticals

**Duration of follow-up:** Until day 42

**Comments:**
- Age range of participants: 122 (14.4%) in the As-Py arm and 68 (16.1%) in M-AS arm were < 12 years of age
- Sample size estimation: Assuming an APCR rate to both treatments of 93%, and a non-inferiority limit of 5%, and a dropout rate of 10%, with two patients receiving pyronaridine-artesunate for every one receiving mefloquine plus artesunate, the sample size was estimated to provide 90% power to demonstrate the non-inferiority of pyronaridine-artesunate with a two-sided 95% CI.
- Recrudescence differentiated from re-infection by PCR genotyping for *P. falciparum* genes merozoite surface proteins 1 and 2 (msp1, msp2), and glutamate-rich protein (glurp) with at least one matching allelic band in all markers at baseline and after day 7
- Grade 3 and 4 toxicity: Adults: Alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase grade 3 toxicity was 5.1 to 10 times and grade 4 toxicity was > 10 times the upper limit of normal. Total bilirubin grade 3 toxicity was 2.6 to 5 times and grade 4 toxicity was > 5 times the upper limit of normal. Children: Alanine aminotransferase, and aspartate aminotransferase, grade 3 toxicity was 10 to 15 times and grade 4 toxicity was > 15 times the upper limit of normal. Total bilirubin grade 3 toxicity was 3.0 to 7.5 times and grade 4 toxicity was > 7.5 times the upper limit of normal.

**Trials registration:** ClinicalTrials.gov identifier: NCT00403260

---

**Risk of bias**

| Bias                                         | Authors’ judgement | Support for judgement |
|----------------------------------------------|--------------------|-----------------------|
| Random sequence generation (selection bias)  | Low risk           | Quote from report: “Averion International (now part of Aptiv Solutions) provided the computer generated randomisation schedule.” Quote from trial protocol, “Patients who meet all entry criteria and present no exclusion criteria will be randomised to receive either pyronaridine artesunate or mefloquine plus artesunate in a 2:1 ratio according to the randomisation scheme provided by the sponsor. Patients will be assigned, in ascending order, a randomisation number according to the order recruited.” |

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
| Bias Type                        | Risk Level | Comment                                                                                                                                 |
|---------------------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Allocation concealment (selection bias) | Low risk   | Quote from trial protocol: “The patient will be allocated an individual numbered treatment pack which contains sufficient tablets for 3 days therapy plus an overage bottle containing tablets in case the patient vomits the first dose.”  
Quote from trial protocol, “Clinical study material will be administered using a third-party single blind design. That is: after determining the eligibility criteria, the investigator shall communicate the patient randomisation number to a qualified study team member (third party) who is not performing clinical assessments. The third party will open the study package and administer the correct amount of tablets as instructed by the investigator to ensure unbiased randomisation.” |
| Blinding (performance bias and detection bias) | Low risk   | Quote from report: “Drugs were administered by an investigator who was aware of group assignments; clinical and parasitological assessments were performed by investigators who were aware of group assignments”  
Comment: The use of blinded outcome assessors minimised the risk of detection bias for objective outcomes |
| Blinding (performance bias and detection bias) | Low risk   | Quote from report: “Clinical and parasitological assessments were performed by investigators who were not aware of group assignments.”  
Comment: Most of the outcomes used in this review were objective outcomes, so participant’s knowledge of treatment allocation is not likely to introduce bias |
| Incomplete outcome data (attrition bias) | Low risk   | Comment: Data regarding all participants recruited provided in results for all outcomes |
| Selective reporting (reporting bias)    | Low risk   | Comment: The trial was prospectively registered and the protocol was also available; all pre-stated outcomes were reported adequately |
### Rueangweerayut 2012 (Continued)

| Other bias | Low risk | Quote from report: “The study was designed by the authors and the study sponsors, the Medicines for Malaria Venture and Shin Poong Pharmaceutical Company. All the authors vouch for the completeness and accuracy of the data and the analysis and for the fidelity of the study to the protocol”
Comment: Some of the authors are employed by the trial sponsors but all authors had access to data and assumed responsibility for reporting accuracy

### Tshefu 2010

| Methods | **Trial design:** Randomized, multi centre, parallel-group, double-blind, double-dummy, non-inferiority trial
**Period of trial:** January 2007 to April 2008

| Participants | **Number randomized:** 1272
**Age range:** Five to 60 years
**Gender:** Both

**Inclusion criteria:**
1. Age between 3 to 60 years
2. Fever in the last 24 hrs
3. Microscopically confirmed mono-infection with *P. falciparum* (parasite density: 1000 to 100,000 asexual parasites/µL of blood)
4. Body weight 20 to 90 kg
5. Written informed consent from participants or their guardians, with assent from children able to understand the trial
6. Able to swallow oral medication
7. Willingness to comply with protocol
8. Negative urine test for pregnancy and agreement to practice contraception (women of child-bearing potential)

**Exclusion criteria:**
1. Complicated or severe malaria
2. Mixed infections
3. Anaemia
4. Severe vomiting
5. Malnutrition
6. Hepatitis
7. Hypersensitivity or allergy to trial drugs
8. Use of antimalarials in the previous two weeks by testing; or use of any trial drug for previous four weeks
9. Treatment with any drug metabolised by CYP2D6
10. Pregnant and lactating women
11. Previous inclusion in a similar trial of artesunate-pyronaridine

**Interventions**

Randomized in a 2:1 ratio to:

**Intervention:**
1. artesunate-pyronaridine combination (180 mg and 60 mg)* once a day for three days according to bodyweight (N = 849)

**Control:**
2. Artemether-lumefantrine combination (20 mg and 120 mg)** twice a day for three days according to bodyweight (N = 423)

*Average dose of pyronaridine: 9 mg/Kg body weight (range 13.8 to 7.2 mg/Kg); artesunate doses ranged from 2.3 to 4.7 mg/kg body weight

**Mean artemether dose: 1.7 mg/kg (range 0.9 to 2.4 mg/kg); lumefantrine doses ranged from 5 to 14.4 mg/kg

**Outcomes**

**Primary outcome**
1. PCR-corrected adequate clinical and parasitological response rate (APCR; absence of parasitaemia, irrespective of axillary temperature, without previous treatment failure) at day 28

(Sensitivity analysis done with crude APCR (non-PCR-corrected) at day 28)

**Secondary outcomes**
1. Parasite clearance time (time from first dose to first negative parasite reading for two consecutive readings 7 to 25 hours apart)
2. Fever clearance time (time from first dose to being afebrile for two consecutive readings 7 to 25 hours apart)

**Exploratory efficacy outcomes**
1. PCR-corrected and uncorrected APCR rate on day 42
2. Number of gametocytes per micro-litre at days 0, 3, 7, 14, 21, and 42

**Safety outcomes**
1. Serious adverse events (death, life threatening, requiring hospital admission or extended hospital stay, resulting in a congenital abnormality or birth defect, persistent disability or incapacity, or other serious adverse event)
2. Other adverse events (during treatment and at follow-up on days 7, 14, 21, 28, 35, and 42)
3. Laboratory abnormalities (days 3, 7; if indicated days 28, 42)

**Outcome reported but not used in quantitative synthesis in this review**
1. Proportion of patients who had cleared parasites at day 1, 2, and 3
2. Proportion of patients without fever at days 1, 2, and 3
3. Electrocardiograph abnormalities (days 2, 7, 14, and 28)

**Notes**

**Countries of recruitment:** Seven countries in Africa (Democratic Republic of Congo, The Gambia, Ghana; Kenya; Mali; Mozambique; and Senegal) recruited over 1000 participants; remainder were from three sites in two countries in southeast Asia (two in Indonesia; one in the Phillipines)

**Setting:** Local hospitals and clinics

**Source of funding:** Primary sponsor: Medicines for Malaria Venture; secondary sponsor: Shin Poong Pharmaceuticals

**Endemicity:** All are high endemic areas

**Comments:**
- Age range of participants: 378 (45%) in the Py-As arm and 182 (43%) in the AL6
arm were aged five to 12 years

- Food was not required for artemether-lumefantrine (to retain blinding)
- Non-inferiority was shown if the lower limit of the two-sided 95% CI for the difference between groups was greater than -5%
- Recrudescence was differentiated from re-infection by PCR genotyping for *P. falciparum* genes merozoite surface proteins 1 and 2 (msp1, msp2), and glutamate-rich protein (glurp) with at least one matching allelic band in all markers at baseline and after day 7

- Grade 3 or 4 toxicity: For alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase, grade 3 toxicity was 5-10 times the upper limit of normal and grade 4 toxicity was more than ten times the upper limit of normal. For total bilirubin, grade 3 toxicity was 2-6 times the upper limit of normal and grade 4 toxicity was more than five times the upper limit of normal.

**Trials registration:** ClinicalTrials.gov identifier: NCT00422084

### Risk of bias

| Bias | Authors’ judgement | Support for judgement |
|------|--------------------|-----------------------|
| Random sequence generation (selection bias) | Low risk | Quote from report: “A computer generated randomisation schedule was provided by Averion AG (Allschwil, Switzerland). Patients were assigned a randomisation code by the investigator in ascending order and allocated to treatment in blocks of nine by study centre.” |
| Allocation concealment (selection bias) | Low risk | Quote from report: “Patients were allocated an individual numbered treatment pack containing sufficient tablets for 3 days therapy plus an average bottle containing an extra dose in case the patient vomited the first dose. Study packages were allocated on the basis of patient randomisation number. A qualified study team member (third party) who was not undertaking clinical assessments opened the study package and administered the correct amount of tablets, based on patient weight at screening, as instructed by the investigator.” |
| Blinding (performance bias and detection bias) | Low risk | Quote from report: “All clinical and laboratory staff and patients were masked to treatment allocation.” Quote from report: “Study drugs and placebos were presented in identical packaging. Artemether-lumefantrine placebo was dosed twice daily to maintain blinding. Placebos were of similar shape and colour
to their respective active drug.”
Quote from report: “Sealed opaque envelopes of treatment allocation were provided for use in an emergency, although no code breaks were necessary.”
Quote from report: “Food was not required for artemether-lumefantrine dosing to retain blinding.”

| Blinding (performance bias and detection bias) Subjective outcomes: adverse events | Low risk |
| --- |
| **Comment:** See quotes above. |

| Incomplete outcome data (attrition bias) All outcomes | Low risk |
| --- |
| **Comment:** Data regarding all participants recruited provided in results for all outcomes |

| Selective reporting (reporting bias) | Low risk |
| --- |
| **Quote from report:** “There were no changes to study outcomes after trial commencement.”
**Comment:** The trial was prospectively registered. No changes were noted in the details provided in the registration document and the study report for outcomes
**Comment:** Day 42 efficacy outcomes and gametocyte counts were not listed in trial registration document and are listed in the report as exploratory |

| Other bias | Unclear risk |
| --- |
| **Comment:** Sponsors designed the trial, were responsible for data collection and analysis, and developed the report; all authors had access to trial data
**Comment:** Participants on artemether-lumefantrine were not expected to take medication after food; unclear if this reduced bioavailability of lumefantrine, particularly for day 42 outcomes and reinfection rate when lumefantrine levels may have been low |
### Characteristics of excluded studies [ordered by study ID]

| Study                  | Reason for exclusion                                                                 |
|------------------------|---------------------------------------------------------------------------------------|
| Cai 1999               | Not a RCT: Case series.                                                                |
| Chang 1997             | Not a RCT: Case series.                                                                |
| Che 1987               | Quasi-RCT. Odd and even numbers used for allocation.                                   |
| Che 1990               | Not a RCT: Controlled clinical trial.                                                 |
| Chen 1989              | Not a RCT: Field trial.                                                               |
| Fleckenstein 2007      | Not a RCT: Controlled clinical trial evaluating drug pharmacokinetics                 |
| Huang 1988             | Quasi-RCT. Randomized according to order of admission.                                 |
| Huang 1989             | Quasi-RCT. Odd and even numbers used for allocation. Compared plain and enteric coated tablets of pyronaridine |
| Huang 1993             | RCT: Conducted in people with complicated falciparum malaria (malignant malaria)      |
| Huang 1996             | RCT: Compared single dose versus two days of the same drug combination                 |
| Liu 2002               | RCT: Compared pyronaridine + dihydroartemisinin versus dihydroartemisinin alone and with pyronaridine alone. No ACT comparator; no data on liver functions provided in report to include for "Adverse event affecting liver functions" |
| Looareesuwan 1996      | Not a RCT: Clinical trial of two doses of pyronaridine monotherapy with group given second dose recruited after results of first dose were analysed |
| Looareesuwan 2007      | RCT: Phase II dose ranging trial.                                                     |
| NCT01156389            | RCT: ongoing trial evaluating drug interactions in healthy volunteers                  |
| No authors listed 1985 | Not a RCT: field trial.                                                               |
| Pang 1989              | Not a RCT: controlled clinical trial comparing tablets versus intramuscular injections of pyronaridine/sulfadoxine/pyrimethamine |
| Piola 2008             | Not a RCT: phase II dose ranging study.                                               |
| Ramharter 2008         | Quasi-RCT. Sequential allocation; Phase II dose ranging trial                           |
| Shao 1991              | Not a RCT: case series.                                                               |
| Tan 2008               | Not a RCT: Pharmacokinetic study in healthy volunteers.                               |
Wattanavijitkul 2008 | Not a RCT: Pharmacokinetic study in healthy volunteers.
## Comparison 1. Artesunate-pyronaridine versus artemether-lumefantrine

| Outcome or subgroup title                                      | No. of studies | No. of participants | Statistical method                  | Effect size |
|----------------------------------------------------------------|----------------|---------------------|-------------------------------------|-------------|
| **Total failure (Day 28)**                                    | 2              |                     | Risk Ratio (M-H, Fixed, 95% CI)     | Subtotals only |
| 1.1 PCR-unadjusted                                             | 2              | 1720                | Risk Ratio (M-H, Fixed, 95% CI)     | 0.60 [0.40, 0.90] |
| 1.2 PCR-adjusted                                               | 2              | 1650                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.69 [0.56, 5.10] |
| **Total failure (Day 42)**                                    | 2              |                     | Risk Ratio (M-H, Random, 95% CI)    | Subtotals only |
| 2.1 PCR-unadjusted                                             | 2              | 1691                | Risk Ratio (M-H, Random, 95% CI)    | 0.85 [0.53, 1.36] |
| 2.2 PCR-adjusted                                               | 2              | 1472                | Risk Ratio (M-H, Random, 95% CI)    | 1.53 [0.73, 3.19] |
| **Early treatment failure**                                   | 2              |                     | Risk Ratio (M-H, Fixed, 95% CI)     | 0.74 [0.12, 4.42] |
| **Parasite clearance time (hours)**                           | 1              | 1170                | Mean Difference (IV, Fixed, 95% CI) | -3.20 [-4.38, -2.02] |
| **Fever clearance time (hours)**                              | 1              | 1170                | Mean Difference (IV, Fixed, 95% CI) | -1.20 [-2.38, -0.02] |
| **Gametocyte clearance time**                                 | 1              | 1170                | Mean Difference (IV, Fixed, 95% CI) | -10.5 [-12.40, -8.60] |
| **Serious adverse events**                                    | 2              | 1787                | Risk Ratio (M-H, Fixed, 95% CI)     | 0.92 [0.20, 4.28] |
| **Adverse events leading to withdrawal from treatment**       | 2              | 1787                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.37 [0.67, 2.82] |
| **Patient reported symptoms**                                 | 2              |                     | Risk Ratio (M-H, Fixed, 95% CI)     | Subtotals only |
| 9.1 Headache                                                  | 1              | 1272                | Risk Ratio (M-H, Fixed, 95% CI)     | 0.86 [0.60, 1.24] |
| 9.2 Cough                                                     | 2              | 1807                | Risk Ratio (M-H, Fixed, 95% CI)     | 0.85 [0.62, 1.17] |
| 9.3 Abdominal pain                                            | 1              | 1272                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.08 [0.67, 1.75] |
| 9.4 Vomiting                                                  | 1              | 535                 | Risk Ratio (M-H, Fixed, 95% CI)     | 1.58 [0.73, 3.44] |
| 9.5 Pyrexia                                                   | 1              | 535                 | Risk Ratio (M-H, Fixed, 95% CI)     | 1.46 [0.67, 3.19] |
| 9.6 Influenza-like illness                                    | 1              | 535                 | Risk Ratio (M-H, Fixed, 95% CI)     | 1.20 [0.54, 2.70] |
| **Patient reported symptoms judged as drug-related**          | 2              |                     | Risk Ratio (M-H, Fixed, 95% CI)     | Subtotals only |
| 10.1 Vomiting                                                 | 2              | 1807                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.25 [0.68, 2.31] |
| 10.2 Headache                                                 | 1              | 1272                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.03 [0.57, 1.85] |
| 10.3 Abdominal pain                                           | 1              | 1272                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.25 [0.60, 2.57] |
| 10.4 Vertigo                                                  | 1              | 1272                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.49 [0.48, 4.61] |
| 10.5 Haematuria                                               | 1              | 1272                | Risk Ratio (M-H, Fixed, 95% CI)     | 2.49 [0.55, 11.32] |
| 10.6 Upper abdominal pain                                     | 1              | 1272                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.12 [0.35, 3.62] |
| 10.7 Anorexia                                                 | 1              | 1272                | Risk Ratio (M-H, Fixed, 95% CI)     | 0.33 [0.09, 1.17] |
| **Abnormal LFTs; grade 3 and 4 toxicity**                     | 2              |                     | Risk Ratio (M-H, Fixed, 95% CI)     | Subtotals only |
| 11.1 Alanine aminotransfer (ALT)                              | 2              | 1807                | Risk Ratio (M-H, Fixed, 95% CI)     | 2.00 [0.43, 9.42] |
| 11.2 Aspartate aminotransfer (AST)                            | 2              | 1807                | Risk Ratio (M-H, Fixed, 95% CI)     | 3.85 [0.70, 21.09] |
| 11.3 Alkaline phosphatase (ALP)                               | 1              | 1272                | Risk Ratio (M-H, Fixed, 95% CI)     | 0.10 [0.00, 2.07] |
| 11.4 Bilirubin                                                | 2              | 1807                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.30 [0.30, 5.62] |
| **Change in haemoglobin**                                    | 2              |                     | Mean Difference (IV, Fixed, 95% CI) | Subtotals only |
| 12.1 Haemoglobin at baseline                                  | 2              | 1807                | Mean Difference (IV, Fixed, 95% CI) | -0.03 [-0.19, 0.13] |
| 12.2 Haemoglobin day 3                                        | 2              | 1755                | Mean Difference (IV, Fixed, 95% CI) | -0.01 [-0.13, 0.11] |
| 12.3 Haemoglobin day 7                                        | 2              | 1741                | Mean Difference (IV, Fixed, 95% CI) | -0.16 [-0.28, -0.05] |
| 12.4 Haemoglobin day 28                                       | 2              | 1702                | Mean Difference (IV, Fixed, 95% CI) | 0.04 [-0.09, 0.18] |
13 Anaemia as an adverse event
   13.1 Anaemia (AE of any cause)
       Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
       1 535 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.68, 2.23]
   13.2 Anaemia (drug-related AE)
       Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
       1 535 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.32, 1.47]

### Comparison 2. Artesunate-pyronaridine versus artemether-lumefantrine; subgroup analysis

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---------------------------|----------------|---------------------|--------------------|-------------|
| 1 Total failure PCR-adjusted (Day 28); subgrouped by age | 2 | 1469 | Risk Ratio (M-H, Fixed, 95% CI) Subtotals only |
| 1.1 Age > 5 years | 2 | 1469 | Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.25, 4.03] |
| 1.2 Age < 5 years | 1 | 216 | Risk Ratio (M-H, Fixed, 95% CI) 3.37 [0.43, 26.38] |
| 2 Total failure PCR-adjusted (Day 28); subgrouped by region | 2 | 1675 | Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.44, 2.76] |
| 2.1 West Africa | 2 | 816 | Risk Ratio (M-H, Fixed, 95% CI) 1.42 [0.29, 6.92] |
| 2.2 East Africa | 2 | 194 | Risk Ratio (M-H, Fixed, 95% CI) 2.64 [0.13, 53.14] |
| 2.3 South-central Africa | 2 | 490 | Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.15, 2.92] |
| 2.4 Asia | 2 | 175 | Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.09, 10.99] |
| 3 Total failure PCR-adjusted (Day 28); subgrouped by country | 2 | 1675 | Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.41, 2.18] |
| 3.1 Burkina Faso | 1 | 25 | Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.05, 22.91] |
| 3.2 DR Congo | 2 | 369 | Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.10, 2.43] |
| 3.3 Gabon | 1 | 78 | Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.01, 4.03] |
| 3.4 Ivory Coast | 1 | 100 | Risk Ratio (M-H, Fixed, 95% CI) 2.25 [0.27, 18.43] |
| 3.5 Kenya | 2 | 194 | Risk Ratio (M-H, Fixed, 95% CI) 2.64 [0.13, 53.14] |
| 3.6 Mali | 2 | 318 | Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0] |
| 3.7 The Gambia | 1 | 90 | Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0] |
| 3.8 Ghana | 1 | 7 | Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0] |
| 3.9 Mozambique | 1 | 121 | Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.06, 36.02] |
| 3.10 Senegal | 1 | 198 | Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0] |
| 3.11 Phillipines | 2 | 107 | Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0] |
| 3.12 Indonesia | 1 | 68 | Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.09, 9.32] |

### Comparison 3. Artesunate-pyronaridine versus artemether-lumefantrine; sensitivity analysis

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---------------------------|----------------|---------------------|--------------------|-------------|
| 1 Total failure PCR-unadjusted (Day 28); Sensitivity analysis | 2 | 1720 | Risk Ratio (M-H, Fixed, 95% CI) Subtotals only |
| 1.1 Primary analysis (Cochrane review) | 2 | 1720 | Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.40, 0.90] |
| 1.2 Missing data included as failures | 2 | 1807 | Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.58, 1.03] |
### Comparison 4. Artesunate-pyronaridine versus artesunate-mefloquine

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---------------------------|----------------|---------------------|--------------------|-------------|
| 1 Total failure (Day 28) | 1              | 1200                | Risk Ratio (M-H, Fixed, 95% CI) | Subtotals only |
| 1.1 PCR-unadjusted        | 1              | 1200                | Risk Ratio (M-H, Fixed, 95% CI) | 0.35 [0.17, 0.73] |
| 1.2 PCR adjusted          | 1              | 1187                | Risk Ratio (M-H, Fixed, 95% CI) | 0.38 [0.14, 1.02] |
| 2 Total failure (Day 42) | 1              | 1259                | Mean Difference (IV, Fixed, 95% CI) | -2.60 [-4.94, -0.26] |
| 2.1 PCR-unadjusted        | 1              | 1146                | Risk Ratio (M-H, Fixed, 95% CI) | 0.86 [0.57, 1.31] |
| 2.2 PCR adjusted          | 1              | 1116                | Risk Ratio (M-H, Fixed, 95% CI) | 1.64 [0.89, 3.00] |
| 3 Early treatment failures| 1              | 1103                | Risk Ratio (M-H, Fixed, 95% CI) | 0.16 [0.01, 3.96] |
| 4 Parasite clearance time (hours) | 1 | 1259 | Mean Difference (IV, Fixed, 95% CI) | -0.10 [-1.52, 1.72] |
| 5 Fever clearance time (hours) | 1 | 1051 | Mean Difference (IV, Fixed, 95% CI) | -5.40 [-21.80, 11.00] |
| 6 Gametocyte clearance time (hours) | 1 | 27 | Mean Difference (IV, Fixed, 95% CI) | |
| 7 Serious adverse events  | 1              | 1271                | Risk Ratio (M-H, Fixed, 95% CI) | 1.00 [0.25, 3.97] |
| 8 Adverse events leading to withdrawal from treatment | 1 | 1271 | Risk Ratio (M-H, Fixed, 95% CI) | 0.62 [0.17, 2.31] |
| 9 Patient reported symptoms | 1 | 7626 | Risk Ratio (M-H, Fixed, 95% CI) | 0.99 [0.80, 1.22] |
| 9.1 Vomiting              | 1              | 1271                | Risk Ratio (M-H, Fixed, 95% CI) | 1.00 [0.45, 2.20] |
| 9.2 Diarrhea              | 1              | 1271                | Risk Ratio (M-H, Fixed, 95% CI) | 0.44 [0.17, 1.14] |
| 9.3 Headache              | 1              | 1271                | Risk Ratio (M-H, Fixed, 95% CI) | 1.15 [0.82, 1.60] |
| 9.4 Dizziness             | 1              | 1271                | Risk Ratio (M-H, Fixed, 95% CI) | 0.46 [0.28, 0.78] |
| 9.5 Cough                 | 1              | 1271                | Risk Ratio (M-H, Fixed, 95% CI) | 1.50 [0.74, 3.03] |
| 9.6 Myalgia               | 1              | 1271                | Risk Ratio (M-H, Fixed, 95% CI) | 1.39 [0.83, 2.32] |
### Abnormal LFTs; Grade 2 toxicity

| Test                        | No. of Studies | Risk Ratio (M-H, Fixed, 95% CI) |
|-----------------------------|----------------|---------------------------------|
| Alanine aminotransferase (ALT) | 1              | 0.0 [0.0, 0.0]                  |
| Aspartate aminotransferase (AST) | 1              | 0.0 [0.0, 0.0]                  |
| Alkaline phosphatase (ALP)   | 1              | 0.0 [0.0, 0.0]                  |
| Bilirubin                    | 1              | 0.0 [0.0, 0.0]                  |

### Abnormal LFTs; Grade 3 or 4 toxicity

| Test                        | No. of Studies | Risk Ratio (M-H, Fixed, 95% CI) |
|-----------------------------|----------------|---------------------------------|
| Alanine aminotransferase (ALT) | 1              | 0.0 [0.0, 0.0]                  |
| Aspartate aminotransferase (AST) | 1              | 0.0 [0.0, 0.0]                  |
| Alkaline phosphatase (ALP)   | 1              | 0.0 [0.0, 0.0]                  |
| Bilirubin                    | 1              | 0.0 [0.0, 0.0]                  |

### Haemoglobin (g/dL)

| Test                        | No. of Studies | Mean Difference (IV, Fixed, 95% CI) |
|-----------------------------|----------------|-----------------------------------|
| Haemoglobin at baseline      | 1              | 0.0 [0.0, 0.0]                    |
| Haemoglobin day 3            | 1              | 0.0 [0.0, 0.0]                    |
| Haemoglobin day 7            | 1              | 0.0 [0.0, 0.0]                    |
| Haemoglobin day 28           | 1              | 0.0 [0.0, 0.0]                    |

### Platelet counts (x 10^9/L)

| Test                        | No. of Studies | Mean Difference (IV, Fixed, 95% CI) |
|-----------------------------|----------------|-----------------------------------|
| Platelet baseline           | 1              | 0.0 [0.0, 0.0]                    |
| Platelet day 3              | 1              | 0.0 [0.0, 0.0]                    |
| Platelet day 7              | 1              | 0.0 [0.0, 0.0]                    |
| Platelet day 28             | 1              | 0.0 [0.0, 0.0]                    |

### White blood counts (x 10^9/L)

| Test                        | No. of Studies | Mean Difference (IV, Fixed, 95% CI) |
|-----------------------------|----------------|-----------------------------------|
| White blood count baseline  | 1              | 0.0 [0.0, 0.0]                    |
| White blood count day 3     | 1              | 0.0 [0.0, 0.0]                    |
| White blood count day 7     | 1              | 0.0 [0.0, 0.0]                    |
| White blood count day 28    | 1              | 0.0 [0.0, 0.0]                    |

### Abnormal ECG finding

| Test                        | No. of Studies | Risk Ratio (M-H, Fixed, 95% CI) |
|-----------------------------|----------------|---------------------------------|
| QT prolongation             | 1              | 0.58 [0.20, 1.73]               |
| ECG abnormalities           | 1              | 1.00 [0.25, 3.97]               |

### Comparison 5. Artesunate-pyronaridine versus artesunate-mefloquine; subgroup analysis

| Outcome or subgroup title                                           | No. of studies | No. of participants | Statistical method | Effect size       |
|---------------------------------------------------------------------|----------------|---------------------|--------------------|-------------------|
| Total failure PCR-adjusted (Day 28); subgrouped by region           | 1              | 1117                | Risk Ratio (M-H, Fixed, 95% CI) | 0.38 [0.14, 1.03] |
| East Africa                                                         | 1              | 38                  | Risk Ratio (M-H, Fixed, 95% CI) | 0.0 [0.0, 0.0]    |
| West Africa                                                        | 1              | 192                 | Risk Ratio (M-H, Fixed, 95% CI) | 1.48 [0.06, 35.75]|
| South central Africa                                               | 0              | 0                   | Risk Ratio (M-H, Fixed, 95% CI) | 0.0 [0.0, 0.0]    |
| Asia                                                               | 1              | 887                 | Risk Ratio (M-H, Fixed, 95% CI) | 0.31 [0.10, 0.93] |
### Comparison 6. Artesunate-pyronaridine versus artesunate-mefloquine; sensitivity analysis

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---------------------------|----------------|---------------------|--------------------|-------------|
| Total failure PCR-unadjusted (Day 28); Sensitivity analysis | 1 | 1200 | Risk Ratio (M-H, Fixed, 95% CI) | Subtotals only |
| 1.1 Primary analysis (Cochrane review) | 1 | 1200 | Risk Ratio (M-H, Fixed, 95% CI) | 0.35 [0.17, 0.73] |
| 1.2 Missing data included as failures | 1 | 1271 | Risk Ratio (M-H, Fixed, 95% CI) | 0.72 [0.49, 1.05] |
| 1.3 Missing data included as successes | 1 | 1271 | Risk Ratio (M-H, Fixed, 95% CI) | 0.35 [0.17, 0.73] |
| 1.4 Intention to treat analysis (of trial authors) | 1 | 1271 | Risk Ratio (M-H, Fixed, 95% CI) | 0.72 [0.49, 1.05] |
| 1.5 Per-protocol analysis (of trial authors) | 1 | 1120 | Risk Ratio (M-H, Fixed, 95% CI) | 0.36 [0.17, 0.78] |
| Total failure PCR-adjusted (Day 28); Sensitivity analysis | 1 | 1187 | Risk Ratio (M-H, Fixed, 95% CI) | Subtotals only |
| 2.1 Primary analysis (Cochrane review) | 1 | 1187 | Risk Ratio (M-H, Fixed, 95% CI) | 0.38 [0.14, 1.02] |
| 2.2 Missing or indeterminate PCR results included as failures | 1 | 1187 | Risk Ratio (M-H, Fixed, 95% CI) | 0.38 [0.14, 1.02] |
| 2.3 New infections included as failures | 1 | 1200 | Risk Ratio (M-H, Fixed, 95% CI) | 0.39 [0.15, 1.03] |
| 2.4 Missing data included as failures | 1 | 1271 | Risk Ratio (M-H, Fixed, 95% CI) | 0.82 [0.54, 1.24] |
| 2.5 Missing data included as successes | 1 | 1271 | Risk Ratio (M-H, Fixed, 95% CI) | 0.39 [0.15, 1.03] |
| 2.6 Intention to treat analysis (by trial authors) | 1 | 1271 | Risk Ratio (M-H, Fixed, 95% CI) | 0.76 [0.51, 1.14] |
| 2.7 Per-protocol analysis (by trial authors) | 1 | 1117 | Risk Ratio (M-H, Fixed, 95% CI) | 0.37 [0.13, 1.05] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|--------------------------|---------------|---------------------|--------------------|-------------|
| 1 Abnormal LFTs; Grade 3 or 4 toxicity | 4 | 3523 | Risk Ratio (M-H, Fixed, 95% CI) | 4.17 [1.38, 12.62] |
| 1.1 Alanine aminotransferase (ALT) | 4 | 3528 | Risk Ratio (M-H, Fixed, 95% CI) | 4.08 [1.17, 14.26] |
| 1.2 Aspartate aminotransferase (AST) | 3 | 2606 | Risk Ratio (M-H, Fixed, 95% CI) | 0.62 [0.15, 2.51] |
| 1.3 Alkaline phosphatase (ALP) | 3 | 3067 | Risk Ratio (M-H, Fixed, 95% CI) | 1.92 [0.59, 6.24] |
| 1.4 Bilirubin | 3 | 3072 | Risk Ratio (M-H, Fixed, 95% CI) | 1.50 [0.30, 7.42] |
| 2 Combined abnormal LFTs | 3 | 3072 | Risk Ratio (M-H, Fixed, 95% CI) | Subtotals only |
| 2.1 ALT > 3 x ULN and Bilirubin > 2 x ULN (Hy's Law case) | 3 | 3072 | Risk Ratio (M-H, Fixed, 95% CI) | Subtotals only |
| 3 Renal function tests | 3 | 1878 | Mean Difference (IV, Fixed, 95% CI) | Subtotals only |
| 3.1 Baseline | 3 | 1764 | Mean Difference (IV, Fixed, 95% CI) | -1.72 [-3.54, 0.10] |
| 3.2 Day 3 | 3 | 1808 | Mean Difference (IV, Fixed, 95% CI) | -2.76 [-4.58, -0.94] |
| 4 Haemoglobin | 4 | 3534 | Mean Difference (IV, Fixed, 95% CI) | Subtotals only |
| 4.1 Haemoglobin at baseline | 4 | 3461 | Mean Difference (IV, Fixed, 95% CI) | -0.24 [-0.32, -0.16] |
| 4.2 Haemoglobin day 3 | 4 | 3394 | Mean Difference (IV, Fixed, 95% CI) | -0.09 [-0.19, 0.01] |
| 4.3 Haemoglobin day 7 | 4 | 3294 | Mean Difference (IV, Fixed, 95% CI) | Subtotals only |
| 4.4 Haemoglobin day 28 | 4 | 3294 | Mean Difference (IV, Fixed, 95% CI) | Subtotals only |
| 5 Abnormal ECG findings | 3 | 2543 | Risk Ratio (M-H, Fixed, 95% CI) | 0.80 [0.26, 2.43] |
| 5.1 ECG abnormalities | 3 | 2991 | Risk Ratio (M-H, Fixed, 95% CI) | 0.25 [0.07, 0.90] |
### Analysis 1.1. Comparison of Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 1 Total failure (Day 28).

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 1 Artesunate-pyronaridine versus artemether-lumefantrine

Outcome: 1 Total failure (Day 28)

| Study or subgroup | AS+Pyr n/N | AL n/N | Risk Ratio M-H,Fixed(95% CI) | Weight M-H,Fixed(95% CI) |
|-------------------|-----------|--------|-----------------------------|-------------------------|
| PCR-unadjusted    |           |        |                             |                         |
| Kayentao 2012     | 37/345    | 23/174 | 57.4 %                      | 0.81 [0.50, 1.32]       |
| Tshefu 2010       | 11/801    | 17/400 | 42.6 %                      | 0.32 [0.15, 0.68]       |
| **Subtotal (95% CI)** | **1146** | **574** | **100.0 %** | **0.60 [0.40, 0.90]** |
| Total events:     | 48 (AS+Pyr), 40 (AL) |                         |                         |
| Heterogeneity:    | Chi² = 4.09, df = 1 (P = 0.04); I² = 76% |                         |                         |
| Test for overall effect: Z = 2.48 (P = 0.013) |                         |                         |
| PCR-adjusted      |           |        |                             |                         |
| Kayentao 2012     | 10/318    | 2/153  | 50.1 %                      | 2.41 [0.53, 10.85]      |
| Tshefu 2010       | 4/794     | 2/385  | 49.9 %                      | 0.97 [0.18, 5.27]       |
| **Subtotal (95% CI)** | **1112** | **538** | **100.0 %** | **1.69 [0.56, 5.10]** |
| Total events:     | 14 (AS+Pyr), 4 (AL) |                         |                         |
| Heterogeneity:    | Chi² = 0.62, df = 1 (P = 0.43); I² = 0.0% |                         |                         |
| Test for overall effect: Z = 0.93 (P = 0.35) |                         |                         |
### Analysis 1.2. Comparison of Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 2: Total failure (Day 42)

**Review:** Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

**Comparison:** 1. Artesunate-pyronaridine versus artemether-lumefantrine

**Outcome:** 2. Total failure (Day 42)

| Study or subgroup | AS+Pyr | AL | Risk Ratio | Weight | Risk Ratio |
|-------------------|--------|----|------------|--------|------------|
|                   | n/N    | n/N | M-H,Random,95% CI |       | M-H,Random,95% CI |
| 1 PCR-unadjusted   |        |    |              |        |             |
| Kayentao 2012      | 81/343 | 38/174 | 49.2 % | 1.08 [0.77, 1.52] |         |
| Tshelu 2010        | 79/788 | 58/386 | 50.8 % | 0.67 [0.49, 0.92] |         |
| **Subtotal (95% CI)** | 1131 | 560 |              |        | 0.85 [0.53, 1.36] |
| **Total events:** 160 (AS+Pyr), 96 (AL) |        |    |              |        |             |
| Heterogeneity: Tau² = 0.09; Chi² = 4.16, df = 1 (P = 0.04); I² = 76% |        |    |              |        |             |
| Test for overall effect: Z = 0.69 (P = 0.49) |        |    |              |        |             |
| 2 PCR-adjusted     |        |    |              |        |             |
| Kayentao 2012      | 19/281 | 6/142 | 67.8 % | 1.60 [0.65, 3.92] |         |
| Tshelu 2010        | 9/718  | 3/331 | 32.2 % | 1.38 [0.38, 5.08] |         |
| **Subtotal (95% CI)** | 999 | 473 |              |        | 1.53 [0.73, 3.19] |
| **Total events:** 28 (AS+Pyr), 9 (AL) |        |    |              |        |             |
| Heterogeneity: Tau² = 0.0; Chi² = 0.03, df = 1 (P = 0.86); I² = 0.0% |        |    |              |        |             |
| Test for overall effect: Z = 1.12 (P = 0.26) |        |    |              |        |             |
### Analysis 1.3. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 3 Early treatment failure.

**Review:** Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

**Comparison:** 1 Artesunate-pyronaridine versus artemether-lumefantrine

**Outcome:** 3 Early treatment failure

| Study or subgroup | AS+Pyr n/N | AL n/N | Risk Ratio M-H,Fixed 95% CI | Weight | Risk Ratio M-H,Fixed 95% CI |
|------------------|-----------|-------|-----------------------------|--------|-----------------------------|
| Kayentao 2012    | 2/339     | 0/167 | 25.0% 2.47 [0.12, 51.17]    |        |                             |
| Tshefu 2010      | 0/784     | 1/386 | 75.0% 0.16 [0.01, 4.02]     |        |                             |
| **Total (95% CI)** | **1123** | **553** | **100.0% 0.74 [0.12, 4.42]** |        |                             |

Total events: 2 (AS+Pyr), 1 (AL)

Heterogeneity: Chi² = 1.46, df = 1 (P = 0.23); I² = 31%

Test for overall effect: Z = 0.33 (P = 0.74)

Test for subgroup differences: Not applicable

### Analysis 1.4. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 4 Parasite clearance time (hours).

**Review:** Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

**Comparison:** 1 Artesunate-pyronaridine versus artemether-lumefantrine

**Outcome:** 4 Parasite clearance time (hours)

| Study or subgroup | AS+Pyr | AL | Mean Difference IV,Fixed 95% CI | Weight | Mean Difference IV,Fixed 95% CI |
|------------------|--------|----|------------------------------|--------|-------------------------------|
| Tshefu 2010      | 784    | 386| -3.20 [-4.38, -2.02]          | 100.0% | -3.20 [-4.38, -2.02]          |
| **Total (95% CI)** | **784** | **386** | **100.0% -3.20 [-4.38, -2.02]** |        |                             |

Heterogeneity: not applicable

Test for overall effect: Z = 5.31 (P < 0.00001)

Test for subgroup differences: Not applicable
### Analysis 1.5. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 5 Fever clearance time (hours).

**Review:** Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

**Comparison:** 1 Artesunate-pyronaridine versus artemether-lumefantrine

**Outcome:** 5 Fever clearance time (hours)

| Study or subgroup | AS+Pyr | AL | Mean Difference | Weight | Mean Difference |
|-------------------|--------|----|----------------|--------|----------------|
|                   | N      | N  | IV,Fixed,95% CI | 100.0% | IV,Fixed,95% CI |
| Tshefu 2010       | 784    | 386| -1.20 [-2.38, -0.02] |        |                |
| Total (95% CI)    | 784    | 386| -1.20 [-2.38, -0.02] |        |                |

Heterogeneity: not applicable

Test for overall effect: Z = 1.99 (P = 0.047)

Test for subgroup differences: Not applicable
**Analysis 1.6. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 6**

Gametocyte clearance time.

**Review:** Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

**Comparison:** 1 Artesunate-pyronaridine versus artemether-lumefantrine

**Outcome:** 6 Gametocyte clearance time

| Study or subgroup | AS+Pyr | AL | Mean Difference | Weight | Mean Difference |
|-------------------|--------|----|----------------|--------|----------------|
|                  | N      | N  |               |        |               |
| Tshefu 2010 (1)   | 784    | 386| -10.50 [-12.40, -8.60] | 100.0% |                |
| **Total (95% CI)** | **784** | **386** |               | **100.0%** | **-10.50 [-12.40, -8.60]** |

Heterogeneity: not applicable

Test for overall effect: Z = 10.82 (P < 0.00001)

Test for subgroup differences: Not applicable

(1) Skewed data (SD times 2 = 1)

**Analysis 1.7. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 7 Serious adverse events.**

**Review:** Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

**Comparison:** 1 Artesunate-pyronaridine versus artemether-lumefantrine

**Outcome:** 7 Serious adverse events

| Study or subgroup | AS+Pyr | AL | Risk Ratio | Weight | Risk Ratio |
|-------------------|--------|----|------------|--------|------------|
|                  | n/N    | n/N | M-H,Fixed 95% CI |        | M-H,Fixed 95% CI |
| Kayentao 2012     | 1/335  | 0/180 | 1.62 [0.07, 39.47] | 19.6%  |           |
| Tshefu 2010       | 3/849  | 2/423 | 0.75 [0.13, 4.46] | 80.4%  |           |
| **Total (95% CI)** | **1184** | **603** |               | **100.0%** | **0.92 [0.20, 4.28]** |

Total events: 4 (AS+Pyr), 2 (AL)

Heterogeneity: Chi² = 0.17, df = 1 (P = 0.68); I² = 0.0%

Test for overall effect: Z = 0.11 (P = 0.91)

Test for subgroup differences: Not applicable
Analysis 1.8. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 8 Adverse events leading to withdrawal from treatment.

**Review:** Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

**Comparison:** 1 Artesunate-pyronaridine versus artemether-lumefantrine

**Outcome:** 8 Adverse events leading to withdrawal from treatment

| Study or subgroup | AS+Pyr n/N | AL n/N | Risk Ratio M-H,Fixed 95% CI | Weight | Risk Ratio M-H,Fixed 95% CI |
|-------------------|-----------|--------|---------------------------|--------|---------------------------|
| Kayentao 2012     | 6/335     | 3/180  | 1.07 [0.27, 4.25]         | 29.5%  |                           |
| Tshefu 2010       | 21/849    | 7/423  | 1.49 [0.64, 3.49]         | 70.5%  |                           |
| **Total (95% CI)** | **1184**  | **603** |                         | **100.0%** | **1.37 [0.67, 2.82]** |

Total events: 27 (AS+Pyr), 10 (AL)

Heterogeneity: $\chi^2 = 0.16$, df = 1 ($P = 0.69$); $I^2 = 0.0$

Test for overall effect: $Z = 0.86$ ($P = 0.39$)

Test for subgroup differences: Not applicable

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Analysis 1.9. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 9 Patient reported symptoms.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 1 Artesunate-pyronaridine versus artemether-lumefantrine

Outcome: 9 Patient reported symptoms

| Study or subgroup | AS+Pyr | AL | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|------------------|--------|----|-----------------------------|--------|-----------------------------|
| Headache         |        |    |                             |        |                             |
| Tshefu 2010 (1)  | 71/849 | 41/423 | 1.000 % | 0.86 [ 0.60, 1.24 ]          |
| **Subtotal (95% CI)** | **849** | **423** | **1.000 %** | **0.86 [ 0.60, 1.24 ]** |
| Total events:    | 71 (AS+Pyr), 41 (AL) |
| Heterogeneity:   | not applicable |
| Test for overall effect: Z = 0.79 (P = 0.43) |
| Cough            |        |    |                             |        |                             |
| Kayentao 2012 (2)| 44/355 | 28/180 | 0.808 [ 0.51, 1.24 ]        |
| Tshefu 2010      | 49/849 | 27/423 | 0.900 [ 0.57, 1.43 ]        |
| **Subtotal (95% CI)** | **1204** | **603** | **1.000 %** | **0.85 [ 0.62, 1.17 ]** |
| Total events:    | 93 (AS+Pyr), 55 (AL) |
| Heterogeneity:   | Chi² = 0.15, df = 1 (P = 0.69); I² = 0.0% |
| Test for overall effect: Z = 1.01 (P = 0.31) |
| Abdominal pain   |        |    |                             |        |                             |
| Tshefu 2010      | 50/849 | 23/423 | 1.080 [ 0.67, 1.75 ]        |
| **Subtotal (95% CI)** | **849** | **423** | **1.000 %** | **1.08 [ 0.67, 1.75 ]** |
| Total events:    | 50 (AS+Pyr), 23 (AL) |
| Heterogeneity:   | not applicable |
| Test for overall effect: Z = 0.33 (P = 0.74) |
| Vomiting         |        |    |                             |        |                             |
| Kayentao 2012    | 25/355 | 8/180  | 1.571 [ 0.73, 3.44 ]        |
| **Subtotal (95% CI)** | **355** | **180** | **100.0 %** | **1.58 [ 0.73, 3.44 ]** |
| Total events:    | 25 (AS+Pyr), 8 (AL) |
| Heterogeneity:   | not applicable |
| Test for overall effect: Z = 1.16 (P = 0.24) |
| Pyrexia          |        |    |                             |        |                             |
| Kayentao 2012    | 23/355 | 8/180  | 1.462 [ 0.67, 3.19 ]        |
| **Subtotal (95% CI)** | **355** | **180** | **100.0 %** | **1.46 [ 0.67, 3.19 ]** |
| Total events:    | 23 (AS+Pyr), 8 (AL) |
| Heterogeneity:   | not applicable |
| Test for overall effect: Z = 0.94 (P = 0.35) |

(Continued...)

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
### Analysis 1.10. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 10
Patient reported symptoms judged as drug-related.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 1 Artesunate-pyronaridine versus artemether-lumefantrine

Outcome: 10 Patient reported symptoms judged as drug-related

| Study or subgroup | AS+Pyr  | AL  | Risk Ratio | Weight | Risk Ratio |
|-------------------|---------|-----|------------|--------|------------|
|                   | n/N     | n/N | M-H,Fixed,95% CI |        | M-H,Fixed,95% CI |
| Vomiting          |         |     |             |        |             |
| Kayentao 2012     | 7/355   | 6/180 | 42.7 % 0.59 [0.20, 1.73] |        |             |
| Tshefu 2010       | 28/849  | 8/423 | 57.3 % 1.74 [0.80, 3.79] |        |             |
| Subtotal (95% CI) | 1204    | 603  | 100.0 % 1.25 [0.68, 2.31] |        |             |

Total events: 35 (AS+Pyr), 14 (AL)
Heterogeneity: Chi^2 = 2.56, df = 1 (P = 0.11); I^2 =61%
Test for overall effect: Z = 0.72 (P = 0.47)

| Headache          |         |     |             |        |             |
| Tshefu 2010       | 33/849  | 16/423 | 100.0 % 1.03 [0.57, 1.85] |        |             |
| Subtotal (95% CI) | 849     | 423  | 100.0 % 1.03 [0.57, 1.85] |        |             |

Total events: 33 (AS+Pyr), 16 (AL)
Heterogeneity: not applicable

(1) Tshfu 2010 reports adverse events of any cause that affect at least 5% of participants.

(2) Kayentao 2012 reports adverse events of any cause that affect at least 5% of participants.
### Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)

**Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.**

| Study or subgroup | AS+Pyr n/N | AL n/N | Risk Ratio M-H,Fixed 95% CI | Weight | Risk Ratio M-H,Fixed 95% CI |
|-------------------|------------|--------|-----------------------------|--------|-----------------------------|
| Test for overall effect: Z = 0.09 (P = 0.93) |
| **3 Abdominal pain** |
| Tshefu 2010 | 25/849 | 10/423 | 100.0 % | 1.25 [0.60, 2.57] |
| **Subtotal (95% CI)** | 849 | 423 | **100.0 %** | 1.25 [0.60, 2.57] |
| Total events: 25 (AS+Pyr), 10 (AL) |
| Heterogeneity: not applicable |
| Test for overall effect: Z = 0.59 (P = 0.55) |
| **4 Vertigo** |
| Tshefu 2010 | 12/849 | 4/423 | 100.0 % | 1.49 [0.48, 4.61] |
| **Subtotal (95% CI)** | 849 | 423 | **100.0 %** | 1.49 [0.48, 4.61] |
| Total events: 12 (AS+Pyr), 4 (AL) |
| Heterogeneity: not applicable |
| Test for overall effect: Z = 0.70 (P = 0.48) |
| **5 Haematuria** |
| Tshefu 2010 | 10/849 | 2/423 | 100.0 % | 2.49 [0.55, 11.32] |
| **Subtotal (95% CI)** | 849 | 423 | **100.0 %** | 2.49 [0.55, 11.32] |
| Total events: 10 (AS+Pyr), 2 (AL) |
| Heterogeneity: not applicable |
| Test for overall effect: Z = 1.18 (P = 0.24) |
| **6 Upper abdominal pain** |
| Tshefu 2010 | 9/849 | 4/423 | 100.0 % | 1.12 [0.35, 3.62] |
| **Subtotal (95% CI)** | 849 | 423 | **100.0 %** | 1.12 [0.35, 3.62] |
| Total events: 9 (AS+Pyr), 4 (AL) |
| Heterogeneity: not applicable |
| Test for overall effect: Z = 0.19 (P = 0.85) |
| **7 Anorexia** |
| Tshefu 2010 | 4/849 | 6/423 | 100.0 % | 0.33 [0.09, 1.17] |
| **Subtotal (95% CI)** | 849 | 423 | **100.0 %** | 0.33 [0.09, 1.17] |
| Total events: 4 (AS+Pyr), 6 (AL) |
| Heterogeneity: not applicable |
| Test for overall effect: Z = 1.71 (P = 0.086) |
| Test for subgroup differences: Chi² = 5.19, df = 6 (P = 0.52), I² =0.0% |
Analysis 1.11. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 11
Abnormal LFTs; grade 3 and 4 toxicity.

Review: Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria

Comparison: 1 Artesunate-pyronaridine versus artemether-lumefantrine

Outcome: 11 Abnormal LFTs; grade 3 and 4 toxicity

| Study or subgroup | AS+Pyr | AL | Risk Ratio Weight Risk Ratio |
|------------------|--------|----|-----------------------------|
|                  | n/N    | n/N| M-H,Fixed 95% CI            | M-H,Fixed 95% CI          |
| 1 Alanine aminotransferase (ALT) |          |    |
| Kayentao 2012 (1) | 1/355  | 1/180 | 49.9 % | 0.51 [0.03, 8.06] |
| Tshefu 2010 (2) | 7/849  | 1/423 | 50.1 % | 3.49 [0.43, 28.25] |
| **Subtotal (95% CI)** | **1204** | **603** | **100.0 %** | **2.00 [0.43, 9.42]** |
| Total events: 8 (AS+Pyr), 2 (AL) | |
| Heterogeneity: Chi² = 1.22, df = 1 (P = 0.27); I² =18% | |
| Test for overall effect: Z = 0.88 (P = 0.38) | |
| 2 Aspartate aminotransferase (AST) |          |    |
| Kayentao 2012 | 3/355  | 1/180 | 66.5 % | 1.52 [0.16, 14.52] |
| Tshefu 2010 | 8/423  | 0/423 | 33.5 % | 8.48 [0.49, 146.57] |
| **Subtotal (95% CI)** | **1204** | **603** | **100.0 %** | **3.85 [0.70, 21.09]** |
| Total events: 11 (AS+Pyr), 1 (AL) | |
| Heterogeneity: Chi² = 0.95, df = 1 (P = 0.33); I² =0.0% | |
| Test for overall effect: Z = 1.55 (P = 0.12) | |
| 3 Alkaline phosphatase (ALP) |          |    |
| Tshefu 2010 | 0/849  | 2/423 | 100.0 % | 0.10 [0.00, 2.07] |
| **Subtotal (95% CI)** | **849** | **423** | **100.0 %** | **0.10 [0.00, 2.07]** |
| Total events: 0 (AS+Pyr), 2 (AL) | |
| Heterogeneity: not applicable | |
| Test for overall effect: Z = 1.49 (P = 0.14) | |
| 4 Bilirubin |          |    |
| Kayentao 2012 (3) | 1/355  | 2/180 | 79.9 % | 0.25 [0.02, 2.78] |
| Tshefu 2010 (4) | 5/849  | 0/423 | 20.1 % | 5.49 [0.30, 99.00] |
| **Subtotal (95% CI)** | **1204** | **603** | **100.0 %** | **1.30 [0.30, 5.62]** |
| Total events: 6 (AS+Pyr), 2 (AL) | |
| Heterogeneity: Chi² = 2.75, df = 1 (P = 0.10); I² =64% | |
| Test for overall effect: Z = 0.36 (P = 0.72) | |
| Test for subgroup differences: Chi² = 4.39, df = 3 (P = 0.22); I² =32% | |
(1) Kayentao 2012 defines ALT and AST Grade 3 toxicity as greater than 10 times the upper limit of normal (this is GRADE 4 in Tshefu 2010).

(2) Tshefu 2010 defines grade 3 toxicity for ALT, AST and ALP as greater than 5.1 times the upper limit of normal.

(3) Kayentao 2012 defines grade 3 toxicity as greater than 3.0 times the upper limit of normal.

(4) Tshefu 2010 defines grade 3 toxicity for Bilirubin greater than 2.6 times the upper limit of normal.

Analysis 1.12. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 12 Change in haemoglobin.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 1 Artesunate-pyronaridine versus artemether-lumefantrine

Outcome: 12 Change in haemoglobin

| Study or subgroup | AS+Pyr | AL | Mean Difference | Weight | Mean Difference |
|-------------------|--------|----|-----------------|--------|-----------------|
| Kayentao 2012     | 355    | 180| -0.10 [-0.35, 0.15] | 43.7%  |                 |
| Tshefu 2010       | 849    | 423| 0.02 [-0.20, 0.24]  | 56.3%  |                 |
| **Subtotal (95% CI)** | **1204** | **603** | **-0.03 [-0.19, 0.13]** | 100.0% |                 |
| Heterogeneity: Chi^2 = 0.52, df = 1 (P = 0.47); I^2 = 0.0% |
| Test for overall effect: Z = 0.39 (P = 0.69) |

2 Haemoglobin day 3

| Study or subgroup | AS+Pyr | AL | Mean Difference | Weight | Mean Difference |
| Kayentao 2012     | 348    | 176| 0.08 [-0.14, 0.30]  | 30.5%  |                 |
| Tshefu 2010       | 819    | 412| -0.05 [-0.19, 0.09] | 69.5%  |                 |
| **Subtotal (95% CI)** | **1167** | **588** | **-0.01 [-0.13, 0.11]** | 100.0% |                 |
| Heterogeneity: Chi^2 = 0.95, df = 1 (P = 0.33); I^2 = 0.0% |
| Test for overall effect: Z = 0.17 (P = 0.87) |

3 Haemoglobin day 7

| Study or subgroup | AS+Pyr | AL | Mean Difference | Weight | Mean Difference |
| Kayentao 2012     | 345    | 173| 0.02 [-0.22, 0.18] | 34.5%  |                 |
| Tshefu 2010       | 817    | 406| -0.24 [-0.39, -0.09] | 65.5%  |                 |
| **Subtotal (95% CI)** | **1162** | **579** | **-0.16 [-0.28, -0.05]** | 100.0% |                 |
| Heterogeneity: Chi^2 = 3.02, df = 1 (P = 0.08); I^2 = 67% |
| Test for overall effect: Z = 2.73 (P = 0.0063) |

4 Haemoglobin day 28

| Study or subgroup | AS+Pyr | AL | Mean Difference | Weight | Mean Difference |
| Kayentao 2012     | 334    | 171| 0.10 [-0.15, 0.35] | 29.4%  |                 |
| Tshefu 2010       | 799    | 398| 0.02 [-0.14, 0.18] | 70.6%  |                 |

(Continued...)

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)  
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
### Analysis 1.13. Comparison 1 Artesunate-pyronaridine versus artemether-lumefantrine, Outcome 13

Anaemia as an adverse event.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 1 Artesunate-pyronaridine versus artemether-lumefantrine

Outcome: 13 Anaemia as an adverse event

| Study or subgroup | AS+Pyr | AL | Risk Ratio | Weight | Risk Ratio |
|------------------|--------|----|------------|--------|------------|
|                  | n/N    | n/N| M-H,Fixed,95% CI |        | M-H,Fixed,95% CI |
| 1 Anaemia (AE of any cause) | 34/355 | 14/180 | | 100.0 % | 1.23 [0.68, 2.23] |
| Kayentao 2012 (1) |  |  | | | |
| **Subtotal (95% CI)** | **355** | **180** | | **100.0 %** | **1.23 [0.68, 2.23]** |
| Total events: 34 (AS+Pyr), 14 (AL) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 0.68 (P = 0.49) | | | | | |
| 2 Anaemia (drug-related AE) | 15/355 | 11/180 | | 100.0 % | 0.69 [0.32, 1.47] |
| Kayentao 2012 (2) |  |  | | | |
| **Subtotal (95% CI)** | **355** | **180** | | **100.0 %** | **0.69 [0.32, 1.47]** |
| Total events: 15 (AS+Pyr), 11 (AL) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 0.96 (P = 0.34) | | | | | |
| Test for subgroup differences: Chi² = 1.38, df = 1 (P = 0.24), I² = 27% | | | | | |
Analysis 2.1. Comparison 2 Artesunate-pyronaridine versus artemether-lumefantrine; subgroup analysis, Outcome 1 Total failure PCR-adjusted (Day 28); subgrouped by age.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 2 Artesunate-pyronaridine versus artemether-lumefantrine; subgroup analysis

Outcome: 1 Total failure PCR-adjusted (Day 28); subgrouped by age

| Study or subgroup | AS-Pyr | AL | Risk Ratio | Weight | Risk Ratio |
|------------------|--------|----|------------|--------|------------|
|                  | n/N    | n/N| M-H, Fixed 95% CI |        | M-H, Fixed 95% CI |
| 1 Age > 5 years  | 2/187  | 1/103 | 32.4 % | 1.10 [0.10, 12.00] |
| Kayentao 2012    |        |      |          |        |            |
| Tshefu 2010      | 4/794  | 2/385 | 67.6 % | 0.97 [0.18, 5.27] |
| **Subtotal (95% CI)** | **981** | **488** | 100.0 % | **1.01 [0.25, 4.03]** |
| Total events: 6 (AS-Pyr), 3 (AL) |        |      |          |        |            |
| Heterogeneity: Chi² = 0.01, df = 1 (P = 0.93); I² = 0.0% |
| Test for overall effect: Z = 0.02 (P = 0.99) |
| 2 Age < 5 years  | 8/152  | 1/64 | 100.0 % | 3.37 [0.43, 26.38] |
| Kayentao 2012    |        |      |          |        |            |
| **Subtotal (95% CI)** | **152** | **64** | 100.0 % | **3.37 [0.43, 26.38]** |
| Total events: 8 (AS-Pyr), 1 (AL) |        |      |          |        |            |
| Heterogeneity: not applicable |
| Test for overall effect: Z = 1.16 (P = 0.25) |
### Analysis 2.2. Comparison 2 Artesunate-pyronaridine versus artemether-lumefantrine; subgroup analysis, Outcome 2 Total failure PCR-adjusted (Day 28); subgrouped by region.

**Review:** Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

**Comparison:** 2 Artesunate-pyronaridine versus artemether-lumefantrine; subgroup analysis

**Outcome:** 2 Total failure PCR-adjusted (Day 28); subgrouped by region

| Study or subgroup | AS-Pyr n/N | AL n/N | Risk Ratio M-H,Fixed 95% CI | Risk Ratio M-H,Fixed 95% CI |
|-------------------|------------|--------|----------------------------|----------------------------|
| **1 West Africa** |            |        |                           |                            |
| Kayentao 2012     | 6/224      | 2/106  | 1.42 [ 0.29, 6.92 ]       |                            |
| Tshetu 2010       | 0/326      | 0/160  | 0.0 [ 0.0, 0.0 ]          |                            |
| **Subtotal (95% CI)** | **550** | **266** | 1.42 [ 0.29, 6.92 ]       |                            |
| Total events: 6 (AS-Pyr), 2 (AL) |          |        |                           |                            |
| Heterogeneity: Chi² = 0.0, df = 0 (P = 1.00); I² =0.0% |          |        |                           |                            |
| Test for overall effect: Z = 0.43 (P = 0.66) |          |        |                           |                            |
| **2 East Africa** |            |        |                           |                            |
| Kayentao 2012     | 2/52       | 0/27   | 2.64 [ 0.13, 53.14 ]      |                            |
| Tshetu 2010       | 0/79       | 0/36   | 0.0 [ 0.0, 0.0 ]          |                            |
| **Subtotal (95% CI)** | **131** | **63**  | 2.64 [ 0.13, 53.14 ]      |                            |
| Total events: 2 (AS-Pyr), 0 (AL) |          |        |                           |                            |
| Heterogeneity: Chi² = 0.0, df = 0 (P = 1.00); I² =0.0% |          |        |                           |                            |
| Test for overall effect: Z = 0.63 (P = 0.53) |          |        |                           |                            |
| **3 South-central Africa** | |        |                           |                            |
| Kayentao 2012     | 2/52       | 1/26   | 1.00 [ 0.10, 10.53 ]      |                            |
| Tshetu 2010       | 2/275      | 2/137  | 0.50 [ 0.07, 3.50 ]       |                            |
| **Subtotal (95% CI)** | **327** | **163** | 0.67 [ 0.15, 2.92 ]       |                            |
| Total events: 4 (AS-Pyr), 3 (AL) |          |        |                           |                            |
| Heterogeneity: Chi² = 0.20, df = 1 (P = 0.65); I² =0.0% |          |        |                           |                            |
| Test for overall effect: Z = 0.54 (P = 0.59) |          |        |                           |                            |
| **4 Asia**        |            |        |                           |                            |
| Kayentao 2012     | 0/11       | 0/7    | 0.0 [ 0.0, 0.0 ]          |                            |
| Tshetu 2010       | 2/104      | 1/53   | 1.02 [ 0.09, 10.99 ]      |                            |
| **Subtotal (95% CI)** | **115** | **60**  | 1.02 [ 0.09, 10.99 ]      |                            |
| Total events: 2 (AS-Pyr), 1 (AL) |          |        |                           |                            |
| Heterogeneity: Chi² = 0.0, df = 0 (P = 1.00); I² =0.0% |          |        |                           |                            |
| Test for overall effect: Z = 0.02 (P = 0.99) |          |        |                           |                            |
| **Total (95% CI)** | **1123** | **552** | 1.10 [ 0.44, 2.76 ]       |                            |
| Total events: 14 (AS-Pyr), 6 (AL) |          |        |                           |                            |
| Heterogeneity: Chi² = 1.07, df = 4 (P = 0.90); I² =0.0% |          |        |                           |                            |
| Test for overall effect: Z = 0.21 (P = 0.83) |          |        |                           |                            |
| Test for subgroup differences: Chi² = 0.87, df = 3 (P = 0.83); I² =0.0% |          |        |                           |                            |

Favours AS-Pyr Favours AL
### Analysis 2.3. Comparison 2 Artesunate-pyronaridine versus artemether-lumefantrine; subgroup analysis, Outcome 3 Total failure PCR-adjusted (Day 28); subgrouped by country.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 2 Artesunate-pyronaridine versus artemether-lumefantrine; subgroup analysis

Outcome: 3 Total failure PCR-adjusted (Day 28); subgrouped by country

| Study or subgroup | AS-Pyr n/N | AL n/N | Risk Ratio M-H,Fixed,95% CI | Risk Ratio M-H,Fixed,95% CI |
|-------------------|------------|-------|-----------------------------|-----------------------------|
| **1 Burkina Faso**|            |       |                             |                             |
| Kayentao 2012     | 1/19 0/19  |       |                             |                             |
| **Subtotal (95% CI)** |           |       | 1.05 [ 0.05, 22.91]        |                             |
| **Total events**: |           |       | 1 (AS-Pyr), 0 (AL)         |                             |
| **Heterogeneity**:|           |       | not applicable              |                             |
| **Test for overall effect**: |          |       | Z = 0.03 (P = 0.98)        |                             |
| **2 DR Congo**    |            |       |                             |                             |
| Kayentao 2012     | 2/50 1/25  |       |                             |                             |
| Tshefu 2010       | 1/194 2/97|       |                             |                             |
| **Subtotal (95% CI)** |           |       | 0.50 [ 0.10, 2.43]         |                             |
| **Total events**: |           |       | 3 (AS-Pyr), 3 (AL)         |                             |
| **Heterogeneity**:|           |       | Chi² = 0.66, df = 1 (P = 0.42); I² = 0% |                             |
| **Test for overall effect**: |          |       | Z = 0.86 (P = 0.39)        |                             |
| **3 Gabon**       |            |       |                             |                             |
| Kayentao 2012     | 0/52 0/26 |       |                             |                             |
| **Subtotal (95% CI)** |           |       | 0.17 [ 0.01, 4.03]         |                             |
| **Total events**: |           |       | 0 (AS-Pyr), 1 (AL)         |                             |
| **Heterogeneity**:|           |       | not applicable              |                             |
| **Test for overall effect**: |          |       | Z = 1.10 (P = 0.27)        |                             |
| **4 Ivory Coast** |            |       |                             |                             |
| Kayentao 2012     | 5/69 1/31 |       |                             |                             |
| **Subtotal (95% CI)** |           |       | 2.25 [ 0.27, 18.43]        |                             |
| **Total events**: |           |       | 5 (AS-Pyr), 1 (AL)         |                             |
| **Heterogeneity**:|           |       | not applicable              |                             |
| **Test for overall effect**: |          |       | Z = 0.75 (P = 0.45)        |                             |
| **5 Kenya**       |            |       |                             |                             |
| Kayentao 2012     | 2/52 0/27 |       |                             |                             |
| Tshefu 2010       | 0/79 0/36|       |                             |                             |
| **Subtotal (95% CI)** |           |       | 2.64 [ 0.13, 53.14]        |                             |
| **Total events**: |           |       | 2 (AS-Pyr), 0 (AL)         |                             |

(Continued ...)

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
| Study or subgroup | AS-Pyr n/N | AL n/N | Risk Ratio (M-H,Fixed,95% CI) |
|------------------|------------|--------|-------------------------------|
| Mali             |            |        |                               |
| Kayentao 2012    | 0/84       | 0/43   | 0.0 [ 0.0, 0.0 ]              |
| Tshefu 2010      | 0/130      | 0/61   | 0.0 [ 0.0, 0.0 ]              |
| **Subtotal (95% CI)** | **214** | **104** | **0.0 [ 0.0, 0.0 ]**          |
| Total events:    |            |        |                               |
| 0 (AS-Pyr), 0 (AL)|           |        |                               |
| Heterogeneity:   |            |        |                               |
| Chi² = 0.0, df = 0 (P = 1.00); I² = 0.0% | |
| Test for overall effect: | | | Z = 0.63 (P = 0.53) |

|                          |            |        |                               |
| The Gambia              |            |        |                               |
| Tshefu 2010             | 0/61       | 0/29   | 0.0 [ 0.0, 0.0 ]              |
| **Subtotal (95% CI)**   | **61**     | **29** | **0.0 [ 0.0, 0.0 ]**          |
| Total events:           |            |        |                               |
| 0 (AS-Pyr), 0 (AL)      |           |        |                               |
| Heterogeneity:          |            |        |                               |
| not applicable          |           |        |                               |
| Test for overall effect:| | | Z = 0.0 (P < 0.00001) |

|                          |            |        |                               |
| Ghana                    |            |        |                               |
| Tshefu 2010              | 0/4        | 0/3    | 0.0 [ 0.0, 0.0 ]              |
| **Subtotal (95% CI)**    | **4**      | **3**  | **0.0 [ 0.0, 0.0 ]**          |
| Total events:            |            |        |                               |
| 0 (AS-Pyr), 0 (AL)       |           |        |                               |
| Heterogeneity:           |            |        |                               |
| not applicable           |           |        |                               |
| Test for overall effect: | | | Z = 0.0 (P < 0.00001) |

|                          |            |        |                               |
| Mozambique               |            |        |                               |
| Tshefu 2010              | 1/81       | 0/40   | 1.50 [ 0.06, 36.02 ]          |
| **Subtotal (95% CI)**    | **81**     | **40** | **1.50 [ 0.06, 36.02 ]**      |
| Total events:            |            |        |                               |
| 1 (AS-Pyr), 0 (AL)       |           |        |                               |
| Heterogeneity:           |            |        |                               |
| not applicable           |           |        |                               |
| Test for overall effect: | | | Z = 0.25 (P = 0.80) |

|                          |            |        |                               |
| Senegal                  |            |        |                               |
| Tshefu 2010              | 0/131      | 0/67   | 0.0 [ 0.0, 0.0 ]              |
| **Subtotal (95% CI)**    | **131**    | **67** | **0.0 [ 0.0, 0.0 ]**          |
| Total events:            |            |        |                               |
| 0 (AS-Pyr), 0 (AL)       |           |        |                               |
| Heterogeneity:           |            |        |                               |
| not applicable           |           |        |                               |
| Test for overall effect: | | | Z = 0.0 (P < 0.00001) |

|                          |            |        |                               |
| Philippines             |            |        |                               |
| Kayentao 2012           | 0/11       | 0/7    | 0.0 [ 0.0, 0.0 ]              |
| Tshefu 2010             | 0/57       | 0/32   | 0.0 [ 0.0, 0.0 ]              |
| **Subtotal (95% CI)**   | **68**     | **39** | **0.0 [ 0.0, 0.0 ]**          |
| Total events:           |            |        |                               |
| 0 (AS-Pyr), 0 (AL)      |           |        |                               |
| Heterogeneity:          |            |        |                               |
| Chi² = 0.0, df = 0 (P < 0.00001); I² = 0.0% | |
| Test for overall effect:| | | Z = 0.0 (P < 0.00001) |

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
| Study or subgroup | AS-Pyr n/N | AL n/N | Risk Ratio M-H,Fixed 95% CI |
|-------------------|-----------|-------|-----------------------------|
| 12 Indonesia Tshefu 2010 | 2/47 | 1/21 | 0.89 [0.09, 9.32] |
| **Subtotal (95% CI)** | 47 | 21 | **0.89 [0.09, 9.32]** |
| Total events: 2 (AS-Pyr), 1 (AL) | | | |
| Heterogeneity: not applicable | | | |
| Test for overall effect: Z = 0.09 (P = 0.93) | | | |
| **Total (95% CI)** | 1123 | 552 | **0.94 [0.41, 2.18]** |
| Total events: 14 (AS-Pyr), 6 (AL) | | | |
| Heterogeneity: Chi² = 3.51, df = 7 (P = 0.83); I² =0.0% | | | |
| Test for overall effect: Z = 0.14 (P = 0.89) | | | |
| Test for subgroup differences: Chi² = 2.92, df = 6 (P = 0.82), I² =0.0% | | | |

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Analysis 3.1. Comparison 3 Artesunate-pyronaridine versus artemether-lumefantrine; sensitivity analysis, Outcome 1 Total failure PCR-unadjusted (Day 28); Sensitivity analysis.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 3 Artesunate-pyronaridine versus artemether-lumefantrine; sensitivity analysis

Outcome: 1 Total failure PCR-unadjusted (Day 28); Sensitivity analysis

| Study or subgroup | AS-Pyr | AL | Risk Ratio | Weight | Risk Ratio |
|-------------------|--------|----|------------|--------|------------|
|                  | n/N    | n/N | M-H,Fixed,95% CI |        | M-H,Fixed,95% CI |
| Primary analysis (Cochrane review) | | | | | |
| Kayentao 2012     | 37/345 | 23/174 | 57.4 % | 0.81 [ 0.50, 1.32 ] | |
| Tshefu 2010       | 11/801 | 17/400 | 42.6 % | 0.32 [ 0.15, 0.68 ] | |
| **Subtotal (95% CI)** | **1146** | **574** | | **100.0 %** | **0.60 [ 0.40, 0.90 ]** |
| Total events: 48 (AS-Pyr), 40 (AL) | | | | | |
| Heterogeneity: Chi² = 4.09, df = 1 (P = 0.04); I² = 76% | | | | | |
| Test for overall effect: Z = 2.48 (P = 0.013) | | | | | |
| 2 Missing data included as failures | | | | | |
| Kayentao 2012     | 47/355 | 29/180 | 41.9 % | 0.82 [ 0.54, 1.26 ] | |
| Tshefu 2010       | 59/849 | 40/423 | 58.1 % | 0.73 [ 0.50, 1.08 ] | |
| **Subtotal (95% CI)** | **1204** | **603** | | **100.0 %** | **0.77 [ 0.58, 1.03 ]** |
| Total events: 106 (AS-Pyr), 69 (AL) | | | | | |
| Heterogeneity: Chi² = 0.15, df = 1 (P = 0.70); I² = 0.0% | | | | | |
| Test for overall effect: Z = 1.78 (P = 0.075) | | | | | |
| 3 Missing data included as successes | | | | | |
| Kayentao 2012     | 37/355 | 23/180 | 57.4 % | 0.82 [ 0.50, 1.33 ] | |
| Tshefu 2010       | 11/849 | 17/423 | 42.6 % | 0.32 [ 0.15, 0.68 ] | |
| **Subtotal (95% CI)** | **1204** | **603** | | **100.0 %** | **0.61 [ 0.41, 0.90 ]** |
| Total events: 48 (AS-Pyr), 40 (AL) | | | | | |
| Heterogeneity: Chi² = 4.15, df = 1 (P = 0.04); I² = 76% | | | | | |
| Test for overall effect: Z = 2.46 (P = 0.014) | | | | | |
| 4 Intention to treat analysis (of trial authors) | | | | | |
| Kayentao 2012     | 47/355 | 29/180 | 41.9 % | 0.82 [ 0.54, 1.26 ] | |
| Tshefu 2010       | 59/849 | 40/423 | 58.1 % | 0.73 [ 0.50, 1.08 ] | |
| **Subtotal (95% CI)** | **1204** | **603** | | **100.0 %** | **0.77 [ 0.58, 1.03 ]** |
| Total events: 106 (AS-Pyr), 69 (AL) | | | | | |
| Heterogeneity: Chi² = 0.15, df = 1 (P = 0.70); I² = 0.0% | | | | | |
| Test for overall effect: Z = 1.78 (P = 0.075) | | | | | |
| 5 Per-protocol analysis (of trial authors) | | | | | |
| Kayentao 2012     | 36/341 | 23/172 | 67.5 % | 0.79 [ 0.48, 1.29 ] | |
| Tshefu 2010       | 9/784  | 11/386 | 32.5 % | 0.40 [ 0.17, 0.96 ] | |

(Continued...)

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review) 73

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Analysis 3.2. Comparison 3 Artesunate-pyronaridine versus artemether-lumefantrine; sensitivity analysis, Outcome 2 Total failure PCR-adjusted (Day 28); Sensitivity analysis.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 3 Artesunate-pyronaridine versus artemether-lumefantrine; sensitivity analysis

Outcome: 2 Total failure PCR-adjusted (Day 28); Sensitivity analysis

| Study or subgroup | AS-Pyr | AL | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|-------------------|--------|----|-----------------------------|--------|-----------------------------|
| Primary analysis (Cochrane review)       |        |    |                             |        |                             |
| Kayentao 2012 (1) | 10/318 | 2/153 | 50.1 % 2.41 [0.53, 10.85] |        |                             |
| Tshefu 2010 (2)  | 4/794  | 2/385 | 49.9 % 0.97 [0.18, 5.27]  |        |                             |
| **Subtotal (95% CI)** | 1112  | 538 | 100.0 % 1.69 [0.56, 5.10] |        |                             |
| Total events: 14 (AS-Pyr), 4 (AL)       |        |    |                             |        |                             |
| Heterogeneity: Chi² = 0.62, df = 1 (P = 0.43); I² =0.0% |        |    |                             |        |                             |
| Test for overall effect: Z = 0.93 (P = 0.35) |        |    |                             |        |                             |
| 2 Missing or indeterminate PCR results included as failures |        |    |                             |        |                             |
| Kayentao 2012 (3) | 10/318 | 2/153 | 40.1 % 2.41 [0.53, 10.85] |        |                             |
| Tshefu 2010 (4)  | 4/794  | 3/386 | 59.9 % 0.65 [0.15, 2.88]  |        |                             |
| **Subtotal (95% CI)** | 1112  | 539 | 100.0 % 1.35 [0.49, 3.73] |        |                             |
| Total events: 14 (AS-Pyr), 5 (AL)       |        |    |                             |        |                             |
| Heterogeneity: Chi² = 1.50, df = 1 (P = 0.22); I² =33% |        |    |                             |        |                             |
| Test for overall effect: Z = 0.58 (P = 0.56) |        |    |                             |        |                             |
| 3 New infections included as successes |        |    |                             |        |                             |
| Kayentao 2012 (5) | 10/345 | 2/174 | 39.9 % 2.52 [0.56, 11.38] |        |                             |

(Continued...)

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)
| Study or subgroup | AS-Pyr n/N | AL n/N | Risk Ratio M-H,Fixed 95% CI | Weight | Risk Ratio M-H,Fixed 95% CI |
|------------------|-----------|-------|-----------------------------|--------|-----------------------------|
| Tshefu 2010 (6)  | 4/801     | 3/400 | 60.1 % 0.67 [0.15, 2.96]     | 0.67   | 0.67 [0.15, 2.96]           |
| **Subtotal (95% CI)** | **1146** | **574** |                           | **100.0 %** | **1.41 [0.51, 3.88]** |
| Kayentao 2012 (7) | 20/355    | 8/180 | 23.4 % 1.27 [0.57, 2.82]     | 1.27   | 1.27 [0.57, 2.82]           |
| Tshefu 2010 (8)  | 52/849    | 26/423| 76.6 % 1.00 [0.63, 1.57]     | 1.00   | 1.00 [0.63, 1.57]           |
| **Subtotal (95% CI)** | **1204** | **603** |                           | **100.0 %** | **1.06 [0.71, 1.57]** |
| Kayentao 2012 (9) | 10/355    | 2/180 | 39.9 % 2.54 [0.56, 11.45]    | 2.54   | 2.54 [0.56, 11.45]          |
| Tshefu 2010 (10) | 4/849     | 3/423 | 60.1 % 0.66 [0.15, 2.92]     | 0.66   | 0.66 [0.15, 2.92]           |
| **Subtotal (95% CI)** | **1204** | **603** |                           | **100.0 %** | **1.41 [0.51, 3.89]** |
| Kayentao 2012 (11) | 22/355    | 13/180| 29.4 % 0.87 [0.44, 1.66]     | 0.86   | 0.86 [0.44, 1.66]           |
| Tshefu 2010 (12) | 54/849    | 31/423| 70.6 % 0.87 [0.57, 1.33]     | 0.87   | 0.87 [0.57, 1.33]           |
| **Subtotal (95% CI)** | **1204** | **603** |                           | **100.0 %** | **0.87 [0.60, 1.24]** |
| Kayentao 2012 (13) | 10/339    | 2/167 | 14.0 % 0.87 [0.44, 1.66]     | 0.86   | 0.86 [0.44, 1.66]           |
| Tshefu 2010 (14) | 4/784     | 3/386 | 60.0 % 0.66 [0.15, 2.92]     | 0.66   | 0.66 [0.15, 2.92]           |
| **Subtotal (95% CI)** | **1123** | **553** |                           | **100.0 %** | **1.38 [0.50, 3.81]** |

Heterogeneity: Chi² = 1.54, df = 1 (P = 0.21), I² = 35%
Test for overall effect: Z = 0.66 (P = 0.51)

4 Missing data included as failures

Heterogeneity: Chi² = 1.45, df = 1 (P = 0.21), I² = 36%
Test for overall effect: Z = 0.66 (P = 0.51)

5 Missing data included as successes

Heterogeneity: Chi² = 0.00, df = 1 (P = 0.98), I² = 0.0%
Test for overall effect: Z = 0.79 (P = 0.43)

6 Intention to treat analysis (by trial authors)

Heterogeneity: Chi² = 1.66, df = 1 (P = 0.21), I² = 36%
Test for overall effect: Z = 0.66 (P = 0.51)

7 Per-protocol analysis (by trial authors)

Heterogeneity: Chi² = 1.52, df = 1 (P = 0.22), I² = 34%
Test for overall effect: Z = 0.62 (P = 0.53)

---

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)  
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Analysis 4.1. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 1 Total failure (Day 28).

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 4 Artesunate-pyronaridine versus artesunate-mefloquine

Outcome: 1 Total failure (Day 28)

| Study or subgroup | AS-Pyr n/N | AS-Mef n/N | Risk Ratio | Weight |
|------------------|------------|------------|------------|--------|
| 1 PCR-unadjusted | 12/801 | 17/399 | 0.35 [0.17, 0.73] | 100.0 % |
| Subtotal (95% CI) | 801 | 399 | 0.35 [0.17, 0.73] | 100.0 % |
| Total events: 12 (AS-Pyr), 17 (AS-Mef) |
| Heterogeneity: not applicable |
| Test for overall effect: Z = 2.81 (P = 0.005) |
| 2 PCR adjusted | 7/796 | 9/391 | 0.38 [0.14, 1.02] | 100.0 % |
| Subtotal (95% CI) | 796 | 391 | 0.38 [0.14, 1.02] | 100.0 % |
| Total events: 7 (AS-Pyr), 9 (AS-Mef) |
| Heterogeneity: not applicable |
| Test for overall effect: Z = 1.92 (P = 0.054) |
### Analysis 4.2. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 2 Total failure (Day 42).

**Review:** Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

**Comparison:** 4 Artesunate-pyronaridine versus artesunate-mefloquine

**Outcome:** 2 Total failure (Day 42)

| Study or subgroup     | AS-Pyr n/N | AS-Mef n/N | Risk Ratio M-H,Fixed,95% CI | Weight % | Risk Ratio M-H,Fixed,95% CI |
|-----------------------|------------|------------|----------------------------|----------|-----------------------------|
| 1 PCR-unadjusted      |            |            |                            |          |                             |
| Rueangveerayut 2012   | 55/763     | 32/383     | 0.86 [0.57, 1.31]          | 100.0%   |                             |
| **Subtotal (95% CI)** | **763**    | **383**    | 100.0%                     | 100.0%   | 0.86 [0.57, 1.31]           |
| Total events:         | 55 (AS-Pyr), 32 (AS-Mef) |                        |            |                             |
| Heterogeneity:        | not applicable |                      |            |                             |
| Test for overall effect: | Z = 0.69 (P = 0.49) |                      |            |                             |
| 2 PCR adjusted        |            |            |                            |          |                             |
| Rueangveerayut 2012   | 44/752     | 13/364     | 1.64 [0.89, 3.00]          | 100.0%   |                             |
| **Subtotal (95% CI)** | **752**    | **364**    | 100.0%                     | 100.0%   | 1.64 [0.89, 3.00]           |
| Total events:         | 44 (AS-Pyr), 13 (AS-Mef) |                        |            |                             |
| Heterogeneity:        | not applicable |                      |            |                             |
| Test for overall effect: | Z = 1.60 (P = 0.11) |                      |            |                             |
### Analysis 4.3. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 3 Early treatment failures.

**Review:** Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

**Comparison:** 4 Artesunate-pyronaridine versus artesunate-mefloquine

**Outcome:** 3 Early treatment failures

| Study or subgroup | AS-Pyr | AS-Mef | Risk Ratio | Weight | Risk Ratio |
|------------------|--------|--------|------------|--------|------------|
|                  | n/N    | n/N    | M-H,Fixed,95% CI |        | M-H,Fixed,95% CI |
| Rueangweerayut 2012 | 0/743 | 1/360 | 100.0 % | 0.16 [ 0.01, 3.96 ] |
| **Total (95% CI)** | 743    | 360    | 100.0 % | 0.16 [ 0.01, 3.96 ] |

Total events: 0 (AS-Pyr), 1 (AS-Mef)

Heterogeneity: not applicable

Test for overall effect: Z = 1.12 (P = 0.26)

Test for subgroup differences: Not applicable

### Analysis 4.4. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 4 Parasite clearance time (hours).

**Review:** Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

**Comparison:** 4 Artesunate-pyronaridine versus artesunate-mefloquine

**Outcome:** 4 Parasite clearance time (hours)

| Study or subgroup | AS-Pyr | AS-Mef | Mean Difference | Weight | Mean Difference |
|------------------|--------|--------|----------------|--------|----------------|
|                  | n     | Mean(SD) | IV,Fixed,95% CI |        | IV,Fixed,95% CI |
| Rueangweerayut 2012 | 839 | 35.9 (19.8) | -2.60 [-4.94, -0.26 ] | 100.0 % |
| **Total (95% CI)** | 839 | 420 | -2.60 [-4.94, -0.26 ] | 100.0 % |

Heterogeneity: not applicable

Test for overall effect: Z = 2.17 (P = 0.030)

Test for subgroup differences: Not applicable
**Analysis 4.5. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 5 Fever clearance time (hours).**

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 4 Artesunate-pyronaridine versus artesunate-mefloquine

Outcome: 5 Fever clearance time (hours)

| Study or subgroup | AS-Pyr | AS-Mef | Mean Difference | Weight |
|------------------|--------|--------|----------------|--------|
|                  | N      | Mean(SD) | N       | Mean(SD) | IV/Fixed,95% CI | IV/Fixed,95% CI |
| Rueangweerayut 2012 | 703    | 19.3 (12.9) | 348   | 19.2 (12.5) | 0.10 | [-1.52, 1.72] |
| **Total (95% CI)** | **703** | **348** | | | 100.0 % | 0.10 | [-1.52, 1.72] |

Heterogeneity: not applicable

Test for overall effect: Z = 0.12 (P = 0.90)

Test for subgroup differences: Not applicable

---

**Analysis 4.6. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 6 Gametocyte clearance time (hours).**

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 4 Artesunate-pyronaridine versus artesunate-mefloquine

Outcome: 6 Gametocyte clearance time (hours)

| Study or subgroup | AS-Pyr | AS-Mef | Mean Difference | Weight |
|------------------|--------|--------|----------------|--------|
|                  | N      | Mean(SD) | N       | Mean(SD) | IV/Fixed,95% CI | IV/Fixed,95% CI |
| Rueangweerayut 2012 | 13     | 25.5 (23.3) | 14 | 30.9 (19.9) | -5.40 | [-21.80, 11.00] |
| **Total (95% CI)** | **13** | **14** | | | 100.0 % | -5.40 | [-21.80, 11.00] |

Heterogeneity: not applicable

Test for overall effect: Z = 0.65 (P = 0.52)

Test for subgroup differences: Not applicable
### Analysis 4.7. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 7 Serious adverse events.

**Review:** Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

**Comparison:** 4 Artesunate-pyronaridine versus artesunate-mefloquine

**Outcome:** 7 Serious adverse events

| Study or subgroup | AS-Pyr n/N | AS-Mef n/N | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|-------------------|------------|------------|-----------------------------|--------|-----------------------------|
| Rueangweerayut 2012 (1) | 6/848 | 3/423 | 100.0 % | 1.00 [ 0.25, 3.97 ] |
| **Total (95% CI)** | **848** | **423** | **100.0 %** | **1.00 [ 0.25, 3.97 ]** |

Total events: 6 (AS-Pyr), 3 (AS-Mef)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable

(1) See appendix 4 for description of serious adverse events

### Analysis 4.8. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 8 Adverse events leading to withdrawal from treatment.

**Review:** Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

**Comparison:** 4 Artesunate-pyronaridine versus artesunate-mefloquine

**Outcome:** 8 Adverse events leading to withdrawal from treatment

| Study or subgroup | AS-Pyr n/N | AS-Mef n/N | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|-------------------|------------|------------|-----------------------------|--------|-----------------------------|
| Rueangweerayut 2012 | 5/848 | 4/423 | 100.0 % | 0.62 [ 0.17, 2.31 ] |
| **Total (95% CI)** | **848** | **423** | **100.0 %** | **0.62 [ 0.17, 2.31 ]** |

Total events: 5 (AS-Pyr), 4 (AS-Mef)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
## Analysis 4.9. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 9 Patient reported symptoms.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 4 Artesunate-pyronaridine versus artesunate-mefloquine

Outcome: 9 Patient reported symptoms

| Study or subgroup | AS-Pyr n/N | AS-Mef n/N | Risk Ratio M-H,Fixed 95% CI | Weight | Risk Ratio M-H,Fixed 95% CI |
|-------------------|------------|------------|-----------------------------|--------|-----------------------------|
| 1 Vomiting        | 18/848     | 9/423      | 7.6 % 1.00 [0.45, 2.20]     |        |                             |
| Subtotal (95% CI) | 848        | 423        |                             |        |                             |
| Total events:     | 18 (AS-Pyr), 9 (AS-Mef) |           |                             |        |                             |
| Heterogeneity:    | not applicable |          |                             |        |                             |
| Test for overall effect: | Z = 0.01 (P = 1.0) |          |                             |        |                             |
| 2 Diarrhea        | 8/848      | 9/423      | 7.6 % 0.44 [0.17, 1.14]     |        |                             |
| Subtotal (95% CI) | 848        | 423        |                             |        |                             |
| Total events:     | 8 (AS-Pyr), 9 (AS-Mef) |           |                             |        |                             |
| Heterogeneity:    | not applicable |          |                             |        |                             |
| Test for overall effect: | Z = 1.69 (P = 0.092) |          |                             |        |                             |
| 3 Headache        | 101/848    | 44/423     | 37.0 % 1.15 [0.82, 1.60]    | 1.15   | 0.82, 1.60                  |
| Subtotal (95% CI) | 848        | 423        |                             |        |                             |
| Total events:     | 101 (AS-Pyr), 44 (AS-Mef) |         |                             |        |                             |
| Heterogeneity:    | not applicable |          |                             |        |                             |
| Test for overall effect: | Z = 0.79 (P = 0.43) |          |                             |        |                             |
| 4 Dizziness       | 26/848     | 28/423     | 23.5 % 0.46 [0.28, 0.78]    | 0.46   | 0.28, 0.78                  |
| Subtotal (95% CI) | 848        | 423        |                             |        |                             |
| Total events:     | 26 (AS-Pyr), 28 (AS-Mef) |         |                             |        |                             |
| Heterogeneity:    | not applicable |          |                             |        |                             |
| Test for overall effect: | Z = 2.90 (P = 0.0038) |          |                             |        |                             |
| 5 Cough           | 30/848     | 10/423     | 8.4 % 1.50 [0.74, 3.03]     | 1.50   | 0.74, 3.03                  |
| Subtotal (95% CI) | 848        | 423        |                             |        |                             |
| Total events:     | 30 (AS-Pyr), 10 (AS-Mef) |         |                             |        |                             |
| Heterogeneity:    | not applicable |          |                             |        |                             |
| Test for overall effect: | Z = 1.12 (P = 0.26) |          |                             |        |                             |

(Continued...)

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Continued

| Study or subgroup | AS-Pyr n/N | AS-Mef n/N | Risk Ratio M-H,Fixed 95% CI | Weight | Risk Ratio M-H,Fixed 95% CI |
|------------------|------------|------------|----------------------------|--------|----------------------------|
| Rueangweerayut 2012 | 53/848 | 19/423 | 16.0 % 1.39 [ 0.83, 2.32 ] |        |                            |
| **Subtotal (95% CI)** | **848** | **423** | **16.0 % 1.39 [ 0.83, 2.32 ]** |        |                            |
| **Total (95% CI)** | **5088** | **2538** | **100.0 % 0.99 [ 0.80, 1.22 ]** |        |                            |

Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.21)
Test for subgroup differences: Chi$^2$ = 14.69, df = 5 (P = 0.01), I$^2$ =66%

(1) Rueangweerayut 2012: reports events experienced by at least 2% of participants

---

**Analysis 4.10. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 10 Abnormal LFTs; Grade 2 toxicity.**

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 4 Artesunate-pyronaridine versus artesunate-mefloquine

Outcome: 10 Abnormal LFTs; Grade 2 toxicity

| Study or subgroup | AS-Pyr n/N | AS-Mef n/N | Risk Ratio M-H,Fixed 95% CI | Risk Ratio M-H,Fixed 95% CI |
|------------------|------------|------------|----------------------------|----------------------------|
| 1 Alanine aminotransferase (ALT) Rueangweerayut 2012 | 25/843 | 2/417 | 6.18 [ 1.47, 25.98 ] |        |
| 2 Aspartate aminotransferase (AST) Rueangweerayut 2012 | 20/843 | 4/417 | 2.47 [ 0.85, 7.19 ] |        |
| 3 Alkaline phosphatase (ALP) Rueangweerayut 2012 | 4/633 | 0/303 | 4.32 [ 0.23, 79.90 ] |        |
| 4 Bilirubin Rueangweerayut 2012 | 6/843 | 5/417 | 0.59 [ 0.18, 1.93 ] |        |

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review) 83
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Analysis 4.11. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 11 Abnormal LFTs; Grade 3 or 4 toxicity.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 4 Artesunate-pyronaridine versus artesunate-mefloquine

Outcome: 11 Abnormal LFTs; Grade 3 or 4 toxicity

| Study or subgroup | AS-Pyr n/N | AS-Mef n/N | Risk Ratio M-H Fixed 95% CI | Risk Ratio M-H Fixed 95% CI |
|------------------|------------|------------|-----------------------------|-----------------------------|
| 1 Alanine aminotransferase (ALT) Rueangweerayut 2012 (1) | 15/843 | 1/417 | 7.42 [0.98, 55.98] | 7.42 [0.98, 55.98] |
| 2 Aspartate aminotransferase (AST) Rueangweerayut 2012 (2) | 9/843 | 0/417 | 9.41 [0.55, 161.28] | 9.41 [0.55, 161.28] |
| 3 Alkaline phosphatase (ALP) Rueangweerayut 2012 | 1/633 | 0/303 | 1.44 [0.06, 35.21] | 1.44 [0.06, 35.21] |
| 4 Bilirubin Rueangweerayut 2012 | 7/843 | 1/417 | 3.46 [0.43, 28.05] | 3.46 [0.43, 28.05] |

(1) Two patients given artesunate-pyronaridine had Grade 4 ALT toxicity (>10 times the upper limit of normal)

(2) Six patients given artesunate-pyronaridine had Grade 4 AST toxicity (>10 times the upper limit of normal)
Analysis 4.12. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 12 Haemoglobin (g/dL).

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 4 Artesunate-pyronaridine versus artesunate-mefloquine

Outcome: 12 Haemoglobin (g/dL)

| Study or subgroup | AS-Pyr | | AS-Mef | | | | Mean Difference | Mean Difference |
|-------------------|--------|--------|--------|--------|--------|--------|----------------|----------------|
|                   | N      | Mean(SD) | N      | Mean(SD) | IV/Fixed| 95% CI | IV/Fixed| 95% CI | |
| 1 Haemoglobin at baseline | 848 | 12.35 (1.98) | 423 | 12.08 (1.99) | 0.27 [ 0.04, 0.50 ] |
| Rueangweerayut 2012 | 842 | -0.73 (1.07) | 416 | -0.51 (1.2) | -0.22 [ -0.36, -0.08 ] |
| 2 Haemoglobin day 3 | 815 | -0.93 (1.17) | 404 | -0.76 (1.24) | -0.17 [ -0.32, -0.02 ] |
| Rueangweerayut 2012 | 794 | 0.26 (1.6) | 392 | 0.47 (1.6) | -0.21 [ -0.40, -0.02 ] |

@ARTESunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)
### Analysis 4.13. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 13 Platelet counts (x 10⁹/L).

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 4 Artesunate-pyronaridine versus artesunate-mefloquine

Outcome: 13 Platelet counts (x 10⁹/L)

| Study or subgroup | AS-Pyr  | AS-Mef  | Mean Difference | Mean Difference |
|-------------------|---------|---------|-----------------|-----------------|
|                   | N       | Mean(SD)| N               | Mean(SD)        |
| 1 baseline        | 847     | 139.9 (70.4) | 423             | 140.1 (65.3)    | -0.20 [-8.02, 7.62] |
| 2 day 3           | 841     | 46.5 (70.7)  | 416             | 58.3 (81.1)     | -11.80 [-20.94, -2.66] |
| 3 day 7           | 816     | 188.5 (124.7) | 404             | 206.4 (125)     | -17.90 [-32.79, -3.01] |
| 4 day 28          | 794     | 101.7 (84.5) | 392             | 102 (72.1)      | -0.30 [-9.55, 8.95]   |

Favours AS-Mef Favours AS-Pyr
### Analysis 4.14. Comparison 4 Artesunate-pyronaridine versus artemesunate-mefloquine, Outcome 14 White blood counts (x 10^9/L).

**Review:** Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

**Comparison:** 4 Artesunate-pyronaridine versus artemesunate-mefloquine

**Outcome:** 14 White blood counts (x 10^9/L)

| Study or subgroup | AS-Pyr | AS-Mef | Mean Difference | Mean Difference |
|-------------------|--------|--------|----------------|----------------|
|                   | N      | Mean(SD) | N       | Mean(SD) | IV,Fixed,95% CI | IV,Fixed,95% CI |
| 1 baseline        |        |         |          |          |                |                |
| Rueangweerayut 2012 | 848   | 6.3 (2.4) | 423    | 6.3 (2.3) | 0.0 [-0.27, 0.27 ] |                |
| 2 day 3           |        |         |          |          |                |                |
| Rueangweerayut 2012 | 842   | -0.7 (2.4) | 416    | -0.6 (2.2) | -0.10 [-0.37, 0.17 ] |                |
| 3 day 7           |        |         |          |          |                |                |
| Rueangweerayut 2012 | 816   | 1.4 (2.6) | 404    | 2.1 (2.7)  | -0.70 [-1.02, -0.38 ] |                |
| 4 day 28          |        |         |          |          |                |                |
| Rueangweerayut 2012 | 794   | 1.2 (2.9) | 392    | 1.4 (2.8)  | -0.20 [-0.54, 0.14 ] |                |
### Analysis 4.15. Comparison 4 Artesunate-pyronaridine versus artesunate-mefloquine, Outcome 15 Abnormal ECG finding.

**Review:** Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

**Comparison:** 4 Artesunate-pyronaridine versus artesunate-mefloquine

**Outcome:** 15 Abnormal ECG finding

| Study or subgroup | AS-Pyr n/N | AS-Mef n/N | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|------------------|------------|------------|-----------------------------|--------|-----------------------------|
| **1 QT prolongation** | | | | | |
| Rueangweerayut 2012 (1) | 1/848 | 3/423 | - | 50.0 % | 0.17 [ 0.02, 1.59 ] |
| **Subtotal (95% CI)** | 848 | 423 | - | 50.0 % | 0.17 [ 0.02, 1.59 ] |
| Total events: 1 (AS-Pyr), 3 (AS-Mef) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 1.56 (P = 0.12) | | | | | |
| **2 ECG abnormalities** | | | | | |
| Rueangweerayut 2012 | 6/848 | 3/423 | - | 50.0 % | 1.00 [ 0.25, 3.97 ] |
| **Subtotal (95% CI)** | 848 | 423 | - | 50.0 % | 1.00 [ 0.25, 3.97 ] |
| Total events: 6 (AS-Pyr), 3 (AS-Mef) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 0.00 (P = 1.0) | | | | | |
| **Total (95% CI)** | 1696 | 846 | - | 100.0 % | 0.58 [ 0.20, 1.73 ] |
| Total events: 7 (AS-Pyr), 6 (AS-Mef) | | | | | |
| Heterogeneity: Chi² = 1.77, df = 1 (P = 0.18); I² = 43% | | | | | |
| Test for overall effect: Z = 0.98 (P = 0.33) | | | | | |
| Test for subgroup differences: Chi² = 1.76, df = 1 (P = 0.18); I² = 43% | | | | | |

(1) Rueangweerayut 2012: “All abnormalities were mild and resolved before study completion”
### Analysis 5.1. Comparison 5 Artesunate-pyronaridine versus artesunate-mefloquine; subgroup analysis, Outcome 1 Total failure PCR-adjusted (Day 28); subgrouped by region.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 5 Artesunate-pyronaridine versus artesunate-mefloquine; subgroup analysis

Outcome: 1 Total failure PCR-adjusted (Day 28); subgrouped by region

| Study or subgroup | AS-Pyr | AS-Mef | Risk Ratio | Risk Ratio |
|-------------------|--------|--------|------------|------------|
|                   | n/N    | n/N    | M-H,Fixed,95% CI | M-H,Fixed,95% CI |
| 1 East Africa     | 0/25   | 0/13   | 0.0 [ 0.0, 0.0 ] |  |
| **Subtotal (95% CI)** | **25** | **13** | **0.0 [ 0.0, 0.0 ]** |  |
|                   |        |        | Heterogeneity: not applicable |  |
|                   |        |        | Test for overall effect: Z = 0.0 (P < 0.00001) |  |
| 2 West Africa     | 1/129  | 0/63   | 1.48 [ 0.06, 35.75 ] |  |
| **Subtotal (95% CI)** | **129** | **63** | **1.48 [ 0.06, 35.75 ]** |  |
|                   |        |        | Heterogeneity: not applicable |  |
|                   |        |        | Test for overall effect: Z = 0.24 (P = 0.81) |  |
| 3 South central Africa | 0      | 0      | 0.0 [ 0.0, 0.0 ] |  |
| **Subtotal (95% CI)** | **0**  | **0**  | **0.0 [ 0.0, 0.0 ]** |  |
|                   |        |        | Heterogeneity: not applicable |  |
|                   |        |        | Test for overall effect: not applicable |  |
| 4 Asia            | 5/595  | 8/292  | 0.31 [ 0.10, 0.93 ] |  |
| **Subtotal (95% CI)** | **595** | **292** | **0.31 [ 0.10, 0.93 ]** |  |
|                   |        |        | Heterogeneity: not applicable |  |
|                   |        |        | Test for overall effect: Z = 2.09 (P = 0.037) |  |
| **Total (95% CI)** | **595** | **292** | **0.31 [ 0.10, 0.93 ]** |  |
|                   |        |        | Heterogeneity: not applicable |  |
|                   |        |        | Test for overall effect: Z = 1.89 (P = 0.058) |  |
|                   |        |        | Test for subgroup differences: Chi² = 0.83, df = 1 (P = 0.36); I² =0.0% |  |
|                   |        |        |  |

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Analysis 5.2. Comparison 5 Artesunate-pyronaridine versus artesunate-mefloquine; subgroup analysis, Outcome 2 Total failure PCR-adjusted (Day 28); subgrouped by country.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 5 Artesunate-pyronaridine versus artesunate-mefloquine; subgroup analysis

Outcome: 2 Total failure PCR-adjusted (Day 28); subgrouped by country

| Study or subgroup | AS-Pyr n/N | AS-Mef n/N | Risk Ratio M-H,Fixed,95% CI | Risk Ratio M-H,Fixed,95% CI |
|------------------|------------|------------|-----------------------------|-----------------------------|
| 1 Thailand       | 2/369      | 8/182      | 0.12 [0.03, 0.57]           |                             |
| **Subtotal (95% CI)** | **369** | **182** | **0.12 [0.03, 0.57]** | **0.12 [0.03, 0.57]** |
| 2 Vietnam        | 0/104      | 0/55       | 0.0 [0.0, 0.0]              |                             |
| **Subtotal (95% CI)** | **104** | **55** | **0.0 [0.0, 0.0]** | **0.0 [0.0, 0.0]** |
| 3 Cambodia       | 3/90       | 0/42       | 3.31 [0.17, 62.62]          |                             |
| **Subtotal (95% CI)** | **90** | **42** | **3.31 [0.17, 62.62]** | **3.31 [0.17, 62.62]** |
| 4 India          | 0/32       | 0/13       | 0.0 [0.0, 0.0]              |                             |
| **Subtotal (95% CI)** | **32** | **13** | **0.0 [0.0, 0.0]** | **0.0 [0.0, 0.0]** |
| 5 Burkina Faso   | 0/81       | 0/37       | 0.0 [0.0, 0.0]              |                             |
| **Subtotal (95% CI)** | **81** | **37** | **0.0 [0.0, 0.0]** | **0.0 [0.0, 0.0]** |
| 6 Ivory Coast    | 1/48       | 0/26       | 1.65 [0.07, 39.20]          |                             |
| Study or subgroup | AS-Pyr n/N | AS-Mef n/N | Risk Ratio M-H,Fixed 95% CI |
|------------------|-----------|-----------|--------------------------|
| Subtotal (95% CI)| 48/26 |          | 1.65 [0.07, 39.20] |
| Total events: 1 (AS-Pyr), 0 (AS-Mef) |
| Heterogeneity: not applicable |
| Test for overall effect: Z = 0.31 (P = 0.76) |
| Tanzania Rueangveerayut 2012 | 0/25 | 0/13 | 0.00 [0.0, 0.0] |
| Subtotal (95% CI) | 25/13 |          | 0.00 [0.0, 0.0] |
| Total events: 0 (AS-Pyr), 0 (AS-Mef) |
| Heterogeneity: not applicable |
| Test for overall effect: Z = 0.00 (P < 0.00001) |
| Total (95% CI) | 749/368 |          | 0.38 [0.14, 1.03] |
| Total events: 6 (AS-Pyr), 8 (AS-Mef) |
| Heterogeneity: Chi² = 4.97, df = 2 (P = 0.08); I² = 60% |
| Test for overall effect: Z = 1.91 (P = 0.056) |
| Test for subgroup differences: Chi² = 4.92, df = 2 (P = 0.09), I² = 59% |

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
### Analysis 6.1. Comparison 6 Artesunate-pyronaridine versus artesunate-mefloquine; sensitivity analysis, Outcome 1 Total failure PCR-unadjusted (Day 28); Sensitivity analysis.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 6 Artesunate-pyronaridine versus artesunate-mefloquine; sensitivity analysis

Outcome: 1 Total failure PCR-unadjusted (Day 28); Sensitivity analysis

| Study or subgroup | AS-Pyr n/N | AS-Mef n/N | Risk Ratio M-H,Fixed 95% CI | Weight | Risk Ratio M-H,Fixed 95% CI |
|-------------------|------------|------------|----------------------------|--------|----------------------------|
| Primary analysis (Cochrane review) | | | | | |
| Rueangweerayut 2012 | 12/801 | 17/399 | 0.35 [0.17, 0.73] | 100.0 % | |
| **Subtotal (95% CI)** | **801** | **399** | | **100.0 %** | **0.35 [0.17, 0.73]** |
| Total events: 12 (AS-Pyr), 17 (AS-Mef) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 2.81 (P = 0.0050) | | | | | |
| 2 Missing data included as failures | | | | | |
| Rueangweerayut 2012 | 59/848 | 41/423 | 0.72 [0.49, 1.05] | 100.0 % | |
| **Subtotal (95% CI)** | **848** | **423** | | **100.0 %** | **0.72 [0.49, 1.05]** |
| Total events: 59 (AS-Pyr), 41 (AS-Mef) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 1.71 (P = 0.088) | | | | | |
| 3 Missing data included as successes | | | | | |
| Rueangweerayut 2012 | 12/848 | 17/423 | 0.35 [0.17, 0.73] | 100.0 % | |
| **Subtotal (95% CI)** | **848** | **423** | | **100.0 %** | **0.35 [0.17, 0.73]** |
| Total events: 12 (AS-Pyr), 17 (AS-Mef) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 2.80 (P = 0.0051) | | | | | |
| 4 Intention to treat analysis (of trial authors) | | | | | |
| Rueangweerayut 2012 | 59/848 | 41/423 | 0.72 [0.49, 1.05] | 100.0 % | |
| **Subtotal (95% CI)** | **848** | **423** | | **100.0 %** | **0.72 [0.49, 1.05]** |
| Total events: 59 (AS-Pyr), 41 (AS-Mef) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 1.71 (P = 0.088) | | | | | |
| 5 Per-protocol analysis (of trial authors) | | | | | |
| Rueangweerayut 2012 | 11/750 | 15/370 | 0.36 [0.17, 0.78] | 100.0 % | |
| **Subtotal (95% CI)** | **750** | **370** | | **100.0 %** | **0.36 [0.17, 0.78]** |
| Total events: 11 (AS-Pyr), 15 (AS-Mef) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 2.59 (P = 0.0095) | | | | | |

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
### Analysis 6.2. Comparison 6 Artesunate-pyronaridine versus artesunate-mefloquine; sensitivity analysis, Outcome 2 Total failure PCR-adjusted (Day 28); Sensitivity analysis.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 6 Artesunate-pyronaridine versus artesunate-mefloquine; sensitivity analysis

Outcome: 2 Total failure PCR-adjusted (Day 28); Sensitivity analysis

| Study or subgroup | AS-Pyr | AS-Mef | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|-------------------|--------|--------|-----------------------------|--------|-----------------------------|
| 1 Primary analysis (Cochrane review) | | | | | |
| Ruenangweerayut 2012 | 7/796 | 9/391 | 100.0% | 0.38 [0.14, 1.02] | 0.38 [0.14, 1.02] |
| Subtotal (95% CI) | 796 | 391 | 100.0% | 0.38 [0.14, 1.02] | 0.38 [0.14, 1.02] |
| Total events: 7 (AS-Pyr), 9 (AS-Mef) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 1.92 (P = 0.054) | | | | | |
| 2 Missing or indeterminate PCR results included as failures | | | | | |
| Ruenangweerayut 2012 | 7/796 | 9/391 | 100.0% | 0.38 [0.14, 1.02] | 0.38 [0.14, 1.02] |
| Subtotal (95% CI) | 796 | 391 | 100.0% | 0.38 [0.14, 1.02] | 0.38 [0.14, 1.02] |
| Total events: 7 (AS-Pyr), 9 (AS-Mef) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 1.92 (P = 0.054) | | | | | |
| 3 New infections included as successes | | | | | |
| Ruenangweerayut 2012 | 7/801 | 9/399 | 100.0% | 0.39 [0.15, 1.03] | 0.39 [0.15, 1.03] |
| Subtotal (95% CI) | 801 | 399 | 100.0% | 0.39 [0.15, 1.03] | 0.39 [0.15, 1.03] |
| Total events: 7 (AS-Pyr), 9 (AS-Mef) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 1.90 (P = 0.058) | | | | | |
| 4 Missing data included as failures | | | | | |
| Ruenangweerayut 2012 | 54/848 | 33/423 | 100.0% | 0.82 [0.54, 1.24] | 0.82 [0.54, 1.24] |
| Subtotal (95% CI) | 848 | 423 | 100.0% | 0.82 [0.54, 1.24] | 0.82 [0.54, 1.24] |
| Total events: 54 (AS-Pyr), 33 (AS-Mef) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 0.95 (P = 0.34) | | | | | |
| 5 Missing data included as successes | | | | | |
| Ruenangweerayut 2012 | 7/848 | 9/423 | 100.0% | 0.39 [0.15, 1.03] | 0.39 [0.15, 1.03] |
| Subtotal (95% CI) | 848 | 423 | 100.0% | 0.39 [0.15, 1.03] | 0.39 [0.15, 1.03] |
| Total events: 7 (AS-Pyr), 9 (AS-Mef) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 1.89 (P = 0.058) | | | | | |
| 6 Intention to treat analysis (by trial authors) | | | | | |
| Ruenangweerayut 2012 | 55/848 | 36/423 | 100.0% | 0.76 [0.51, 1.14] | 0.76 [0.51, 1.14] | (Continued . . .)
| Study or subgroup | AS-Pyr n/N | AS-Mef n/N | Risk Ratio M-H,Fixed 95% CI | Weight | Risk Ratio M-H,Fixed 95% CI |
|------------------|------------|------------|---------------------------|--------|---------------------------|
| Subtotal (95% CI)| 848/423    |            | 100.0 % 0.76 [0.51, 1.14] |        |                            |
| Total events:    |            |            | 55 (AS-Pyr), 36 (AS-Mef)  |        |                            |
| Heterogeneity:   |            |            | not applicable             |        |                            |
| Test for overall effect: | Z = 1.32 (P = 0.19) |        |                            |        |                            |
| 7 Per-protocol analysis (by trial authors) |        |            |                            |        |                            |
| Rueangweerayut 2012 | 6/749      | 8/368      | 100.0 % 0.37 [0.13, 1.05] |        |                            |
| Subtotal (95% CI)| 749/368    |            | 100.0 % 0.37 [0.13, 1.05] |        |                            |
| Total events:    |            |            | 6 (AS-Pyr), 8 (AS-Mef)     |        |                            |
| Heterogeneity:   |            |            | not applicable             |        |                            |
| Test for overall effect: | Z = 1.86 (P = 0.063) |        |                            |        |                            |
### Analysis 7.1. Comparison of Pyronaridine alone or with artesunate versus another antimalarial: laboratory findings, Outcome 1 Abnormal LFTs; Grade 3 or 4 toxicity.

**Review:** Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

**Comparison:** 7 Pyronaridine alone or with artesunate versus another antimalarial: laboratory findings

**Outcome:** 1 Abnormal LFTs; Grade 3 or 4 toxicity

| Study or subgroup | Pyronaridine | Comparator | Risk Ratio (95% CI) | Weight | Risk Ratio (95% CI) |
|-------------------|--------------|------------|---------------------|--------|--------------------|
| **1. Alanine aminotransferase (ALT)** | | | | | |
| Kayentao 2012 (1) | 1/355 | 1/180 | 29.5% | 0.51 [0.03, 8.06] | |
| Paravuth 2011 (2) | 3/228 | 0/228 | 11.1% | 7.00 [0.36, 134.75] | |
| Rueangveerayut 2012 (3) | 1/843 | 1/417 | 29.7% | 7.42 [0.98, 55.98] | |
| Tshefu 2010 (4) | 7/849 | 1/423 | 29.7% | 3.49 [0.43, 28.25] | |
| **Subtotal (95% CI)** | 2275 | 1248 | 100.0% | 4.17 [1.38, 12.62] | |
| **2. Aspartate aminotransferase (AST)** | | | | | |
| Kayentao 2012 (5) | 3/355 | 1/180 | 36.2% | 1.52 [0.16, 14.52] | |
| Paravuth 2011 | 1/228 | 1/228 | 27.3% | 1.00 [0.06, 15.89] | |
| Rueangveerayut 2012 | 9/848 | 0/417 | 18.3% | 9.35 [0.55, 160.33] | |
| Tshefu 2010 | 8/849 | 0/423 | 18.2% | 8.48 [0.49, 146.57] | |
| **Subtotal (95% CI)** | 2280 | 1248 | 100.0% | 4.08 [1.17, 14.26] | |
| **3. Alkaline phosphatase (ALP)** | | | | | |
| Paravuth 2011 | 1/199 | 0/199 | 11.1% | 3.00 [0.12, 73.20] | |
| Rueangveerayut 2012 | 1/633 | 0/303 | 15.0% | 1.44 [0.06, 35.21] | |
| Tshefu 2010 | 0/849 | 2/423 | 73.9% | 0.10 [0.00, 2.07] | |
| **Subtotal (95% CI)** | 1681 | 925 | 100.0% | 0.62 [0.15, 2.51] | |
| **4. Bilirubin** | | | | | |
| Kayentao 2012 (6) | 1/355 | 2/180 | 57.0% | 0.25 [0.02, 2.78] | |
| Rueangveerayut 2012 (7) | 7/843 | 1/417 | 28.7% | 3.46 [0.43, 28.05] | |

Heterogeneity: Chi² = 2.69, df = 3 (P = 0.44); I² = 0.0%

Test for overall effect: Z = 2.53 (P = 0.012)

**Heterogeneity: Chi² = 2.31, df = 3 (P = 0.51); I² = 0.0%**

Test for overall effect: Z = 2.20 (P = 0.028)

**Heterogeneity: Chi² = 2.59, df = 2 (P = 0.27); I² = 23%**

Test for overall effect: Z = 0.67 (P = 0.50)

**Heterogeneity: Chi² = 2.59, df = 2 (P = 0.27); I² = 23%**

Test for overall effect: Z = 0.67 (P = 0.50)

**Heterogeneity: Chi² = 2.59, df = 2 (P = 0.27); I² = 23%**

Test for overall effect: Z = 0.67 (P = 0.50)

(Continued...)
### Study or subgroup  
| Pyronaridine | Comparator | Risk Ratio | Weight | Risk Ratio |
|--------------|------------|------------|--------|------------|
| n/N          | n/N        | M-H,Fixed,95% CI |        | M-H,Fixed,95% CI |
| **Tshefu 2010 (8)** | 5/849 | 0/423 | 14.3 % | 5.49 [ 0.30, 99.00 ] |
| **Subtotal (95% CI)** | **2047** | **1020** | 100.0 % | **1.92 [ 0.59, 6.24 ]** |

Total events: 13 (Pyronaridine), 3 (Comparator)  
Heterogeneity: $\chi^2 = 3.56$, df = 2 ($P = 0.17$); $I^2 = 44\%$  
Test for overall effect: $Z = 1.09$ ($P = 0.28$)  
Test for subgroup differences: $\chi^2 = 5.38$, df = 3 ($P = 0.15$); $I^2 = 44\%$

### Notes:

- **AST Grade 3 toxicity as 10 - 15 x ULN, Grade 4 toxicity as > 15 x ULN**

1. Kayentao 2012: compares artesunate-pyronaridine with artemether-lumefantrine. Kayentao 2012 uses another toxicity grading scale as the remaining studies, and defines for ALT, ALP and
2. Poravuth 2011 compares artesunate-pyronaridine with chloroquine.
3. Rueangweerayut 2012 compares artesunate-pyronaridine versus artesunate plus mefloquine
4. Tshefu 2010 compares artesunate-pyronaridine with artemether-lumefantrine
5. Kayentao 2012 reports grade 4 toxicity only
6. Kayentao 2012 uses a different toxicity grading scale with higher cut offs than Tshefu 2010. Total bilirubin grade 3 toxicity 3.0-7.5 x ULN.
7. Rueangweerayut 2012: no grade 4 toxicity reported
8. Thsefu 2010 defines grade 3 toxicity for Bilirubin 2.6 - 5 x ULN and grade 4 toxicity > 5 x UNL
**Analysis 7.2. Comparison 7 Pyronaridine alone or with artemesunate versus another antimalarial: laboratory findings, Outcome 2 Combined abnormal LFTs.**

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 7 Pyronaridine alone or with artemesunate versus another antimalarial: laboratory findings

Outcome: 2 Combined abnormal LFTs

| Study or subgroup | Pyronaridine n/N | Comparator n/N | Risk Ratio M-H,Fixed,95% CI | Weight M-H,Fixed,95% CI |
|------------------|-----------------|----------------|-----------------------------|-------------------------|
| 1 AL T > 3 x ULN and Bilirubin > 2 x ULN (Hy's Law case) |  Kayentao 2012 (1) 1/355 | 1/180 | 49.8 % 0.51 [ 0.03, 8.06 ] | |
|                  | Rueangweerayut 2012 (2) 2/848 | 0/417 | 25.1 % 2.46 [ 0.12, 51.16 ] | |
|                  | Tshefu 2010 (3) 2/849 | 0/423 | 25.0 % 2.49 [ 0.12, 51.83 ] | |
| **Subtotal (95% CI)** | 2052 | 1020 | **100.0 % 1.50 [ 0.30, 7.42 ]** | |

Total events: 5 (Pyronaridine), 1 (Comparator)

Heterogeneity: Chi² = 0.80, df = 2 (P = 0.67); I² =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable

(1) Kayentao 2011: compares artemesunate-pyronaridine to artemether-lumefantrine. outcome defined as ALT elevation > 3 x ULN and Bilirubin elevation > 2 x ULN. Hy's Law case, a prognostic

(2) Rueangweerayut 2012: compares artemesunate-pyronaridine to artemesunate-mefloquine. no event (ALT 3 x ULN and Bilirubin 2 x ULN) reported in the comparator group, we therefore assumed

(3) Thesfu 2010: compares pyronaridine-artemethere-lumefantrine
Analysis 7.3. Comparison 7 Pyronaridine alone or with artesunate versus another antimalarial: laboratory findings, Outcome 3 Renal function tests.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 7 Pyronaridine alone or with artesunate versus another antimalarial: laboratory findings

Outcome: 3 Renal function tests

| Study or subgroup | Pyronaridine | Comparator | Mean Difference | Weight | Mean Difference |
|-------------------|--------------|------------|----------------|--------|----------------|
| 1 Baseline        |              |            |                |        |                |
| Kayentao 2012 (1) | 349 41.8 (17.1) | 177 42.6 (18) | -0.80 [-4.00, 2.40] | 37.3 % |                |
| Ringwald 1998 (2) | 41 52 (16)   | 40 56.3 (22.9) | -4.30 [-12.92, 4.32] | 5.1 % |                |
| Rueangweerayut 2012 (3) | 848 78.4 (22.1) | 423 77.7 (22.1) | 0.70 [-1.88, 3.28] | 57.5 % |                |
| **Subtotal (95% CI)** | **1238** | **640** | **-0.12 [-2.07, 1.84]** |        |                |
| Heterogeneity: Chi$^2$ = 1.46, df = 2 (P = 0.48); I$^2$ = 0.0%
| Test for overall effect: Z = 0.12 (P = 0.91) |
| 2 Day 3           |              |            |                |        |                |
| Kayentao 2012     | 339 -3.5 (18.3) | 167 -2.9 (20.1) | -0.60 [-4.22, 3.02] | 25.4 % |                |
| Rueangweerayut 2012 | 841 -8.7 (20.1) | 417 -6.6 (16.8) | -2.10 [-4.21, 0.01] | 74.6 % |                |
| **Subtotal (95% CI)** | **1180** | **584** | **-1.72 [-3.54, 0.10]** |        |                |
| Heterogeneity: Chi$^2$ = 0.49, df = 1 (P = 0.48); I$^2$ = 0.0%
| Test for overall effect: Z = 1.85 (P = 0.064) |
| 3 Day 7           |              |            |                |        |                |
| Kayentao 2012     | 339 -3.4 (17.7) | 170 -3.6 (17.6) | 0.20 [-3.05, 3.45] | 31.4 % |                |
| Ringwald 1998     | 41 52 (16)   | 40 56.3 (22.9) | -4.30 [-12.92, 4.32] | 4.5 % |                |
| Rueangweerayut 2012 | 814 -9.6 (19.4) | 404 -5.5 (18.9) | -4.10 [-6.37, -1.83] | 64.1 % |                |
| **Subtotal (95% CI)** | **1194** | **614** | **-2.76 [-4.58, -0.94]** |        |                |
| Heterogeneity: Chi$^2$ = 4.65, df = 2 (P = 0.099); I$^2$ = 57%
| Test for overall effect: Z = 2.97 (P = 0.0030)
| Test for subgroup differences: Chi$^2$ = 3.79, df = 2 (P = 0.15), I$^2$ = 47%

(1) Kayentao 2012: compares artesunate-pyronaridine versus artemether-lumefantrine. Creatinin umol/l

(2) Ringwald 1998: compares pyronaridine to chloroquine. Kreatinin umol/l

(3) Rueangweerayut 2012: compares artesunate-pyronaridine to artesunate-mefloquine. Creatinin umol/l

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review) 98

Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Analysis 7.4. Comparison 7 Pyronaridine alone or with artesunate versus another antimalarial: laboratory findings, Outcome 4 Haemoglobin.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 7 Pyronaridine alone or with artesunate versus another antimalarial: laboratory findings

Outcome: 4 Haemoglobin

| Study or subgroup | Pyronaridine | Comparator | Mean Difference | Weight | Mean Difference |
|------------------|--------------|------------|----------------|--------|----------------|
|                  | N Mean(SD)   | N Mean(SD) | IV,Fixed,95% CI |        | IV,Fixed,95% CI |
| 1 Haemoglobin at baseline |
| Kayentao 2012 (1) | 355 10.2 (1.3) | 180 10.3 (1.4) | -0.10 [-0.35, 0.15] |
| Poravuth 2011 (2) | 228 12.53 (1.7) | 228 12.34 (1.84) | 0.19 [-0.14, 0.52] |
| Rueangweerayut 2012 (3) | 848 12.35 (1.98) | 423 12.08 (1.99) | 28.2 % 0.27 [0.04, 0.50] |
| Tshefu 2010 (4) | 849 12.06 (1.82) | 423 12.04 (1.87) | 32.4 % 0.02 [-0.20, 0.24] |
| **Subtotal (95% CI)** | 2280 1254 | | 100.0 % 0.08 [-0.04, 0.21] |
| Heterogeneity: Chi$^2$ = 5.38, df = 3 (P = 0.15); I$^2$ =44% |
| Test for overall effect: Z = 1.35 (P = 0.18) |

2 Haemoglobin day 3

| Study or subgroup | Pyronaridine | Comparator | Mean Difference | Weight | Mean Difference |
|------------------|--------------|------------|----------------|--------|----------------|
|                  | N Mean(SD)   | N Mean(SD) | IV,Fixed,95% CI |        | IV,Fixed,95% CI |
| Kayentao 2012 | 348 -0.6 (1.2) | 176 -0.68 (1.2) | 13.1 % 0.08 [-0.14, 0.30] |
| Poravuth 2011 | 226 -0.55 (0.85) | 222 -0.37 (0.89) | 23.8 % -0.18 [-0.34, -0.02] |
| Rueangweerayut 2012 | 842 -0.73 (1.07) | 416 -0.51 (1.2) | 33.4 % -0.22 [-0.36, -0.08] |
| Tshefu 2010 | 819 -0.57 (1.23) | 412 -0.52 (1.21) | 29.8 % -0.05 [-0.19, 0.09] |
| **Subtotal (95% CI)** | 2235 1226 | | 100.0 % -0.12 [-0.20, -0.04] |
| Heterogeneity: Chi$^2$ = 6.76, df = 3 (P = 0.08); I$^2$ =56% |
| Test for overall effect: Z = 3.01 (P = 0.0026) |

3 Haemoglobin day 7

| Study or subgroup | Pyronaridine | Comparator | Mean Difference | Weight | Mean Difference |
|------------------|--------------|------------|----------------|--------|----------------|
|                  | N Mean(SD)   | N Mean(SD) | IV,Fixed,95% CI |        | IV,Fixed,95% CI |
| Kayentao 2012 | 345 -0.28 (1.1) | 173 -0.26 (1.1) | 16.5 % -0.02 [-0.22, 0.18] |
| Poravuth 2011 | 219 -0.6 (0.91) | 215 -0.07 (1) | 20.5 % -0.53 [-0.71, -0.35] |
| Rueangweerayut 2012 | 815 -0.93 (1.17) | 404 -0.76 (1.24) | 31.6 % -0.17 [-0.32, -0.02] |
| Tshefu 2010 | 817 -0.85 (1.27) | 406 -0.61 (1.2) | 31.4 % -0.24 [-0.39, -0.09] |
| **Subtotal (95% CI)** | 2196 1198 | | 100.0 % -0.24 [-0.32, -0.16] |
| Heterogeneity: Chi$^2$ = 15.47, df = 3 (P = 0.001); I$^2$ =81% |
| Test for overall effect: Z = 5.79 (P < 0.00001) |

4 Haemoglobin day 28

| Study or subgroup | Pyronaridine | Comparator | Mean Difference | Weight | Mean Difference |
|------------------|--------------|------------|----------------|--------|----------------|
|                  | N Mean(SD)   | N Mean(SD) | IV,Fixed,95% CI |        | IV,Fixed,95% CI |
| Kayentao 2012 | 334 0.85 (1.3) | 171 0.75 (1.4) | 15.9 % 0.10 [-0.15, 0.35] |
| Poravuth 2011 | 203 0.29 (1.19) | 203 0.57 (1.19) | 18.9 % -0.28 [-0.51, -0.05] |
| Rueangweerayut 2012 | 794 0.26 (1.6) | 392 0.47 (1.6) | 27.0 % -0.21 [-0.40, -0.02] |

(Continued ...)

Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
| Study or subgroup | Pyronaridine | Comparator | Mean Difference | Weight | Mean Difference |
|-----------------|-------------|-----------|----------------|--------|----------------|
|                 | N Mean(SD)  | N Mean(SD) | IV,Fixed,95% CI |        | IV,Fixed,95% CI |
| Tshefu 2010     | 799 0.2 (1.36) | 398 0.18 (1.35) | 38.2% 0.02 [ -0.14, 0.18 ] |        |                |
| Subtotal (95% CI) | 2130 | 1164 | 100.0% -0.09 [ -0.19, 0.01 ] |        |                |

Heterogeneity: Chi² = 8.00, df = 3 (P = 0.05); I² =62%
Test for overall effect: Z = 1.68 (P = 0.094)
Test for subgroup differences: Chi² = 19.52, df = 3 (P = 0.00), I² =85%

(1) Kayentao 2012: compares artesunate-pyronaridine to artemether-lumefantrine
(2) Poravuth 2011: compares artesunate-pyronaridine with Chloroquine
(3) Ruenagweerayut 2012: compares artesunate-pyronaridine to artesunate-mefloquine
(4) Tshefu 2010 compares artesunate-pyronaridine to artemether-lumefantrine
Analysis 7.5. Comparison 7 Pyronaridine alone or with artesunate versus another antimalarial: laboratory findings, Outcome 5 Abnormal ECG findings.

Review: Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria

Comparison: 7 Pyronaridine alone or with artesunate versus another antimalarial: laboratory findings

Outcome: 5 Abnormal ECG findings

| Study or subgroup | Pyronaridine | Comparator | Risk Ratio M-H,Fixed 95% CI | Weight M-H,Fixed 95% CI |
|-------------------|-------------|-----------|----------------------------|------------------------|
| ECG abnormalities |             |           |                            |                        |
| Tshefu 2010 (1)   | 2/849       | 2/423     | 40.0% 0.50 [0.07, 3.52]    |                        |
| Rueangweerayut 2012 (2) | 6/848   | 3/423     | 60.0% 1.00 [0.25, 3.97]    |                        |
| **Subtotal (95% CI)** | **1697**       | **846**   | **100.0% 0.80 [0.26, 2.43]** |                        |
| QT prolongation   |             |           |                            |                        |
| Tshefu 2010       | 1/849       | 0/423     | 6.2% 1.50 [0.06, 36.66]    |                        |
| Poravuth 2011 (3) | 1/226       | 6/222     | 56.4% 0.16 [0.02, 1.35]    |                        |
| Rueangweerayut 2012 | 1/848    | 3/423     | 37.3% 0.17 [0.02, 1.59]    |                        |
| **Subtotal (95% CI)** | **1923**       | **1068**  | **100.0% 0.25 [0.07, 0.90]** |                        |

Total events: 8 (Pyronaridine), 5 (Comparator)

Heterogeneity: Chi² = 0.32, df = 1 (P = 0.57); I² =0.0%

Test for overall effect: Z = 0.40 (P = 0.69)

2 QT prolongation

Heterogeneity: Chi² = 1.48, df = 2 (P = 0.48); I² =0.0%

Test for overall effect: Z = 2.13 (P = 0.033)

Test for subgroup differences: Chi² = 1.82, df = 1 (P = 0.18), I² =45%

(1) Tshefu 2010: compares artesunate-pyronaridine to artemether-lumefantrine

(2) Rueangweerayut 2012: compares artesunate-pyronaridine to artesunate-mefloquine

(3) Poravuth 2011: compares artesunate-pyronaridine to chloroquine

### ADDITIONAL TABLES

**Table 1. Primary outcome measure (Total failure)**

| Analysisa | Participants | PCRb-unadjusted | PCR-adjusted |
|-----------|--------------|----------------|--------------|
|           |              | Numerator | Denominator | Numerator | Denominator |
| Primary analysis | Exclusions after enrolment | Excludedc | Excluded | Excluded | Excluded |
Table 1. Primary outcome measure (Total failure) (Continued)

| Criterion | Missing or indeterminate PCR | New infections | Sensitivity analysis 1<sup>d</sup> | Sensitivity analysis 2<sup>e</sup> | Sensitivity analysis 3<sup>f</sup> | Sensitivity analysis 4<sup>g</sup> |
|-----------|-------------------------------|---------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|           | Included as failures          | Included       | Included as failures              | -                                 | Included as failures              | Included as successes             |
|           | Excluded                      | Excluded       | Excluded                          | Excluded                          | Excluded                          | Included as successes             |

<sup>d</sup>As 'Primary analysis' except: missing or indeterminate PCR.

<sup>e</sup>To re-classify all PCR-confirmed new infections as treatment successes in the PCR-adjusted analysis. (This analysis may overestimate efficacy as PCR is not wholly reliable and some recrudescences may be falsely classified as new infections. Also some participants may have gone on to develop a recrudescence after the new infection).

<sup>f</sup>To re-classify all exclusions after enrolment (losses to follow-up, withdrawn consent, other antimalarial use, or failure to complete treatment) as treatment failures. For PCR-unadjusted total failure this represents a true worse-case scenario.

<sup>g</sup>To re-classify all exclusions after enrolment (losses to follow-up, withdrawn consent, other antimalarial use, or failure to complete treatment) as treatment successes.

Note: we removed participants that did not satisfy the inclusion criteria after randomization from all calculations.

PCR: polymerase chain reaction.

‘Excluded’ means removed from the calculation.

<sup>d</sup>To re-classify all indeterminate or missing PCR results as treatment failures in the PCR-adjusted analysis.

Table 2. Adverse events risk of bias assessment methods

| Criterion                              | Assessment     | Explanation                                                                 |
|----------------------------------------|----------------|-----------------------------------------------------------------------------|
| Patient-reported symptoms              |                |                                                                             |
| Was monitoring active or passive?      | Active, Passive, Unclear | We classified monitoring as ‘active’ when authors reviewed participants at set timepoints and enquired about symptoms |
| Was blinding for participants and outcome assessors adequate? | Adequate, Inadequate | We classified blinding as ‘adequate’ when both participants and outcome assessors were blinded to the intervention group, and the methods of blinding (including |
Table 2. Adverse events risk of bias assessment methods (Continued)

| Was outcome data reporting complete or incomplete? | Complete | Incomplete | Unclear | We classified outcome data reporting as ‘complete’ when data was presented for all the time-points where it was collected |
| Were all participants included in reporting? | | | | We report the percentage of randomized participants included in adverse event reporting |
| Was the analysis independent of study sponsor? | Yes | No | Unclear | We classified the analysis of trials sponsored by pharmaceutical companies as independent of the sponsor when it was clearly stated that the sponsor had no input to the trial analysis |

Laboratory tests

| Number of tests undertaken | - | We extracted the type and number of laboratory tests were taken |
| Timing of tests | Adequate | Inadequate | We classified the number and timing of tests as ‘adequate’, when tests were taken at baseline, plus two other timepoints within the first week after treatment, plus the last day of the study. We classed the number of test taken as “inadequate”, if either the laboratory controls in the first week or controls at four weeks were not performed |
| Reporting of test results | Complete | Incomplete | We classified reporting as ‘complete’ when test results of all time points were reported. For the trials with inadequate number of tests taken, we considered completeness of reporting as inconsequential, and therefore did not record a judgement |
| Independence of data analysis | Yes | No | Unclear | We classified the analysis of trials sponsored by pharmaceutical companies as independent of the sponsor when it was clearly stated that the sponsor had no input to the trial analysis |

Table 3. Dosing regimens of artesunate-pyronaridine

| Trial ID | Actual or target dose | Intervention (mg/kg/dose) | Comparator (mg/kg/dose) |
| --- | --- | --- | --- |
|  |  | Artesunate | Pyronaridine | Artemisinin-derivative | Partner drug |
| Kayentao 2012 | Actual dose | 2.2 to 4.4 | 6.7 to 13.3 | 1.3 to 4.0 | 8.0 to 24.0 |
Table 3. Dosing regimens of artesunate-pyronaridine (Continued)

| Trial ID        | Target dose | 2.4 to 4.6 | 7.2 to 13.8 | NS | NS |
|-----------------|-------------|------------|-------------|----|----|
| Tshefu 2010     | Actual dose | 2.4 to 4.7 | 7.1 to 14.0 | 2.5 to 5.0 | 6.2 to 12.5 |
| Rueangweerayut 2012 | Target dose | 2.4 to 4.6 | 7.2 to 13.8 | - | 10, 5, 5 |
| Poravuth 2011   | Target dose | -          | 16, 8, 8    | - | 10, 5, 5 |
| Ringwald 1996   | Target dose | -          | 8, 8, 8     | - | 10, 10, 5 |
| Ringwald 1998   |             |            |             |    |    |

NS = Not specified.

Table 4. Risk of bias for patient reported symptoms

| Trial ID        | Monitoring active or passive? | Outcome data reporting | Blinding adequate? | % of participants included in AE reporting | Independent data analysis |
|-----------------|-------------------------------|------------------------|--------------------|------------------------------------------|--------------------------|
|                 |                               | Days data collected    | Days data reported | Patient | Clinician | Data analysis | AS-Pyr | Control |
| Tshefu 2010     | Unclear                       | 0 to 3, 7, 14, 21, 28, 35, 42 | Unclear | Yes | Yes | Unclear | 100% | 100% | No |
| Kayentao 2012   | Unclear                       | Unclear                | Unclear            | No | No | Yes | 100% | 100% | No |
| Rueangweerayut 2012 | Unclear                       | Unclear                | Unclear            | No | No | Unclear | 100% | 100% | No |
| Poravuth 2011   | Unclear                       | Unclear                | Unclear            | Yes | Yes | Yes | 100% | 100% | Yes |
| Ringwald 1996   | Unclear                       | Unclear                | Unclear            | No | No | Unclear | Unclear | Unclear | Yes |
| Ringwald 1998   | Unclear                       | Unclear                | Unclear            | No | No | Unclear | 100% | 100% | Yes |
Table 5. Risk of bias table for biochemical liver function tests

| Trial ID          | Number of tests | Days tested | Days reported | Days tested adequate? | For adequate testing, was reporting complete? | Data analysis independent of sponsor? |
|-------------------|-----------------|-------------|---------------|------------------------|-----------------------------------------------|---------------------------------------|
| Tshefu 2010       | 4¹              | 0, 3, 7, 28²| 3, 7, 28      | Adequate               | Complete                                      | No                                    |
| Kayentao 2012     | 4¹              | 0, 3, 7, 28| 3, 7          | Adequate               | Incomplete ³                                  | No                                    |
| Rueangweerayut 2012 | 4¹            | 0, 28, 42  | 0, “post baseline” | Inadequate             | -                                             | No                                    |
| Poravuth 2011     | 4¹              | 0, 3, 7, 28²| 3, 7, 28      | Adequate               | Complete                                      | Yes                                   |
| Ringwald 1996     | 4¹              | 0, 7        | 0, 7          | Inadequate             | -                                             | Yes                                   |
| Ringwald 1998     | 5¹, 5          | 0, 7        | 0, 7          | Inadequate             | -                                             | Yes                                   |

¹ Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL).
² Plus day 42 if clinically indicated.
³ Does not report the outcome data for day 28 in additional file 3.
⁴ The trial did not report ALP values for all participants (ALT and AST values for 848 patients in the artemesate pyronaridine arm and for 423 participants in the artemesate mefloquine arm at baseline; AST values only for 635 participants and 308 participants respectively at baseline).
⁵ Plus conjugated bilirubin in addition.

Table 6. Additional data from Kayentao 2012

| Trial ID   | Outcome                        | Artesunate-pyronaridine | Artemether-lumefantrine | P value |
|------------|--------------------------------|--------------------------|--------------------------|---------|
| Kayentao 2012 | Median parasite clearance time | 24.1 hours (95% CI 24.0 to 24.1) | 24.2 hours (95% CI 24.1 to 32.0) | 0.02    |
|            | Median fever clearance time    | 8.1 hours (95% CI 8.0 to 8.1) | 8.1 hours (95% CI 8.0 to 15.8) | 0.049   |
|            | “Post-baseline gametocytes”     | 95/354 (26.8%)           | 44/178 (24.7%)           | 0.6     |
|            | Gametocyte development (in those negative at baseline) | 53/354 (15%) | 20/178 (11.2%) | 0.24    |
Table 7. Summary of ECG monitoring and results

| Trial ID          | Days tested | ECG results |
|-------------------|-------------|-------------|
|                   |             | Pyronaridine arm | Comparator arm |
| Kayentao 2012     | 0, 2, 7, 14, and 28 | "no post baseline clinically important ECG results" | "no post baseline clinically important ECG results" |
| Tshefu 2010       | 0, 2, 7, 14, and 28 | 1 patient with T-wave inversion at day 21 | 1 patient with sinus bradycardia and sinus arrhythmia on day 21 |
|                   |             | 1 patient with ventricular premature complexes and extended QTc (manual reading QTcB 461 ms, QTcF 458 ms) at day 21 | 1 patient with sinus bradycardia on day 2 |
| Rucangweerayut 2012 | Unclear   | 6/848 (0.7%) patients with abnormal ECGs - “All were mild and resolved before study completion” | 3/423 (0.7%) patients with abnormal ECGs - “All were mild and resolved before study completion” |
|                   |             | 1/848 with QT prolongation - None had a QT interval that exceeded 480 msec | 3/423 with long or prolonged QT interval - None had a QT interval that exceeded 480 msec |
| Poravuth 2011     | 0, 2, 7, 14, and 42 | 1/226 (0.4%) patients with QTc prolongations | 6/222 (2.7%) patients with QTc prolongations (1/222 not drug-related) |

A P P E N D I C E S

Appendix 1. Search methods: search strategies

| Search set | CIDG SR | CENTRAL | MEDLINE | EMBASE | LILACS |
|------------|---------|---------|---------|--------|--------|
| 1          | malaria | malaria | malaria | malaria | malaria |
| 2          | pyronaridine | pyronaridine | pyronaridine | pyronaridine | pyronaridine |
| 3          | 1 and 2 | 1 and 2 | NAPHTYRIDINES | PYRONARIDINE | 1 and 2 |
| 4          | -       | -       | 2 or 3  | 2 or 3  | -      |
| 5          | -       | -       | 1 and 4 | 1 and 4 | -      |
| 6          | -       | -       | Limit 5 to human | Limit 5 to human | - |

*Cochrane Infectious Diseases Group Specialized Register.

*bSearch terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Higgins 2005); upper case: MeSH or EMTREE heading; lower case: free text term.
## Appendix 2. Artesunate-pyronaridine versus artemether-lumefantrine adverse events GRADE table

### Artesunate-pyronaridine compared to artemether-lumefantrine for treating uncomplicated *P. falciparum* malaria

**Patient or population:** Patients with uncomplicated *P. falciparum* malaria  
**Settings:** Malaria endemic areas  
**Intervention:** Artesunate-pyronaridine (AS-Pyr)  
**Comparison:** Artemether-lumefantrine (AL6)

| Outcomes                        | Number of participants having adverse events (95% CI) | Number of participants (trials) | Quality of the evidence (GRADE) |
|---------------------------------|------------------------------------------------------|--------------------------------|---------------------------------|
|                                 | AL6 | AS-Pyr |                                    |                                |                                |
| **Serious adverse events (including deaths)** | 3 per 1000 | 0 more per 1000 (From 2 fewer to 10 more) | 1787 (2 trials) | low\(^1,2,3,4\) |
| **Adverse events leading to withdrawal** | 17 per 1000 | 6 more per 1000 (From 6 fewer to 31 more) | 1787 (2 trials) | low\(^1,2,3,4\) |
| **Gastroenterological**         |     |        |                                    |                                |                                |
| Vomiting                        | 4 per 100 | 2 more per 100 (From 1 fewer to 10 more) | 535 (1 trial) | low\(^5,6,7\) |
| Diarrhoea                       | -   | -     |                                    | -                              | .\(^8\)                        |
| Abdominal pain                  | 5 per 100 | 0 more per 100 (From 2 fewer to 4 more) | 1272 (1 trial) | low\(^5,9,10\) |
| **Neuro-psychiatric**           |     |        |                                    |                                |                                |
| Headache                        | 3 per 100 | 0 more per 100 (From 1 fewer to 1 more) | 1272 (1 trial) | low\(^5,9,10\) |
| Dizziness                       | -   | -     |                                    | -                              | .\(^8\)                        |
| **Cardio-respiratory**          |     |        |                                    |                                |                                |
| Cough                           | 9 per 100 | 1 fewer per 100 (From 3 fewer to 2 more) | 1807 (2 trials) | moderate\(^1,2,3,10\) |
| ECG abnormality                 | 4 per 1000 | 2 fewer per 1000 (From 4 fewer to 10 more) | 1272 (1 trial) | moderate\(^5,9,10,11\) |
| Prolonged QT interval           | 0 per 1000 | 1 more per 1000 (From 0 fewer to 36 more) | 1272 (1 trial) | moderate\(^5,9,10,11\) |
Musculoskeletal/dermatological

|                    | Myalgia          |
|--------------------|------------------|
| Biochemical        |                  |
| Alanine aminotransferase | 3 per 1000  |
| Grade 3 or 4 toxicity |                   |
|                    | 3 more per 1000  |
|                    | (From 2 fewer to 25 more) |
|                    | 1807 (2 trials)  |
|                    | low\(^1,2,3,4\)  |
| Aspartate aminotransferase | 1 per 1000  |
| Grade 3 or 4 toxicity |                   |
|                    | 3 more per 1000  |
|                    | (From 0 fewer to 20 more) |
|                    | 1807 (2 trials)  |
|                    | low\(^1,2,3,4\)  |

The **assumed risk** of adverse events in the artemether-lumefantrine group is the average risk across trials. The **corresponding risk** with artesunate-pyronaridine (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval.

GRADE Working Group grades of evidence

- **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.
- **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
- **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
- **Very low quality:** We are very uncertain about the estimate.

1. No serious risk of bias: Both trials were at low risk of bias.
2. No serious inconsistency: Statistical heterogeneity was low.
3. Downgraded by one for serious indirectness: These two trials included only 232 children aged below five years.
4. Downgraded by one for imprecision: These trials do not exclude the possibility of rare but clinically important adverse effects.
5. No serious risk of bias: This single trial was at low risk of bias.
6. Downgraded by one for serious indirectness: This trial included only 232 children aged less than five years and only 15 less than one year.
7. Downgraded by one for serious imprecision: The 95% CI is wide and includes both no difference and clinically important differences.
8. This outcome was not reported.
9. Downgraded by two for very serious indirectness: This trial excluded children aged less than five years.
10. No serious imprecision: The finding is of no difference between treatments and the sample size is adequately powered to detect differences if they existed.
11. The second trial only reports that there were “no clinically important post baseline ECG results”

Appendix 3. Artesunate-pyronaridine versus artesunate plus mefloquine adverse event GRADE table
### Artesunate-pyronaridine compared to artesunate plus mefloquine for treating uncomplicated *P. falciparum* malaria

**Patient or population:** Patients with uncomplicated *P. falciparum* malaria  
**Settings:** Malaria endemic areas  
**Intervention:** Artesunate-pyronaridine (AS-Pyr)  
**Comparison:** Artesunate plus mefloquine (AS+MQ)

| Outcomes                                    | Number of participants having adverse events (95% CI) | No of participants (trials) | Quality of the evidence (GRADE) |
|---------------------------------------------|-----------------------------------------------------|-----------------------------|---------------------------------|
|                                             | AS+MQ                   | AS-Pyr                      |                                 |
| Serious adverse events (including deaths)   | 7 per 1000              | 0 more per 1000 (From 5 fewer to 21 more) | 1271 (1 trial) | low<sup>1,2,3,4</sup> |
| Adverse events leading to withdrawal        | 9 per 1000              | 3 fewer per 1000 (From 7 fewer to 7 more) | 1271 (1 trial) | low<sup>1,2,3,4</sup> |
| Gastroenterological                         | Vomiting                | 2 per 100                   | 0 more per 100 (From 1 fewer to 2 more) | 1271 (1 trial) | low<sup>1,2,5,6</sup> |
|                                             | Diarrhoea               | 2 per 100                   | 1 fewer per 100 (From 2 fewer to 0 more) | 1271 (1 trial) | low<sup>1,2,5,6</sup> |
|                                             | Abdominal pain          | -                           | -                               | -                 | -                     |
| Neuropsychiatric                            | Headache                | 10 per 100                  | 2 more per 100 (From 2 fewer to 6 more) | 1271 (1 trial) | low<sup>1,2,5,6</sup> |
|                                             | Dizziness               | 7 per 100                   | 4 fewer per 100 (From 5 fewer to 2 fewer) | 1271 (1 trial) | low<sup>1,2,5,6</sup> |
| Cardiorespiratory                           | Cough                   | 2 per 100                   | 2 more per 100 (From 1 fewer to 4 more) | 1271 (1 trial) | low<sup>1,2,5,6</sup> |
|                                             | ECG abnormality         | 7 per 1000                  | 0 more per 1000 (From 7 fewer to 21 more) | 1271 (1 trial) | low<sup>1,2,3,8</sup> |
|                                             | Prolonged QT interval   | 7 per 100                   | 7 fewer per 100 (From 7 fewer to 4) | 1271 (1 trial) | moderate<sup>1,2,3,6</sup> |
The assumed risk of adverse events in the artesunate plus mefloquine group is the risk from the single trial. The corresponding risk with artesunate-pyronaridine (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval.

| GRADE Working Group grades of evidence | High quality: Further research is very unlikely to change our confidence in the estimate of effect. | Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. | Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. | Very low quality: We are very uncertain about the estimate. |
|---|---|---|---|---|
| No serious risk of bias: This single trial is at low risk of bias. | No serious inconsistency: Not applicable as only one trial. | Downgraded by one for serious indirectness: This trial excluded children aged below five years. | Downgraded by one for imprecision: Trials of this size do not exclude the possibility of rare but clinically important adverse effects. | Downgraded by two for very serious indirectness: This trial excluded children aged less than five years. |
| Downgraded by two for very serious indirectness: This trial excluded children aged less than five years. | No serious imprecision: The finding is of no difference between treatments and the sample size is adequately powered to detect differences if they existed. | This outcome was not reported. | Downgraded by one for serious imprecision: The 95% CI is wide and includes both no difference and clinically important differences |

### Appendix 4. Descriptions of serious adverse events

| Trial ID | Number of participants | Comparator | All serious adverse events | Serious adverse events judged to be related to the medication |
|---|---|---|---|---|
| | | | Artesunate-pyronaridine | Comparator |
| | | | Artesunate-pyronaridine | Comparator |
Continued

| Date         | Event        | Description                                                                 |
|--------------|--------------|-----------------------------------------------------------------------------|
| 11 November 2008 | Amended     | We converted to the new review format with minor editing.                     |

**CONTRIBUTIONS OF AUTHORS**

B Unnikrishnan (BU) and Suma Nair (SN) co-drafted the initial version of the protocol. HB revised the protocol, and together with PT independently selected trials, assessed quality, extracted and entered data that was checked by BU and SN. Christine Kramer extracted adverse events data. HB used GRADE profiler to create and import ‘Summary of findings’ tables. HB wrote the initial draft of the review and worked with all the authors to finalise the review. All authors approved the final review version.
DECLARATIONS OF INTEREST

None known.

SOURCES OF SUPPORT

Internal sources
- Manipal University, India.
  Employment and logistic support for Drs. Unnikrishnan and Nair
- South Asian Cochrane Centre, Vellore, India.
  Protocol Development and Review Completion workshops
- Christian Medical College, Vellore, India.
  Employment for Prof. Tharyan, and logistic support for the South Asian Cochrane Centre

External sources
- Department for International Development (DFID), UK.
  Fellowships to Drs. Unnikrishnan and Nair, via the Effective Health Care Research Partnership Consortium grant to Prof. Tharyan,
  to complete the review at the South Asian Cochrane Centre
- Indian Council of Medical Research, India.
  Funding for the Prof. BV Moses & ICMR Centre for Advanced Research and Training in Evidence-Informed Healthcare; CMC Vellore

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We stated in the protocol that we intended to assess the methods used to generate the allocation sequence and conceal allocation concealment as adequate, inadequate, or unclear according to Juni 2001, and note who was blinded to the interventions in each trial. However, since the introduction of Review Manager 2011, we made these assessments using the methods described in Higgins 2011.

In keeping with the Cochrane Collaboration policy to use 'Summary of findings' tables, which was introduced after publication of the protocol, we generated them using GRADE profiler (GRADE 2008) and interpreted the evidence for each outcome and comparison using the GRADE approach (Schünemann 2008).

We revised the list of outcomes to reflect current WHO standards for assessing outcomes in antimalarial trials.

Although gametocyte carriage was not included as an outcome in the protocol, we included it as a secondary outcome due to its importance in malaria transmission.

In the protocol we stated that we intended to assess the effectiveness of pyronaridine both as a monotherapy and in combination with an artemisinin. However, we revised this to focus only on pyronaridine-artemisinin combinations. In addition, due to concerns regarding pyronaridine's effect on the liver, assessment of the effects of the comparisons on liver function now include randomized comparisons in both falciparum and vivax malaria. Accordingly, we updated the background and methods sections considerably to reflect the changing scenario in malaria policies and epidemiology.

PT and HB joined the review team. Rajeev Aravindakshan withdrew from the team due to conflicting demands on his time.